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There is a great demand for the development of highly fluorescent and specific 
probes that enable a sensitive and early detection of malignancies and a separation 
from healthy tissue in a non-invasive way by in vivo imaging. The main drawback of 
fluorescence imaging in vivo is the autofluorescence, which hampers the detection of 
probe-derived signals. In this study, two novel fluorescence probes were investigated 
concerning their suitability for visualization of tumors in mice: a pH-sensitive dye, 
CypHer5E conjugated to the tumor specific antibody Herceptin (pH-Her) as well as 
polystyrene nanoparticles (PSNPs) of different sizes (15, 25, and 100 nm) and 
surface modifications (NH2, polyethylene glycol, and Herceptin) loaded with the 
broadband fluorophore Itrybe. For this purpose, time-domain near-infrared (NIR) 
fluorescence imaging was applied in nude mice bearing orthotopic HER2-positive 
(KPL-4) and HER2-negative (MDA-MB-231) breast tumor xenografts. The pH-
sensitivity and functionality of pH-Her was confirmed by spectroscopic measurements 
and in cell-based assays. In HER2-positive tumor-bearing mice, pH-Her, which 
increases fluorescence in the acidic environment of the tumor only, combined with 
subtraction of autofluorescence led to an increased contrast to noise ratio (CNR) and 
thereby an improved sensitivity of tumor detection, when compared to the always-on 
fluorescent conjugate Alexa Fluor 647-Herceptin (Alexa-Her). In contrast, LT-gated 
imaging with pH-Her and Alexa-Her did not improve tumor-detection sensitivity in 
vivo. The broad excitation and emission spectra of Itrybe enclosed in PSNPs enable 
excitation and sensitive detection of this dye at different wavelengths in the NIR 
region, in vivo. Furthermore, Herceptin-conjugated 100 nm NPs bind specifically to 
HER2 as demonstrated in immunoassays as well as on KPL-4 tumor cells and -
sections in vitro. However, a certain amount of unspecific binding/uptake was 
observed. In vivo accumulation of PEGylated NPs of all sizes was detected in MDA-
MB-231- but not in KPL-4 tumors as shown by ex vivo scans of excised tumors. 
Biodistribution analyses in healthy mice illustrated a high and rapid uptake of NPs of 
all sizes in the liver, accompanied by a fast elimination of NPs from the blood, 
thereby reducing efficient tumor accumulation. In conclusion, the pH-sensitive dye, 
CypHer5E in combination with tumor-specific ligands is highly suitable for sensitive in 
vivo monitoring of tumors and may also be a promising tool for the detection of weak 
signals deriving e.g. from small metastatic lesions.  Highly fluorescent Itrybe-loaded 
NPs have great potential for imaging applications as they provide 3D platforms for 
various modifications and thus help to address different biological questions in vivo. 
However, the bioavailability of Itrybe-loaded NPs has to be improved by modification 
of their surface or composition to enable efficient tumor targeting in vivo. 
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Introduction 
1. INTRODUCTION 
A considerable progress in the diagnostic and monitoring of cancer was the 
development of noninvasive imaging methods that enable detection and 
characterization of malignancies over time in living objects. For the anatomical 
illustration of tissue, structural imaging techniques are applied, like computed 
tomography (CT), ultra sonography (US), and magnetic resonance imaging (MRI). 
Characterization of cancerous tissue by its altered functionality, concerning e.g. 
irregular metabolic activity or altered expression of proteins is facilitated by 
functional imaging methods, such as positron emission tomography (PET), single 
photon emission computed tomography (SPECT) and optical imaging. Each technique 
has a combination of advantages and disadvantages affecting its selection for 
application in a particular study1. 
Optical imaging by the use of fluorescence light has become especially attractive due 
to its comparatively easy use and low costs as well as high sensitivity2. In addition 
and in contrast to most other imaging techniques, fluorescence imaging, enables the 
visualization of multiple target structures or biological processes in one model 
organism by simultaneously using different fluorescence labels3. While the current 
clinical use of fluorescence imaging is mainly limited to microscopic and 
(micro)endoscopic techniques for diagnostic purposes and during surgical 
procedures, the routine application of fluorescence methods in the clinic and preclinic 
is certain to increase1. In recent years the use of functional tumor-specific 
fluorescence probes has become focus of several studies that aimed to improve 
sensitivity of tumor detection in tumor-bearing mice4-8. However, the majority of 
these probes is still limited in their specificity and sensitivity, regarding penetration 
depth and real-time imaging of biological processes in vivo. 
Therefore, there is an ever growing demand for the development of highly 
fluorescent and specific as well as activatable probes that enable a sensitive and 
early detection of malignancies and metastatic lesions and a precise separation from 
healthy tissue in a non-invasive way in vivo.    
1.1. The principle of fluorescence imaging 
Fluorescence imaging relies on the detection of photons, emitted by a substance that 
has absorbed light of a distinct wavelength. Emission of fluorescence takes place 
when an orbital electron of an atom, molecule or nanostructure, after being excited 
to a higher quantum state, relaxes to its ground state, thereby emitting light.  
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Different techniques can be applied to measure fluorescence in living organisms. 
Most systems are based on planar measurements of fluorescence that are usually 
overlaid with photographic images of the surface of the scanned sample. Normally 
such devices consist of a multispectral light source or a laser for excitation of the 
fluorescent species, appropriate filters and a device for signal detection, like a CCD 
camera or a photo multiplier tube. Planar imaging can be performed in an epi-
illumination mode, known as fluorescence reflectance imaging (FRI), in which the 
excitation source and the detector are located on the same side thereby measuring 
the returning fluorescence response. When the excitation source and the detector are 
placed on the opposite sides of the scanned object, imaging is performed in a 
transillumination mode, in which the light penetrating the object is collected9. Recent 
developments in tomographic fluorescence imaging including fluorescence-mediated 
(-molecular) tomography (FMT) provide three-dimensional (3D) information about 
the fluorescence distribution, as well as probe concentration and depth1,9-11. 
The introduction of time-domain imaging has demonstrated a great improvement in 
fluorescence imaging as it allows the calculation of the fluorescence lifetime (LT)12. 
This parameter characterizes a fluorescence probe by describing the average time a 
fluorophore spends in its excited state before returning to the ground state. In this 
method FRI is applied with a pulsed laser diode as an excitation source. After each 
single excitation pulse the emitted photons are measured time-resolved using e.g. a 
photomultiplier tube, thereby allowing calculations of the LT13. As each fluorescence 
probe has a characteristic LT, the determination of LTs permits the identification of 
probe-derived signals, e.g. originating from different fluorescent probes14 and/or 
their separation from autofluorescence1,2,15,16. In vivo autofluorescence is defined as 
fluorescence that derives from unlabeled sources, like collagen, elastin, beta 
carotene, or oils, pigments, and proteins from ingested food17. This endogenous 
fluorescence poses one of the biggest problems in in vivo fluorescence imaging as it 
hampers the detection of probe-derived signals. This could be overcome by gating 
fluorescence intensity maps of scanned objects to the characteristic LT of the applied 
fluorescence probe, thereby only illustrating probe-derived signals. If the LT of the 
probe substantially differs from the LT of unspecific signals in this object, e.g. owing 
to autofluorescence, this method enables the selective illustration of only probe-
derived signals and thus might lead to an improved sensitivity in detection of the 
target.  
1.2. Fluorescence labels  
For optimal detection of fluorescence light in vivo it is important to consider 
fluorescence probes that are very bright, relatively photostable and require minimal 
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exposure to excitation light in order to sustain cell viability18-20. Of particular 
advantage for in vivo imaging are fluorophores absorbing and emitting in the near-
infrared (NIR) wavelength region of 650 to 900 nm. The benefits of this spectral 
range are not only a decreased autofluorescence but also less absorbance by 
haemoglobin, water and lipids, allowing an increased tissue penetration of up to 2 
cm1,21 (Figure 1). In addition, the considerably high absorption by melanin is 
decreasing towards longer wavelength1,21.  
 
 
Figure 1. Tissue optical 
window  
The absorption (illustrated as 
absorption coefficient) by major 
light absorbers in tissue is 
illustrated at distinct 
wavelengths. In the NIR optical 
window (700 to 900 nm; light 
blue) absorption by hemoglobin 
(Hb), oxygenated hemoglobin 
(HbO2), and water (H2O) is low. 
Picture was taken from Phan et 
al.22. 
 
Different types of fluorescence labels are applied for in vivo imaging and can be 
divided into endogenous fluorescence labels and exogenous fluorescence probes that 
can further be grouped in non-targeted contrast agents, target-specific fluorescence 
probes, and activatable probes. 
1.2.1. Endogenous fluorescence labels 
Endogenous fluorescent labels are produced by genetic manipulation of the model 
organism leading to the expression of a fluorescent protein in order to visualize 
distinct biological functions. A break-through in the application of fluorescence 
imaging was the identification of the first fluorescent protein, green fluorescent 
protein (GFP) that was isolated from jellyfish, and purified and characterized in the 
early 1970’s23. Today fluorescent proteins in many colors exist that fluoresce in the 
visible spectrum in colors of deep blue (~400 nm) to far red (~670 nm). In addition, 
NIR fluorescent proteins have been expressed in mammalian cells24,25. Such 
genetically encoded probes have been shown to be suitable for in vitro and in vivo 




1.2.2. Exogenous fluorescence labels 
Most of the fluorescent probes are used to specifically target particular markers or 
molecular events in model organisms. Requirements for the efficient detection of 
exogenous labels are for instance, absorption- and emission-maxima in the NIR 
region, a high molar absorption coefficient at the excitation wavelength, a high 
fluorescence quantum yield, as well as sufficient thermal and photochemical 
stability19,20. Furthermore, suitable fluorescence dyes have to be soluble and stable in 
buffers and body fluids and the resulting fluorescence probe should show a good 
targeting efficiency with minimal nonspecific binding as well as a low toxicity20.  
There are few classes of NIRF dyes available for in vivo applications. Most of them 
are cyanine dyes, such as indocyanine green (ICG), cypate, AlexaFluor-dyes, or Cy-, 
DY-, and IR-dyes19,26. Although a large variety of fluorescent probes is continuously 
developed and improved, ICG is the only dye approved by the FDA (Food and Drug 
Administration-USA) for use in patients27,28. 
To characterize or monitor malignancies in vivo by the use of fluorescence probes, 
appropriate model organisms have to be selected. In this regard, nude mice are very 
suitable. These hairless mice discovered in 196229 have a mutation in the forkhead 
box N1 (Foxn1) gene, leading to defective differentiation of hair and thymic 
disgenesis and therefore resulting in T cell deficiency and partial defects in B cell 
development30,31. As the immune system of these mice is compromised, they do not 
reject human tumor cells and thereby provide excellent model organisms to study 
tumor biology in vivo32. In addition, the lack of fur presents an advantage for in vivo 
fluorescence imaging as fur can cause scattering and absorption of light, hampering 
the detection of probe-derived signals. 
1.2.2.1. Non-targeted contrast agents 
Non-targeted contrast agents are designed to passively accumulate in the tissue of 
interest. Such probes are mainly applied for imaging of blood vessels and/or tumors. 
An important prerequisite for such probes is a sufficiently long blood circulation time, 
allowing their accumulation at the site of interest. Tumor imaging by non-targeted 
probes is enabled by the enhanced permeability and retention (EPR) effect, involving 
hyperpermeable and leaky vasculature, as well as suppression of lymphatic 
function33. 
1.2.2.2. Target-specific fluorescence probes 
Target-specific fluorescence probes are directed against molecular markers that are 
overexpressed or uniquely expressed on the target structure. The majority of such 
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probes consists of fluorescence dyes or nanomaterials conjugates to ligands, like 
whole IgG antibodies, antibody fragments, or small peptides, all targeting a tissue or 
disease specific marker. Numerous aspects have to be considered when choosing the 
right ligand for the design of target-specific probes. Most important, the ligand 
should show maximal targeting efficiency and minimal unspecific binding20. 
Furthermore, the biodistribution and pharmacokinetics of ligands are strongly 
influenced by their size. Molecules smaller than antibodies such as antibody 
fragments or peptides, can be advantageous for in vivo imaging due to a rapid 
clearance from blood, leading to a better signal to background contrast. However, if 
clearance is too fast, small ligands will have insufficient time to penetrate the target 
tissues before being cleared from the blood. In comparison, larger whole antibodies 
are cleared more slowly from the blood circulation and only slowly penetrate into 
tissues, which may result in a high background and subsequently a poor tissue to 
background contrast34. Furthermore, the so called “binding site barrier”, postulated 
by Weinstein in the early ‘90s35,36 can influence the diffusion of ligands into the target 
tissue. This may be caused by a (too) high affinity and/or interaction of a particular 
ligand for/with its antigen, which may result in a reduced or even inhibited tumor 
penetration35.  
1.2.2.3. Activatable fluorescence probes 
Activatable fluorescence probes (also termed “smart probes”) evolved to detect and 
monitor molecular events, such as the activity of enzymes, changes in pH, or oxygen 
concentration, either by switching their fluorescence “on” or “off” or due to shifts in 
fluorescence absorption and/or emission spectra in response to distinct molecular 
processes. Such probes may be applied to selectively illustrate target structures, 
such as tumor tissue, based on a selective activation at the targeted tumor site only, 
thereby circumventing background fluorescence caused by unbound probes in the 
blood stream. 
Probes based on the “on” and “off” principle require efficient quenching in the “off”-
state. The term quenching refers to processes which lead to a decrease of the 
fluorescence intensity of a given probe and can be achieved by distinct photochemical 
mechanisms, such as Förster (or fluorescence) resonance energy transfer (FRET), H-
dimer formation or photon induced electron transfer (PeT). 
FRET takes place between two molecules that are in close contact to each other. 
Here, a donor chromophore, initially in its electronic excited state, may transfer 
energy to an acceptor chromophore while dropping down to its ground state. FRET 
may occur between two fluorophores of the same type (homo-FRET) which absorb 
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energy from each other (self-quenching) that would have otherwise resulted in 
fluorescence37, or between an excited donor fluorophore and a quencher (hetero-
FRET) that absorbs the energy from the donor and gives it off as heat6,37. 
Furthermore, some fluorophores, like ICG tend to perform autoquenching after 
conjugation to antibodies, most likely occurring via a noncovalent interaction 
between the ICG and hydrophobic amino acids on the IgG7,37. In addition, some 
dyes, such as Xanthene derivates at high concentrations or protein-conjugated 
fluorophores when in close proximity to each other, like the rhodamin dye TAMRA, 
tend to form H-dimers5. This can lead to shifts of absorbance spectra resulting in 
quenched emission spectra5,37. In PeT, electron transfer from a PeT donor to an 
excited acceptor fluorophore, diminishes the fluorescence signal of the acceptor but 
when the donor is cleaved from the fluorophore, fluorescence occurs. Intramolecular 
PeT occurs when one molecule comprises an electron donor as well as an acceptor 
fluorophore37-39. 
Activatable NIR fluorophores are applied for instance for sensing of proteases, where 
signals are generated as a result of lysosomal protease activity after probe 
internalization in cells1,4. Furthermore, activatable probes are used as substrates for 
bacterial ß-d-galactosidase (ß-gal), thereby enabling the measurement of ß-gal 
activity in vivo1,40-42. In addition, activatable NIR probes can be applied for sensing of 
metal ions, such as calcium, mercury, and zinc or for sensing of nitric oxide43 as well 
as oxygen44,45. NIR fluorescent lanthanide-based complexes (e.g. Tb3+ or Eu3+) exist 
that may be applied as markers of cellular stress43. Another wide application area for 
activatable dyes is sensing of pH. 
1.3. pH-sensing with fluorescence dyes 
Although the detection of changes in pH is well established on tumor cells in vitro46, 
pH sensing in vivo remains challenging. A change in pH is a characteristic of 
numerous diseases like inflammation or cancer. So far only few NIR-emitting pH-
sensitive probes exist, but most of the pH probes consist of fluorophores with spectra 
in the visible region1,38. pH-activatable NIRF probes can be divided in two groups. The 
first group comprises NIRF dyes coupled to target specific proteins in either a low dye 
to protein (DP) ratio, resulting in autoquenching7 or in a high DP ratio resulting in 
self-quenching by homo FRET8. Such probes are activated by enzymatic cleavage of 
fluorophores, e.g. by degradation in the lysosome, allowing spatial separation from 
each other47. The second group consists of norcyanine- or norsquarine-based NIR pH 
probes which have a protonatable amine group within the fluorophore core. Examples 
are modified ICG, H-ICG43,48 or Square-650-pH49, and also CypHer5E, applied in this 
study. Accordingly, such dyes are fluorescent when protonated in an acidic 
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environment but fluorescence is greatly reduced when non-protonated. Here, 
initiation of fluorescence is reversible, in contrast to activation via enzymatic 
cleavage of protein-fluorophore conjugates.  
pH-responsive protonatable dyes may improve the sensitivity of detection and 
monitoring of acidic tumors in vivo. Following intravenous (i.v.) injection, always-on 
fluorescent probes systematically distribute in the entire object causing high 
background signals. Moreover, the tumor is undetectable until the fluorophore has 
concentrated in the tumor and the unbound probe is cleared from the object (Figure 
2a). In contrast, pH-activatable dyes are non-fluorescent after application, thereby 
causing no background fluorescence of unbound probe and only become fluorescent 
in the acidic tumor environment, resulting in a high tumor contrast even before the 
unbound (non-fluorescent) probe is cleared from the object (Figure 2b).  
 
 
Figure 2. Improvement of tumor 
detection sensitivity by the use of pH-
activatable probes 
a. Always-on fluorescence probes cause 
high background signals from the unbound 
probe when applied in vivo. After a certain 
time, following the probe’s accumulation at 
the tumor, fluorescence intensity at the 
tumor site increases while background 
fluorescence decreases due to systemic 
clearance of the probe. Due to a certain 
amount of unbound fluorescent probe, the 
tumor to background ratio is low, 
especially at early time points after probe 
application. b. pH-activatable probes may 
avoid background fluorescence after 
application in vivo and only activate at the 
tumor site. This would result in an early 
detection of the fluorescent tumor even 
before the circulating probe is cleared from 
the organism, leading to a high tumor to 
background ratio. c. A mechanism of 
activation of pH-sensitive probes at the 
tumor site is internalization of tumor-
specific ligands via receptor-mediated 
endocytosis, exemplified here for Trastuzumab (Herceptin). Here, the conjugated pH-sensitive 
fluorophores are activated in the acidic pH of the late endosome and lysosome. Figure was taken from 




Activation of such pH-sensitive probes may also occur after internalization in the 
targeted tumor cell. This can be achieved, for example, by conjugation of the 
fluorophore to a tumor-specific antibody that binds to a receptor on the targeted 
tumor cell, followed by internalization of the antibody-conjugate receptor complex 
and localization in the endosomal and lysosomal compartments. There, the low pH of 
5 to 6 leads to activation of the dye, resulting in fluorescence (Figure 2c)38. 
1.3.1. CypHer5E for sensitive tumor imaging 
A promising candidate for in vivo imaging of tumors is the pH-activatable NIRF dye 
CypHer5 (1-(5-Carboxypentyl)-2-[1E,3E)-5-(3,3-Dimethyl-5-Sulfo-1,3-
Dihydro-2H-Indol-2-Vlidene)-1,3-Pentadienyl]-3,3-Dimethyl-3H 
Indolium-5-Sulfonate(V)). CypHer5 is a pentamethine cyanine (CyTM 5) dye 
derivative that increases its fluorescence intensity with decreasing pH. In addition, 
CypHer5 has a reactive functional group (hydroxyl succinimidyl ester) allowing 
covalent linking of proteins, like antibodies, via aliphatic amino groups. Coupling of 
CypHer5 to an antibody and thereby following internalization of G-protein-coupled 
receptor from the cell membrane into the endolysosomes was the first report of an 
application of a NIR pH probe39,43. 
CypHer5 has been further developed to CypHer5E enhanced pH-sensitive dye (4-{2-
[(1E,3E,5E)-5-(3-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexylis e-3-
methyl-5-sulfo-1,3 dihydro-2H-indol-2-ylidene)penta-1,3-dienyl]-3,3-
dimethyl-5-sulfo-3H-indolium-1yl}butane-1-sulfonate) which is also 
commercially available. In comparison to CypHer5, CypHer5E comprises a better 
extinction coefficient resulting in increased excitability as well as an improved 
solubility by additional sulfonate groups. The structure of CypHer5E is shown in 
Figure 3. This pH-sensitive dye is capable of fluorescence emission when protonated 
at the nitrogen atom in an acidic environment but non-fluorescent in a basic to 
neutral environment when the amine group in not protonated. This deprotonation 
leads to a shift in the absorption maximum of the dye at 645 nm and subsequently to 
a decrease in fluorescence (Figure 4). As CypHer5E has a pKa in vitro of 7.3, it is 
perfectly suitable for pH sensing in a biological environment. CypHer5E has already 
been shown to be functional in cell assays for studying phagocytosis50, for 
quantification of internalization of cellular target molecules51,52, and for monitoring of 
synaptic vesicle recycling53. Although CypHer5E, having NIR spectra, a good water 
solubility, and functional groups for bioconjugation, is a promising candidate for in 
vivo imaging of structures with a low pH, like a tumor, so far no reports have been 






Figure 3. Chemical structure of CypHer5E 
In a basic to neutral solution, where the nitrogen atom of CypHer5E is not protonated, the dye is not 
fluorescent. When protonated in an acidic environment, the chromophore system of a classic cyanine dye 






Figure 4. Absorption characteristics of CypHer5E at different pH 
CypHer5E has two absorption bands that peak in the range of 490 and 645 nm. Photon absorption around 
645 nm results in fluorescence emission with a peak intensity at 663 nm. The absorption band in the 
shorter wavelength region (~490 nm; not leading to fluorescence emission) increases with increasing pH 
of the PBS measurement solution, whereas the absorption band at longer wavelength (~645 nm) 





1.4. Nanoparticles as fluorescence probes  
Even though organic fluorophores compose the major group of fluorescence probes 
for in vivo applications they often suffer from limited sensitivity, a low fluorescence 
quantum yield, and low photostability. Moreover, organic dyes may form quenched 
aggregates and are sensitive to environmental changes in tissue or blood, influencing 
their spectroscopic properties. Furthermore, many of them possess a certain level of 
toxicity that hampers their application in vivo20.  
A promising possibility to generate fluorescent probes for in vivo applications is to 
enclose fluorophores in nanomaterials, such as polymeric nanoparticles (NPs), which 
can be generated from a number of materials in diverse compositions and labeled 
with various fluorophores. This has the benefit of improved stability of the 
fluorophores due to reduced interactions with the environment, e.g. with quenching 
agents, solvent molecules, or chemically reactive species55. In reverse, by 
enclosement in NPs, the environment can be protected against potentially toxic 
fluorophores. In most cases, enclosure in NPs does not alter the dye spectral 
characteristics, but it minimizes dye aggregation and subsequent dye quenching, and 
offers an improved photostability. As NPs are capable of carrying large numbers of 
fluorophores, very bright fluorescence probes can be produced, compared to a single 
dye molecule. NPs can further be applied for simultaneous imaging by different 
modalities, e.g. by generating NPs that are loaded with contrast agents for MRI and 
surface labeled with fluorescence dyes56,57.  
The core of NPs may be surrounded by a shell layer that insulates and protects the 
core and mediates solubility of NPs and/or linkage to bioligands58. NPs with many 
different configurations have been designed which, due to their large surface area 
can be easily modified with polymeric compounds such as polyethylene glycol (PEG) 
or various target-specific biomolecules, like peptides or antibodies, thereby creating 
highly fluorescent target-specific 3D probes for in vivo imaging59 (see Figure 5). 
Especially, PEGylation has a particular relevance as it can modify the 
pharmacokinetics of NPs by reducing their clearance through the mononuclear 
phagocytic system (MPS) and thereby not only increasing plasma half-lives of the 
NPs but also their stability and water solubility60-62. 
NPs of diverse compositions have been developed for imaging purposes. Most 
particles can be classified into two groups: NPs that are mostly composed of organic 
molecules, like dendrimers63,64, liposomes64,65, poly(lactic-co-glycolic acid) (PLGA)66, 
polystyrene (PS)67,68, or chitosan59,69. And those that mainly consist of inorganic 
materials, such as silica70, gold71, and semiconductor nanocristals, the so called 
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quantum dots (QDs) that comprise a core/shell structure, such as CdSe/ZnS, 
CdS/ZnS, or CdTe/ZnS72.  
 
 
Figure 5. Compositions and surface-
modifications of nanoparticles 
A. A scheme of NP components and possible 
configurations is shown. NPs can be 
composed of (i) a core directly surrounded 
by targeting biomolecules or (ii) surface 
ligands can be used to anchor the target 
molecules to the particle core. (iii) 
Biomolecules can also interact with a shell 
layer that surrounds the NP core or (iv) be 
anchored to the core/shell particle via 
intermediate ligands. On the other hand, (v) 
the targeting biomolecules can be located 
inside a porous NP core or (vi) be entrapped 
by a porous NP core surrounded by a shell 
layer. (vii) Furthermore, the NP core can be 
much smaller than the biomolecule and in 
addition (viii) be attached to the core by an 
intermediate ligand. B. A representative 
fluorophore-loaded NP, coated with a PEG 
layer is illustrated. Multiple target-specific 
molecules can be attached to the PEG chains 
in three dimensions. Specific targeting and 
detection of biomolecules by NPs may be 
achieved for instance via surface-conjugation 
with nucleic acids, target-specific small 
peptides, proteins, or antibodies. Figure was 
taken from Sapsford et al.58. 
 
 
The composition of the NPs should be selected according to the application purpose 
of the particle. NPs formulated from biodegradable substances, like liposomes are 
especially favorable for drug delivery and are already used as chemotherapeutic 
vehicles in different human tumors64. Such drug vehicles are advantageous as they 
especially enable the delivery of hydrophobic agents, like the anti-cancer drugs 
paclitaxel and docetaxel that are not soluble in aqueous environments64. In addition, 
other biodegradable NPs, composed of chitosan, gelatin, or PLGA are being 
investigated as non-viral gene-delivery systems73. On the other hand, the use of 
non-biodegradable NPs, like PS, may be advantageous for imaging purposes as 
enclosed fluorophores are prevented from release into the surrounding environment, 
where they could potentially cause unknown toxic effects. Instead they are excreted 
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from the body in the same composition as they were administered. Moreover, in the 
case of hydrophobic imaging agents, the incorporation in NPs enables these agents to 
be used in aqueous environments and consequently in vivo68.  
Despite the growing effort in the development of potent NPs for diagnosis and 
therapy of diseases, the biodistribution, behavior and risks of NPs in living organisms 
have to be examined further74. In particular, most NP formulations, such as QDs20, 
still suffer from potentially toxic effects or from a too rapid clearance from the body 
due to a low transport of relatively large particles across the endothelium and/or a 
rapid elimination of NPs by the MPS75.  
1.4.1. Polystyrene nanoparticles as potent imaging tools 
Polystyrene nanoparticles (PSNPs; Figure 6) are especially advantageous for in vivo 
imaging purposes, as they are commercially available in different sizes from 15 nm to 
several micrometers. Moreover, in general PSNPs are regarded to have no impact on 
the metabolic activity of cells and low levels of cytotoxicity. Nevertheless, as is the 
case for other NP formulations, this may depend on the used concentrations of NPs 
and incubation times, as well as on particle size, and surface charge76-79. A further 
advantage is that the loading of PSNPs with inorganic and organic fluorophores is well 
established, thereby enabling a simple and homogeneous production of bright 
fluorescent reporters for imaging applications68. As PSNPs are available with various 
surface chemistries, this further enables a simple and efficient modification of 
particles with target-specific biomolecules. 
 
 
Figure 6. Transmission electron microscopy image of 
100 nm PSNPs 
The morphology of 100 nm PSNPs is illustrated. Scale bar 







1.4.2. Highly fluorescent nanoparticles loaded with Itrybe 
A very promising dye for imaging applications in combination with NPs is the 
broadband fluorophore Itrybe. This hydrophobic asymmetric cyanine dye has a broad 
absorption (450 to 750 nm) and emission spectrum (650 to 900 nm) in the NIR 
region making it especially favorable for in vivo imaging. Furthermore, compared to 
other NIR fluorophores, Itrybe has a large Strokes shift which is the difference 
between the positions of the band maxima of the absorption and emission spectra. 
This enables a good separation of excitation and emission light, using appropriate 
filter combinations. Due to the broad spectra of Itrybe it is also possible to achieve a 
high compatibility of the dye with many different imaging devices equipped with 
various laser and/or filter settings. In contrast, most other NIR dyes are 
characterized by a narrow absorption- and emission spectrum and a considerably 
smaller Strokes shift as well as highly overlapping absorption- and emission spectra. 
In contrast to other NIR fluorophores, Itrybe, does also not form quenched 
aggregates at high concentrations, which otherwise could result in decreased 
fluorescence. This allows the loading of high amounts of Itrybe molecules into solid 
matrices, like PS, leading to a significantly higher brightness of these probes. A 
further advantage of this dye as a potent imaging tool in combination with NPs, is its 
outstanding thermal and photochemical stability (Thomas Behnke, BAM I.5, Berlin, 
personal communication). 
On these grounds, a patent application has been submitted by the BAM in Berlin 
together with the Max-Planck-Institute for Experimental Medicine and the University 
Medicine in Göttingen on the application of Itrybe in combination with NPs for 
imaging purposes (see list of publications). 
1.5. Specific targeting of tumors 
NIR fluorescence imaging offers an inexpensive and safe alternative to imaging 
methods like PET and SPECT which use potentially harmful, highly energetic 
radiation. Therefore, NIRF imaging provides an attractive tool for preclinical studies 
of tumor development and progression and/or evaluation of cancer therapies in 
animal models. As cancer is the leading cause of death worldwide80 there is a 
continuous need for the development of novel improved probes for an early detection 
and characterization of tumors as well as for a better understanding of cancer onset 
and progression. Cancer development is a multistep process during which cells 
acquire several capabilities, enabling them to become tumorigenic and finally 
malignant. One emerging hallmark of potential generality of cancer is reprogramming 
of energy metabolism which is needed to promote tumor cell growth and division81. 
 13 
Introduction 
The tumor microenvironment is known to be hypoxic, resulting from an inefficient 
perfusion due to a chaotic tumor vasculature. Under anaerobic conditions, cells favor 
glycolysis instead of energy production in the oxygen consuming mitochondria81. Otto 
Warburg first observed an abnormal behavior of energy metabolism in cancer cells, in 
that even in the presence of oxygen cancer cells can reprogram their energy 
metabolism to glycolysis82,83. The upregulation of glycolysis results in an increased 
acid production and subsequently in microenvironmental acidosis84. It is further 
known that the extracellular pH decreases with increasing tumor size and that 
gradients of interstitial pH exist in tumors. Moreover, the acidity can vary among 
different tumor types. For instance, the extracellular pH investigated in two breast 
cancer cell lines was determined to be 6.8 in MDA-MB-435 cells and 7.1 in MCF-7 
cells when grown in SCID mice to a comparable size85.  
The characteristic of an acidic environment, that most tumors possess, can be 
effectively used to increase tumor contrast by using pH-sensitive fluorescence probes 
that are selectively activated in the acidic tumor environment.    
1.5.1. The role of HER2 in cancer 
Imaging probes, such as free fluorophores or dye-loaded NPs, which are 
systematically applied in order to detect tumors, have to be functionalized to 
specifically bind to tumor associated antigens on cancer cells. Easily accessible target 
structures might be for example membrane-associated proteins, like receptors86, ion-
channels87, or cell-adhesion molecules, such as integrins2.  
In the case of breast cancer detection and monitoring, a well known biomarker is the 
human epithelial growth factor receptor 2 (HER2, also known as c-neu, Neu or ErbB-
2). HER2 is highly expressed on 25 to 30 % of all breast cancers88 but also in 10 to 
15 % of ovarian cancers89,90 and in 5 to 15 % of other tumor types like gastric, 
cervix, colon, oral, endometrial, esophageal, lung and pancreatic cancers91. 
Therefore, HER2 has become not only an interesting target structure for therapy, but 
due to its localization at the cell membrane, making it easily accessible by 
exogenously applied ligands, also an attractive marker for the diagnosis and 
monitoring of cancer.  
HER2 is a member of the EGFR superfamily, also known as the ErbB protein family 
that form dimers upon ligand stimulation leading to activation of downstream 
signaling cascades associated with cell growth, proliferation, survival, cell motility 
and angiogenesis91,92. HER2 is a 185 kDa transmembrane glycoprotein consisting of 
an extracellular binding domain, a transmembrane segment, and a tyrosine kinase 
domain with a regulatory carboxyl terminal segment91,93,94. In addition, a truncated 
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membrane-bound fragment of the HER2 protein, p95 exists that can be detected in 
breast tumors. p95 is generated after proteolytic cleavage of the extracellular domain 
of HER2 and is associated with an increased tyrosine kinase activity and thus an 
enhanced intracellular signaling95,96. An overexpression or amplification of HER2 
results in increased intracellular cell signaling, leading to a deregulation of cell 
proliferation and survival, which in turn may cause uncontrolled cell proliferation and 
subsequently malignancy91. The prolonged duration of intracellular signaling in HER2 
overexpressing cells is caused by a slowdown of the dissociation of ligand-receptor 
complexes which results in slower internalization of the complexes through clathrin-
coated pits and thereby slower degradation of the active receptors in lysosomes92. 
1.5.2. Targeting of HER2 by Herceptin 
Owing to its expression on the cell membrane of tumor cells, HER2 is an optimal 
target not only for therapy but also for tumor recognition. In this context a 
humanized monoclonal antibody, trastuzumab (Herceptin®, in the following referred 
to as Herceptin) was developed from the murine antibody 4D5. Herceptin was 
approved by the FDA in 1998 for treatment of patients with metastatic breast cancer 
overexpressing HER291. In heavily pretreated patients, Herceptin has a response rate 
of 10 to 15 % and in untreated patients of 25 %91. 
Herceptin is known to bind to the extracellular domain IV of HER285 and to induce 
formation of HER2 homodimers, leading to ligand-mediated endocytosis of the 
receptor and to a considerable removal of HER2 from the plasma membrane and 
subsequently to a decreased receptor-initiated constitutive signaling97. However, the 
mechanism by which Herceptin causes its antitumor effect in cancer cells is not 
entirely understood. Other mechanisms of Herceptin action may include suppression 
of angiogenesis98, sterical blocking of the proteolytic cleavage of the extracellular 
region of HER299, and disruption of  interaction of HER2 with other proteins99. 
Another hypothesis favors an immunological mechanism, where antibody dependent 
cellular cytotoxicity (ADCC) caused by Herceptin bound to the tumor cell results in 
tumor cell lysis98.  
As Herceptin is a very well evaluated and clinically proven antibody, it presents an 
attractive device for the detection and monitoring of breast tumors100. Therefore, 
Herceptin is an optimal ligand for the bioconjugation of novel fluorescence probes, 
like pH-activatable dyes and dye-loaded NPs, to be evaluated as novel probes for in 
vivo imaging of breast tumors. 
For the evaluation of tumor detection sensitivity of fluorescence probes tumor models 




orthotopic breast tumor model in this study as these cells are known to have an 
overamplification of the HER2 gene as well as a high HER2 protein expression101. 
Orthotopic MDA-MB-231 cell implantation was performed to obtain control tumors in 
nude mice that do not overexpress HER2102. Orthotopic breast tumor xenorafts in 
mice generated by KPL-4103 as well as by MDA-MB-231102 cells have already been 
shown to be suitable model organisms for the evaluation of Herceptin binding in vivo. 
Therefore, both tumor models were used in this study to investigate in vivo binding 
and biodistribution of Herceptin-conjuagted fluorescence probes. 
 
Aims of the study 
AIMS OF THE STUDY 
The aim of the work presented here was to characterize and to evaluate novel and 
innovative fluorescent probes regarding their suitability for fluorescence imaging in 
vivo, in order to improve tumor-detection sensitivity in breast tumor-bearing mice. 
For this purpose, 1.) a pH-sensitive NIR dye, CypHer5E and 2.) PSNPs loaded with a 
broadband NIR fluorophore, Itrybe, were investigated in orthotopic breast-tumor 
xenografts in nude mice. To achieve tumor targeting capacity, both probes were 
conjugated to Herceptin, in order to take advantage of the knowledge already 
available for the kinetics of the tumor targeting moiety Herceptin and thereby 
allowing me to focus on the behavior of the fluorescent labels. This is the first report 
of an in vivo imaging application and evaluation of CypHer5E as well as for Itrybe-
loaded PSNPs. 
The following issues will be addressed: 
1.)  The suitability of pH-activatable CypHer5E-Herceptin conjugates to improve 
 tumor- detection sensitivity in vivo in comparison to always-on fluorescence 
 conjugates, AlexaFluor 647-Herceptin 
a. The in vitro characterization of fluorescence probes upon the influence 
of different environmental factors 
 b. The functionality of pH-sensitive conjugates in vitro in cell based  
  assays 
 c. The capability of CypHer5E-Herceptin probes to improve tumor contrast 
  in vivo in KPL-4 and MDA-MB-231 breast tumor-bearing mice in  
  combination with two different techniques for suppression of   
  background fluorescence: subtraction of autofluorescence and   
  LT-gated imaging 
2.) The biodistribution of Itrybe-loaded PSNPs of distinct sizes (100, 25, and 15 
nm) and with different surface modifications (amino groups, PEG chains of 
different sizes, or Herceptin coupled to PEG chains) and their feasibility for 
application in in vivo imaging of breast tumors in mice   
 a. The spectroscopic characterization of Itrybe-loaded PSNPs and  
  the influence of environmental factors on fluorescence of the probes 
b. The binding of Herceptin-modified NPs to HER2 in immuno- and cell-
based assays 
 c. The influences of NPs on cell viability  
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 d. The biodistribution of probes in vivo and ex vivo  
 e. The tumor-targeting capacity of PSNPs in KPL-4 and MDA-MB-231  
  breast-tumor bearing mice in vivo and ex vivo   
 
The results of this study will contribute to an improved knowledge about the 
characteristics of pH-sensitive probes and Itybe-loaded NPs and their suitability for 
application in non-invasive detection of breast tumors.  
Material and Methods 
2. MATERIAL AND METHODS  
2.1. Material 
2.1.1. Equipment 
Analytical balance, Competence CP64  Sartorius, Göttingen 
Anesthesia system     VisualSonics, Toronto, Ontario,  
        Canada 
Apparatus for tissue processing, TP 1020  Leica, Bensheim 
Camera, EOS 1000D     Canon, Krefeld   
Centrifuge 5810     Eppendorf, Hamburg 
Chemi-Doc luminescence detection system Bio-Rad, Munich 
Centrifuge 5424     Eppendorf, Hamburg 
Cryostat, Jung Frigocut 2800E    Leica, Bensheim 
Extrudate 1439      Altromin, Lage 
Fluorescence microscope, Axiovert 200M   Carl Zeiss, Göttingen 
Incubator, Heraeus BB6220    Kendro, Laboratory products, Hanau 
LightCycler 480      Roche, Mannheim 
Light microscope, Axioscope 2    Carl Zeiss, Göttingen  
Light microscope, Telaval 31   Carl Zeiss, Göttingen  
Microtome HM 340E      Thermo Scientific, Braunschweig 
Nano photometer, Pearl    Implen, Munich 
Neubauer counting chamber    Schütt Labortechnik, Göttingen 
Odyssey infrared imaging system   Li-Cor Biosciences, Bad Homburg 
Optix MX2       ART, Montreal, Canada 
ORCA-ER digital camera     Hamamatsu, Herrsching am  
        Ammersee  
pH-meter, SevenEasy    Mettler-Toledo, Giessen 
Quartz glass precision cuvette   Helma, Müllheim 
Scantainer       Scanbur, Koge, Denmark  
Spectrofluorometer, QuantaMaster   Photon Technology International,  
        Seefeld 
Staining cuvette     VWR International, Ismaning 
Steamer, MultiGourmet    Braun, Kronberg 
Thermomixer compact    Eppendorf, Hamburg 
Tissue lyzer      Qiagen, Hilden 
Ultrasonic cleaner     Schütt Labortechnik, Göttingen 
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Vortexer, Vortex Genie 2    Bender & Hobein,Zurich,   
        Switzerland 
Wallac 1420 Victor 2 multilabel counter  American Instrument Exchange,  
        Haverhill, MA,    USA 
2.1.2. Consumable supplies 
Cell culture flasks      Sarstedt, Nümbrecht 
Chambered coverglasses, 4 well   Nalge Nunc International,   
        Rochester, NY, USA 
Cover glasses 12 mm Ø     Thermo Scientific, Bonn 
Cryotube vials      Nunc, Roskilde, Denmark 
Culture dishes      Sarstedt, Nümbrecht 
Culture plates 24-wells, 96-wells   Greiner Bio-One, Solingen 
Falcontubes 15 ml, 50 ml     BD, Heidelberg 
Filter tips, 10 µl, 100 µl, 1000 µl    Sarstedt, Nümbrecht 
Insulin syringes with integrated needle  Braun, Melsungen  
 (30G x ½)  
Insulin syringes with integrated needle  BD, Heidelberg  
 (30G) 
Insulin syringes, Omnifix 40 solo   Braun, Melsungen  
Microscope slides     Paul Marienfeld, Lauda-Königshofen 
Needles, Sterican, 26G x ½    Braun, Melsungen  
Hybridization transfer membranes   Amersham/GE Healthcare, Munich  
Nunc-Immuno modules, maxisorp loose  Nunc A/S, Roskilde, Denmark 
NuPAGE Novex 3-8 % TRIS-acetate gels  Invitrogen, Darmstadt  
Pasteurpipettes      Sarstedt, Nümbrecht 
Permanox cell culture slides    Nalge Nunc International, Naper  
        Ville, IL, USA  
Serological pipettes 5 ml, 10 ml    Greiner Bio-One, Solingen 
Serological pipettes 25 ml    Corning Incorporated, Corning, NY, 
        USA 
Surgical suture materials, absorbable,   Johnson & Johnson, Neuss 
 Vicryl, 4/0  
Tissue Tek cassettes     Vogel, Giessen   
2.1.3. Chemicals and reagents  
ABTS single solution     Invitrogen, Darmstadt 
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AEC peroxidase substrate    Vector, Peterborough, United  
        Kingdom 
Antibody diluent     Dako, Hamburg 
Aquatex, aqueous mounting medium  Merck, Darmstadt 
Blocking buffer – fish    SurModics, Eden Prairie, MN, USA 
BSA       Sigma-Aldrich, Seelze   
Casein       Roche, Mannheim 
Chemiluminescent HRP substrate    Millipore, Billerica, MA, USA 
Chloroform      Merck, Darmstadt 
Coomassie R250      Biomol, Hamburg 
DEPC       Sigma-Aldrich, Seelze 
DePex, hydrophobic mounting medium  Serva, Heidelberg 
DMEM       Gibco, Invitrogen, Darmstadt 
DPBS       Gibco, Invitrogen, Darmstadt 
EDTA       Sigma-Aldrich, Seelze 
Eosin G        Merck, Darmstadt 
Ethanol       Merck, Darmstadt  
FCS         PAN Systems, Aidenbach 
Formaldehyde      Merck, Darmstadt 
GLP Nafag feed 890      Provimi Kliba AG, Kaiseraugst 
Goat serum      Gibco, Invitrogen, Darmstadt 
Haematoxylin      Merck, Darmstadt 
HEPES       Carl Roth, Karlsruhe 
Hoechst 33342 trihydrochloride,   Invitrogen, Darmstadt 
 trihydrate 
Hydrochloric acid, 37%    Merck, Darmstadt 
Hydrogen peroxid     Sigma-Aldrich, Seelze 
Fluorescent mounting medium   Merck, Darmstadt 
 containing DAPI  
Isoflurane       Baxter, Unterschleißheim 
Ketamine 10%     Medistar, Holzwickede 
LDS sample buffer     Invitrogen, Darmstadt 
NuPAGE Antioxidant     Invitrogen, Darmstadt 
Paraffin (TM 60 °C)     Süsse, Guxhagen 
PBS tablets      Gibco, Invitrogen, Darmstadt 
Poly-L-lysine      Sigma-Aldrich, Seelze 
Precision Plus protein standard     BIO-RAD Laboratories, Munich 
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ProLong gold antifade reagent     Invitrogen, Darmstadt 
 with DAPI 
Protease inhibitor cocktail     Roche, Mannheim 
QIAzol lysis reagent     Qiagen, Hilden 
Reducing agent      Invitrogen, Darmstadt 
Regime 210, U8959A01R     Scientific Animal Food and   
        Engineering, Augy, France 
Sodium chloride      Merck, Darmstadt 
Sodium chloride, isotone, 0.9%   Braun, Melsungen   
Sodium hydroxide      Merck, Darmstadt 
Target retrieval solution    Dako, Hamburg 
TRIS        Sigma-Aldrich, Seelze  
TRIS-acetate SDS running buffer   Invitrogen, Darmstadt 
Triton X-100      Sigma-Aldrich, Seelze 
Tween 20      Sigma-Aldrich, Seelze  
Western blot stripping buffer   Thermo Scientific, Bonn 
WST-1 cell proliferation reagent   Clontech, Mountain View, CA, USA 
Xylazine 2%      Riemser, Greifswald 
Xylol        Merck, Darmstadt 
2.1.4. Kits  
BCA protein assay kit    Thermo Scientific, Bonn   
Mycoplasma PlusTM PCR primer set  Agilent Technologies, Waldbronn 
Ready-to-use hot-start PCR master mix  Roche, Mannheim 
RNase-free DNase set    Qiagen, Hilden 
RNeasy mini kit     Qiagen, Hilden 
SuperScript first-strand synthesis system  Invitrogen, Darmstadt 
 for RT-PCR 
2.1.5. Probes  
substance application provider 
Itrybe-loaded NPs fluorescence imaging BAM I.5, Berlin 
CypHer5E fluorescence imaging GE Healthcare, Munich 
Alexa Fluor 647 fluorescence imaging Invitrogen, Darmstadt 
humanized anti-HER2 IgG, 
Herceptin (Trastuzumab) 
tumor targeting Roche Diagnostics, Mannheim 
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substance application provider 
rabbit anti-HER2 IgG,      
Neu (C-18): sc-284 Western blot Santa Cruz, Heidelberg 
goat anti-actin IgG,       
(C-11): sc-1615 Western blot Santa Cruz, Heidelberg 
donkey anti-rabbit IgG, 
HRP-labeled: NA934 Western blot GE Healthcare, Munich 
rabbit anti-goat IgG, HRP-
labeled: 172-1034 Western blot 
BIO-RAD Laboratories, 
Munich 
HER2 extracellular domain 
(ECD) protein immunoassay 
Roche Diagnostics, 
Mannheim 
rat anti-mouse CD31 IgG: 
DIA 310 M immunohistology Dianova, Hamburg 
goat anti-rat IgG, HRP 





Trypsine-EDTA (0.25 %)    PAA Laboratories, Pasching, A  
DNase I      Qiagen, Hilden 
RNase H      Invitrogen, Darmstadt 
Super Script II RT     Invitrogen, Darmstadt 
Uracil-DNA-glycosylase    New England BioLabs, Frankfurt  
        am Main 
2.1.7. Eukaryotic cell lines 
 KPL-4, provided by J. Kurebayashi, Department of Breast and Thyroid 
Surgery, Kawasaki Medical School, Kurashiki, Japan 
Human breast cancer cell line, isolated from the malignant pleural effusion of a 
breast cancer patient with an inflammatory skin metastasis101. 
 
 MDA-MB-231, American type culture collection (ATCC)/LGC, Wesel 
Human breast cancer cell line, adenocarcinoma from the mammary gland derived 
from a metastatic pleural effusion.  
 
 3T3, Swiss albino mouse fibroblasts, Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DMSZ), Braunschweig 
Fibroblasts, established from disaggregated Swiss albino mouse embryos. 
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2.1.8. Animals 
Female athymic nude mice, strain NMRI-Fox1nu/nu, Central Institution of Animal 
Experiments of the University Medicine, Göttingen. 
2.1.9.  Application specific computer programs 
Program:      Used for: 
Application Software, Version 2.1   Odyssey infrared imaging system 
AxioVision Rel.4.6     Axiovert 200M fluorescence  
        microscope 
FeliX32 Analysis 1.0     Spectroflourometer QuantaMaster 
Image 1.42l104      Image processing 
LightCycler 480 Software 1.5   LightCycler 480 
OptiView 1.00.00, ART, Montreal, Canada  Optix MX2 in vivo imaging system  
Quantity One 4.6.2     Chemi-doc luminescence detection 
        system 
Wallac 1420 Manager, Version 2.0   Victor 2 multilabel counter  
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2.2. Methods 
2.2.1. Molecular Biology  
2.2.1.1. Total RNA isolation and cDNA synthesis 
Purification of RNA from cells: 
RNA from cells was isolated via use of RNeasy mini kit according to the instruction 
manual. Briefly, cells (~1 x 106) were disrupted in buffer containing guanidine 
isothiocyanate and homogenized. Ethanol was then added to the lysate to bind RNA 
to the RNeasy silica-gel membrane and contaminants were washed away. DNase 
treatment was performed to eliminate genomic DNA (according to the instruction 
manual). After wash steps, the RNA was eluted in 30 µl RNase-free 
diethylpyrocarbonat (DEPC) water. 
Purification of RNA from tumor tissue: 
RNA from tumor tissue was isolated via phenol-chloroform extraction in combination 
with use of RNeasy mini kit. Tumor tissue (< 100 mg) was homogenized with 1 ml 
QIA-zol lysis reagent containing phenol and guanidine thiocyanate using a tissue 
lyzer. 200 µl chloroform was added and samples were vortexed and incubated for 5 
min at room temperature (RT).  After 15 min of centrifugation at 12,000 x g at 4 °C 
the aqueous phase was transferred in a new cup, supplemented with 600 µl 70 % 
ethanol and vortexed. The suspension was transferred to a RNeasy mini spin column 
and centrifuged at maximal speed for 15 sec. Total RNA bound to the membrane and 
contaminants were washed away. DNase treatment and elution of RNA was 
performed as described above.  
cDNA synthesis: 
cDNA synthesis for reverse transcriptase-polymerase chain reaction (RT-PCR)  was 
performed with the SuperScript first-strand synthesis system. cDNA was synthesized 
from 2.5 μg of total RNA upon addition of 0.5 μg oligo (dT) and DEPC-water to advice 
a RNA concentration of 0.2 μg/μl in a volume of 12 μl. At each step the samples were 
mixed by vortexing and collected by brief centrifugations. The reaction mixture was 
heated at 70 °C for 10 min and rapidly cooled on ice for 1 min. Subsequently 
reaction buffer was added containing: 2 μl of reverse transcriptase buffer, 2 μl MgCl2 
25 mM, 2 μl of dithiothreitol (DTT) 0.1 M and 1 μl of dNTPs 10 mM. The reaction 
mixture was heated for 5 min at 42 °C. The negative samples were supplemented 
with 1 μl of DEPC-water, whereas to the positive samples 200 units of reverse 
transcriptase enzyme were added. Probes were incubated for 50 min at 42 °C 
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following inactivation of the reverse transcriptase at 70 °C for 15 min. To degrade 
RNA present in the samples 2 units of RNase H were incubated with the mixture for 
20 min at 37 °C. At the end of the procedure the mixture was diluted with DEPC-
water to advice a reaction volume of 25 μl with a final cDNA concentration of 0.1 
μg/μl.  
RNA and cDNA concentration and purity were determined by optical density 
measurements at 260 and 280 nm using the spectrofluorometer. 
2.2.1.2. Quantitative real-time PCR 
Real-time PCR was performed using the TaqMan system in the LightCycler 480. 
Primers and probes were chosen from the Universal Probe Library from Roche105. The 
TaqMan probes contain a reporter dye fluorescein amidite (FAM) at the 5´end of the 
probe and a Dark Quencher Dye at the 3´end of the probe. When cleaved by the Taq 
DNA polymerase during PCR the reporter and quencher dye of the probe are 
separated, resulting in fluorescence of the reporter. For analyzing the mRNA 
expression of the human epidermal growth factor receptor 2 (hHER2) and human 
transferrin receptor type 1 (hTfR), used to control for RNA integrity and 
quantification, the following primers and probes were used: 
Primer     Sequence 
hTfR forward    5’-TTG AGA AAA CAA TGC AAA ATG TG-3’ 
hTfR reverse    5’-CCC AGT TGC TGT CCT GAT ATA GA-3’ 
TaqMan probe # 61   5’-FAM CTG GGC AA Dark Quencher Dye-3’ 
hHER2 forward   5‘-CAA GTA ATC CGG GGA CGA A-3‘ 
hHER2 reverse   5’-CAC TGC CCA GTT CCC TCA-3’ 
TaqMan probe # 23   5’-FAM GGG CTG GG Dark Quencher Dye-3’ 
 
Real-time PCR was performed with 100 ng cDNA, 200 nM forward and reverse 
primer, 100 nM TaqMan probe, 0.2 U Uracil-DNA-glycosylase, and a ready-to-use 
hot-start PCR mix containing Taq DNA polymerase, dNTP mix, as well as buffer and 
MgCl2.  
PCR conditions were:  
2 min 50 °C; 10 min 95 °C; (10 sec 95 °C; 30 sec 60 °C; and 10 sec 40 °C) x 45 
cycles. The number of PCR cycles to reach cycle threshold (Ct) was used to 
determine the relative mRNA expression. The results were standardized to the 
amount of hTfR in the respective probe and to the amount of mRNA expression in the 
calibrator (human brain RNA).  
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For this purpose the ∆∆Ct-Method was applied:  
 
Normalized ratio: 2 ∆Ct1 / 2 ∆Ct2 
 
∆Ct1 = Ct hHER2 (calibrator) – Ct hHER2 (sample) 
∆Ct2 = Ct hTfR (calibrator) – Ct hTfR (sample) 
 
2.2.2. Protein extraction, protein separation on protein gel,     
and Western blot 
2.2.2.1. Protein extraction 
To obtain cell lysates, cell cultures were detached from the dish as described in 
2.2.5.1, transferred to a 15 ml falcon tube, washed twice with PBS, and resuspended 
in 3 ml of lysis buffer. After 30 min of incubation at RT, cell debris were centrifuged 
for 15 min at 18,000 g at 4 °C and the supernatant was used as total cell extract. 
 Lysis buffer:  
50 mM trishydroxymethylaminomethane (TRIS)-HCl, pH 7.4  
300 mM NaCl  
5 mM ethylene-diamine-tetraacetic acid (EDTA)  
1% Triton X-100  
Protease inhibitor cocktail (1 tablet for 25 ml)  
2.2.2.2. BCA protein assay 
Protein concentration was determined using the bicinchoninic acid (BCA) protein 
assay kit that employs bovine serum-albumin (BSA) as a standard curve. The 
samples (triplicates) in a volume of 25 μl were incubated for 30 min at 37 °C 
together with the BCA reagent, composed by solution A (sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 
solution B (4 % cupric sulfate). Absorbance was measured in the Wallac 1420 Victor 
2 multilabel counter at 550 nm. 
2.2.2.3. SDS-PAGE  
50 µg of total protein extract per sample were separated on a gradient SDS-PAGE 
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) NuPAGE Novex TRIS-
acetate 3-8 % gel, according to the instruction manual. Depending on the application 
the SDS-gels were either used for western blot analysis or stained with Coomassie 
for protein detection. 
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2.2.2.4. Western blot analysis 
For Western blot analysis the proteins were transferred to nitrocellulose hybridization 
transfer membranes. Membranes were blocked for 1 h with 0.1 % casein in TRIS 
buffer containing Tween-20 (TBST) buffer, incubated with rabbit anti-HER2 antibody 
(1:200 dilution) in 0.1 % casein for 1 h, washed with deionized water for 7 times and 
then incubated in TBST buffer for 5 min. Following, the membranes were incubated 
with horseradish peroxidase (HRP)-coupled donkey anti-rabbit antibody (1:8000 
dilution) for 1 h. After washing, the bound antibody was visualized using 
chemiluminescent HRP substrate. Signals were detected in a Chemi-Doc 
luminescence detection system. To verify equal amounts of proteins in each loaded 
sample, the membranes were stained afterwards with anti-actin antibody. For this 
purpose, the membranes were stripped by incubation in stripping buffer at 37 °C for 
20 min and washed and blocked as described above. The primary goat anti-actin 
antibody was used at a 1:200 dilution and the HRP-coupled rabbit anti-goat antibody 
was used at a 1:8000 dilution. 
 TBST buffer: 
140 mM NaCl 
20 mM TRIS-HCl, pH 7.5 
0.05% Tween-20 
2.2.3. Fluorescence probes 
In the following we analyzed properties and characteristics of activatable and always-
on fluorescence probes as well as of the fluorophore, Itrybe encapsulated in 
functionalized NPs, in combination with the tumor specific antibody Herceptin.  
2.2.3.1. General information 
The fluorescence spectra of the pH-sensitive hydrophilic fluorescence dye, CypHer5E  
can be seen in Figure 7 (left). The quantum yield of CypHer5E in PBS is 0.26 at a pH 
of 7.8 and 0.27 at a pH of 5.3 (experiments performed by Jutta Pauli, BAM I.5, 
Berlin). CypHer5E in its hydrolyzed form has a molecular weight of 751 g/mol. 
The fluorescence spectra of the hydrophilic fluorescence dye Alexa Fluor 647 are 
depicted in Figure 7 (right). The quantum yield of the dye in PBS is 0.33 and the LT 
in water is 1.0 ns106. Alexa Fluor 647 in its hydrolyzed form has a molecular weight of 
~1200 g/mol.  
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Figure 7. Normalized spectrum of wavelength of CypHer5E and Alexa Fluor 647  
CypHer5E has an absorption maximum at 645 nm and an emission maximum at 663 nm. Alexa Fluor 647 
has similar spectra with an absorption maximum at 650 nm and an emission maximum at 670 nm. 
Spectra were taken from GE website (left)54 and Invitrogen website (right)106 and were modified. 
 
The hydrophobic asymmetric cyanine dye Itrybe has an absorption maximum at 
~590 nm and an emission maximum at ~750 nm. The quantum yield is 0.23 in 
ethanol.  
2.2.3.2. Coupling of Herceptin antibodies to fluorescence dyes 
Herceptin was coupled to the near-infrared fluorescence (NIRF) dyes, CypHer5E or 
Alexa Fluor 647, via their succinimidyl ester. Coupling resulted in conjugates with 
different dye to protein (DP) ratios of 0.5 to 6.4 dye molecules per antibody. 
Coupling was performed by Squarix Biotechnology GmbH, Marl. Purification was done 
via gel chromatography followed by a preparative gel filtration. DP ratios were 
determined photometrically by Jutta Pauli from the Bundesanstalt für 
Materialforschung und -Prüfung (BAM) I.5, Berlin. 
2.2.3.3. Modification of NPs 
Loading of polystyrene nanoparticles (PSNPs)68 with Itrybe as well as surface 
modification with polyethylene glycol (PEG) and Herceptin107 were performed by 
Thomas Behnke, BAM I.5, Berlin. A scheme of surface-modified nanoparticles (NPs) 
is shown in Figure 8. For surface modification 500 nmol PEG was added to the 
reaction solution per 1 mg polystyrene (PS). For bioconjugation in a second step 0.48 
nmol Herceptin was added per mg PEGylated PS.  
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Figure 8. Schematic illustration of surface-modified PSNPs  
PEG chains were coupled to Itrybe-loaded PSNPs via surface amino groups (NH2). Thiolated Herceptin 
antibodies were coupled to PEG via its maleimid group in a Michael-Addition107. Figure was modified from 
Steinhauser et al.107. 
 
The amounts of PSNPs used in this study are given as mg PS. Therefore, the number 
of particles per mg PS as well as the surface area are listed for different NP sizes in 
Table 1.  
 
Table 1. Characteristics of Itrybe-loaded PSNPs  
size 15 nm 25 nm 100 nm 
Itrybe molecules/ 
NP 10 46 3100 
NPs/mg PS [1/mg] 5.4 x 1014 1.2 x 1014 1.8 x 1012 
relative amount: 
NPs/mg PS*  296 64 1 
surface area/       
mg PS [m2/mg] 0.38 0.23 0.06 
(Calculations were performed by Thomas Behnke, BAM I.5., Berlin.) 
* relative to 100 nm NPs 
 
Itrybe-loaded NPs of distinct sizes and surface modifications were analyzed in this 
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Table 2. Itrybe-loaded NPs of different sizes and surface modifications 
NP size surface group 
PEG chain 
size antibody abbreviation 
100 nm NH2 - - 100 nm-NH2 
100 nm NH2 1.5 kDa - 100 nm-PEG 1.5 kDa 
100 nm NH2 1.5 kDa Herceptin 100 nm-PEG 1.5 kDa-Her 




100 nm-PEG 1.5 kDa-HER x2 
100 nm NH2 10 kDa Herceptin 100 nm-PEG 10 kDa-Her 
25 nm NH2 - - 25 nm-NH2 
25 nm NH2 1.5 kDa - 25 nm-PEG 1.5 kDa 
25 nm NH2 1.5 kDa Herceptin 25 nm-PEG 1.5 kDa-Her 




25 nm-PEG 1.5 kDa-Her x5 
25 nm NH2 10 kDa - 25 nm-PEG 10 kDa 
25 nm NH2 10 kDa Herceptin 25 nm-PEG 10 kDa-Her 
15 nm NH2 - - 15 nm-NH2 
15 nm NH2 10 kDa - 15 nm-PEG 10 kDa 




15 nm-PEG 10 kDa-Her x5 




15 nm-PEG 1.5 kDa-Her x5 
15 nm NH2 
1/10 





15 nm-PEG 1.5 kDa-1/10-Her x5  
* X/X amount and X-fold amount refers to variations in the amount of PEG (500 nmol/mg PS) or Herceptin 
(0.48 nmol/mg PS) used for coupling procedure.  
 
The amount of Herecptin that was successfully coupled to the surface of 100 nm 
particles was determined in a BCA assay following measurement of absorption 
spectra and correction for absorbance by Itrybe and scattering of the particles. 
Experiments were performed by Thomas Behnke, BAM I.5, Berlin. Table 3 shows the 
amount of Herceptin molecules per 100 nm NP used in this study. 
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Table 3. Number of Herceptin molecules successfully coupled on NPs 
probe Herceptin molecules/ NP 
Herceptin molecules/ 
mg PS 
100 nm-PEG 1.5 kDa-Her ~70 1.3 x 1014 
100 nm-PEG 1.5 kDa-Her x2 ~100 1.8 x 1014 
100 nm-PEG 10 kDa-Her, 
probe 1* 
~10 1.8 x 1013 
100 nm-PEG 10 kDa-Her, 
probe 2* 
~10 1.8 x 1013 
* probe 1 and 2 refers to two independently produced probes.  
 
2.2.3.4. Spectroscopic analysis 
Fluorescence conjugates: 
As dyes were coupled to Herceptin at different DP ratios, the amount of pH-Her and 
Alexa-Her used in the study always refers to the amount of Immunoglobulin G (IgG) 
in the respective conjugates. Fluorescence emission spectra of CypHer5E-Herceptin 
(in the following referred to as pH-Her) and Alexa Fluor 647-Herceptin (in the 
following referred to as Alexa-Her) conjugates were measured in a concentration of 5 
µg IgG in 75 µl phosphate buffered saline (PBS; 0.07 g/l). In order to evaluate the 
influence of pH-changes on fluorescence intensity of the conjugates they were 
measured in a solution with a pH of 7.5 and 5.5. The pH of PBS was adjusted with 1 
M NaOH and 1 M HCl solution and pH values were controlled again after addition of 
fluorescence probes and adjusted again to the respective value if necessary. 
Itrybe-loaded NPs: 
Excitation and emission spectra of Itrybe-loaded NPs with different surface-
modifications and sizes were recorded. For this purpose 0.5 g/l of 100 nm and 25 nm 
NPs and 2 g/l of 15 nm NPs were measured in 75 µl H2O.  
Measurements were performed in a spectrofluorometer. The settings used for 
recording of spectra are listed in section 2.2.7.5. 
2.2.3.5. In vitro determination of fluorescence intensities 
Fluorescence intensities of Itrybe-loaded NPs were measured to analyze influences of 
the environment on fluorescence of NPs. Itrybe-loaded NPs were measured in PBS or 
PBS containing 5 % BSA with a pH of 7.5 and 5.5, respectively.  The pH value of the 
solutions was adjusted as described in 2.2.3.4. For measurement 0.25 g/l of 100 nm 
and 25 nm and 0.5 g/l of 15 nm NPs in 150 µl of the respective solution were placed 
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in 96-well plates. Measurements were done in the Optix MX2 as described in section 
2.2.7.8.  
2.2.3.6. In vitro determination of fluorescence lifetimes 
Fluorescence lifetime (LT) analyses were performed in vitro in order to identify 
probe-derived signals in vivo according to their LT. LTs of the fluorescence 
conjugates pH-Her and Alexa-Her as well as of the respective free, hydrolyzed 
fluorescence dyes (in the following referred to as pH-OH and Alexa-OH) were 
determined in PBS or PBS containing 5 % BSA with a pH of 7.5 and 5.5, respectively. 
The pH of the solutions was adjusted as described in section 2.2.3.4. For 
measurement 3 µg (0.02 g/l) IgG or 0.03 nmol (0.2 mM) free dye in 150 µl of the 
respective solution were placed in 96-well plates. Measurements were performed in 
the Optix MX2 as described in section 2.2.7.8. 
2.2.4. Immunological methods 
2.2.4.1. Immunoassays 
Functionality of Herceptin after surface-conjugation to Itrybe-loaded NPs was 
evaluated via immunoassays. Here, specific binding to antigen-coated plates was 
analyzed and compared to the unspecific binding to uncoated plates and to binding of 
non-Herceptin-modified NPs. The extracellular domain of HER2, in the following 
referred to as HER2 antigen, was used as antigen. 
All steps of the immunoassay were performed at RT. 96-well plates were either 
coated over night with 2.5 g/l HER2 antigen in 70 µl TRIS buffered saline (TBS) 
buffer or treated only with TBS buffer. Unspecific binding sites were blocked with 3 % 
BSA in TBS for 1h. NP-probes were added to the wells at different concentrations 
(from 0.02 to 2 g/l) in 70 µl TBS buffer. For competitive binding experiments a 
mixture of 14 µg Herceptin-labeled NP probe (0.2 g/l) and increasing amounts of free 
Herceptin (0.005 to 1 µg) in 70 µl TBS were added per well. Probes were incubated 
for 2 h. After three washing steps with TBST buffer (see section 2.2.2.4) the wells 
were covered with 100 µl TBS buffer and fluorescence was directly measured in the 
Odyssey infrared imaging system.  
 TBS buffer: 
140 mM NaCl 
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2.2.5. Cell biological methods 
2.2.5.1. Cell culture conditions 
Cultivation: 
KPL-4, MDA-MB-231, and 3T3 cells were propagated in standard Dulbecco's Modified 
Eagle's Medium (DMEM) containing 4.5 g/l glucose and L-glutamine. The medium 
was supplemented with 10 % fetal calf serum (FCS). Cells were cultivated under 
standard cell culture conditions at 37 °C in a humidified atmosphere under 5 % CO2 
in an incubator and grown up to about 80 % confluency.  
For sub-cultivation medium was removed from the cells, cells were washed twice 
with sterile Dulbecco's Phosphate Buffered Saline (DPBS), and treated with 0.05 % 
trypsine-EDTA solution until they had detached from the dish. The enzyme was 
inhibited by addition of medium in which the cells were subsequently resuspended. 
When necessary, cells were counted in a Neubauer counting chamber and plated in 
the desired concentration.  
Cryoconservation: 
For cryoconservation eukaryotic cells were detached as described, centrifuged (1,200 
x g for 2 min at RT), resuspended in freezing medium (1-5 x 106 cells/ml) and 
aliquoted into storage vials. Vials were placed in an insulated box in a -80 °C freezer 
overnight and finally stored in liquid nitrogen. 
 Freezing medium: 
90 % FCS 
10 %  dimethyl sulfoxide (DMSO) 
Revitalization: 
For revitalization cryoconserved cells were quickly thawed in a 37 °C water bath after 
being removed from liquid nitrogen. Then, cells were pipetted in pre-warmed 
medium and centrifuged (1,200 x g for 2 min at RT). The medium was removed from 
the cells and cells were resuspended in medium and then placed into a flask 
containing medium.  
Mycoplasma test: 
Mycoplasma contamination may cause adverse effects, such as changes in 
metabolism, growth rate, viability, DNA, RNA and protein synthesis, morphology etc., 
which lead to unreliable experimental results. Therefore, cell cultures were regularly 
tested for the presence of mycoplasma using Mycoplasma Plus PCR Primer Set 
according to the manufacturer’s instructions. 
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2.2.5.2. Incubation of cells with fluorescence probes 
Fluorescence conjugates: 
To ensure better attachment of KPL-4 and MDA-MB-231 breast cancer cells to 4-well 
chambered coverglasses, they were covered with sterile poly-L-lysine solution (0.1 
g/l). After 3 h incubation at 37 °C, coverslips were washed several times with sterile 
PBS, and used for seeding of cells. 48 h prior to incubation with fluorescence probes 
cells were seeded at a density of 2 x 104 KPL-4 cells and of 1.2 x 104 MDA-MB-231 
cells per well in 500 µl DMEM. After 48 h the medium was removed and cells were 
washed once with PBS. Cells were supplemented with 500 µl DMEM and 0.1 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer containing 5 µg 
fluorescence conjugates or 0.2 nmol of the free fluorescence dyes (corresponding to 
the amount of dye in 5 µg conjugate with a DP ratio of 6) and incubated for 8 h at 37 
°C. In order to analyze signals deriving from membrane bound conjugates, probes 
were also incubated with the cells for 8 h at 4 °C where internalization should be 
strongly reduced5. Afterwards, the medium was removed and the cells were washed 
several times with PBS to remove unbound substances. Subsequently, cells were 
incubated with 1 µg Hoechst 33342 in 500 µl PBS (2 mg/l) for 10 min in order to 
stain the nuclei of living cells. Hoechst solution was removed and cells were covered 
with 500 µl PBS and directly used for fluorescence microscopy. The settings used for 
detection of fluorophores are listed in section 2.2.7.7. 
Itrybe-loaded NPs: 
Adherent breast cancer cells were seeded on poly-L-lysine-coated cover slips (treated 
as described above) in 24-well chambers 48 h prior to incubation with Itrybe-loaded 
NPs. KPL-4 cells were seeded at a density of 3 x 104 cells and MDA-MB-231 cells 
were seeded at a density of 1.8 x 104 cells per well in 500 µl DMEM. After 48 h the 
medium was removed and cells were washed once with PBS and supplemented with 
500 µl DMEM and 0.1 M HEPES buffer containing NPs at a concentration of 1 g/l. The 
cells were incubated for different time periods (30 min to 5 h) at 37 °C and 4 °C. 
Afterwards, the medium was removed and the cells were washed 3 times with PBS to 
remove unbound substances. Subsequently, cells were fixed with 4 % formaldehyde 
in PBS for 10 min on ice and then washed 3 times with PBS again. The cells were 
mounted with an antifade reagent supplemented with 4',6-diamidino-2-phenylindole 
(DAPI) for counter stain of cell nuclei. Samples were allowed to dry for 24 h at 4 °C 
and subsequently used for fluorescence microscopy. The settings used for detection 
of fluorophores are listed in section 2.2.7.7. 
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2.2.5.3. Assessment of cell viability  
Effects of NPs on proliferation and viability of cells were quantified via use of WST-1 
cell proliferation reagent. This assay is based on the enzymatic cleavage of the 
tetrazolium salt WST-1[2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium] (WST-1) to a water-soluble formazan dye by mitochondrial 
succinate-tetrazolium reductase which is active in viable cells. Absorbance of the dye 
is directly proportional to the amount of viable cells. 
3T3 mouse fibroblasts were seeded at a density of 5 x 103 cells/well in 96 well plates 
24 h before NP treatment. Cells were incubated with 0.01 to 2 g/l of 100 nm NPs or 
left untreated in DMEM for 24 h at 37 °C. To consider the absorbance caused by the 
Itrybe-loaded NPs itself, prior to addition of WST-1-reagent absorbance was 
measured in the Wallac 1420 Victor 2 Multilabel Counter at 450 nm. 10 µl of WST-1 
ready-to-use solution was added to the wells and after 30 min of incubation at 37 °C 
absorbance was measured again at 450 nm. To obtain only the signals derived from 
the formazan dye, absorbance measured prior to addition of WST-1 was subtracted 
from the respective wells measured after incubation with WST-1. 
2.2.5.4. Cell preparation for animal experiments  
One day before implantation, KPL-4 or MDA-MB-231 cells were sub-cultivated to 
achieve exponential growth. On the day of implantation cells were trypsinized and 
washed twice with medium. The cell number was determined as described in 2.2.5.1 
and suspension volumes containing 5 x 106 KPL-4 cells or 1 x 106 MDA-MB-231 cells 
were pelletized under centrifugation at 1000 x g, the medium was removed, and cells 
were resuspended in 500 µl medium. 
2.2.6. In vivo experiments 
All animal experiments were according to § 8 of the animal protection law in the 
version of 2006 and all animal protocols were approved by the administration of 
lower Saxony with the animal experiment number 33.14-42502-04-10/0064.  
2.2.6.1. Animal models 
Experimenst were performed on female athymic nude mice, strain NMRI-Fox1nu/nu. 
Feeding occurred via pelletized Extrudate 1439 food and acidulated water with a pH 
of 2.5. Two weeks before the mice were scanned in the Optix MX2 they received 
chlorophyll-depleted low fluorescent food, GLP Nafag feed 890 or Regime 210, 
U8959A01R. The mice were maintained in a sterile environment in special cages with 
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filter huts placed in a scantainer. Cages, bedding, and water were autoclaved and the 
food was gamma irradiated. 
2.2.6.2. Orthotopic implantation of breast tumor cells in mice 
KPL-4 and MDA-MB-231 breast tumor cells were implanted in the right abdominal 
mammary fat pad of female nude mice at the age of 6 to 12 weeks. For this purpose 
mice were anesthetized by intraperitoneal (i.p.) injection of 15 mg/kg body weight 
xylazine und 75 mg/kg body weight ketamine in a 1:1 dilution with isotone sodium 
chloride (NaCl, 0.9 %) solution using an insulin syringe (Ominifix 40 solo) and a 
sterican needle (26G x ½). The solution containing the respective amount of tumor 
cells (5 x 106 KPL-4 cells or 1 x 106 MDA-MB-231 cells, prepared as described in 
section 2.2.5.4) was centrifuged, the medium was discarded, and cells were 
resuspended in a volume of 30 µl PBS and taken up with an insulin syringe with 
integrated needle (30G). Anesthetized mice were placed under a laminar flow in a 
dorsal position and the skin was opened with a small incision in the region over the 
right abdominal mammary fat pad. Tumor cells were implanted very slowly into the 
mammary fat pad. The needle was slowly withdrawn after a 1-minute delay. The 
mammary gland was then returned, and the incision was closed using absorbable 
surgical suture material, 4/0. Afterwards, mice were placed in cages on a heating 
plate at 37 °C for 3 h. In time intervals of three days body weight and general 
condition of the mice were controlled. 
2.2.6.3. Application of probes 
Mice were used for in vivo fluorescence imaging experiments 1 to 4 month after 
tumor implantation when tumors reached sizes of approximately 0.3 cm3. 
Biodistribution experiments with NPs were carried out on tumor-free nude mice. All 
fluorescent probes were injected solved in NaCl, 0.9 % with an insulin syringe with 
integrated needle (30G x ½). During injection, the animals were anesthetized with 
vaporized isoflurane at 0.8 – 1 % concentration.  
The amounts of fluorescence probes injected in mice and the different application 
methods are listed in Table 4. Before and after probe injection, mice were imaged in 
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Table 4. Amount and application methods of fluorescent probes injected in mice  
Different amounts of fluorescent Herceptin-conjugates, the respective free fluorescence dyes, or Itrybe-
loaded NPs were injected in mice, either intravenously (i.v.), subcutaneously (s.c.), or intratumoral (i.t.).   
probe amount volume application 
fluorescence conjugates 25 µg IgG 150 µl i.v. 
free dyes 0.8 nmol* 150 µl i.v. 
fluorescence conjugates 10 µg IgG 50 µl s.c. 
free dyes 0.1 nmol 50 µl s.c. 
100 nm NPs 400 µg 200 µl i.v. 
25 nm NPs 400 µg 200 µl i.v. 
15 nm NPs 1 mg 200 µl i.v. 
15 nm NPs 0.8 – 100 µg 30 µl s.c. 
15 nm NPs 1.6 µg 30 µl i.t. 
* Amount corresponds to the amount of dye in the Herceptin-conjugates with a DP ratio of 5. 
2.2.6.4. Dissection 
At the end of the in vivo experiments mice were sacrificed by cervical dislocation 
under high concentration of isoflurane anesthesia. The animals were examined 
macroscopically for noticeable abnormalities and tumor development. Subsequently, 
tumors were excised and tumor sizes were measured by a caliper. Under the 
assumption that the tumor shape is ellipsoid the tumor volume was calculated 
according to the formula V [cm3] = (length x width x height) / 2. Furthermore, the 
abdomen and the thoracic cavity were opened and liver, kidneys, spleen, lung, heart, 
stomach, and gut were isolated and imaged ex vivo.  
2.2.6.5. Tumor preparation 
One half of the tumor was stored in a cryotube at - 80 °C and used for mRNA and/or 
protein analysis. The other half was fixed with formaldehyde (4 % in PBS) over night, 
embedded in paraffin and used for microscopic examination of tumor tissue. For this 
purpose, the formalin fixed tumors were placed in Tissue Tek cassettes, rinsed under 
the water-tap for half an hour and dehydrated and paraffinized in the apparatus for 
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The following steps were performed: 
repetition cycles time  applied substance 
three 1 h 75 % ethanol 
two 1 h 30 min 96 % ethanol 
three 1 h 15 min 100 % ethanol 
two 2 h xylol 
two 1 h paraffin  
 
2.2.7. Histological examinations of tumor tissue 
2.2.7.1. Generation of paraffin sections from tumor tissue 
Sections of the paraffin-fixed tumors were made with the microtome in 2.5 to 5 µm 
thickness. Sections were attached to object slides, and stored at RT until staining.  
2.2.7.2. Haematoxylin-Eosin (HE) staining of paraffin-embedded 
tumor sections 
Sections were incubated over night at 37 °C in the incubator to improve attachment 
of the tissue to the microscope slides. Afterwards the tumor sections were 
deparaffinized twice with xylol followed by rehydration in decreasing concentrations 
of ethanol (each for 2 min). The Haematoxylin staining of cell nuclei was done for 5 
to 10 min and after washing with water the cell structures were stained with Eosin G 
(1: 10 dilution in H2O) for 5 to 10 min. Tumor sections were washed with water and 
dehydrated with increasing concentrations of ethanol (50 %, 70 %, 90 %, 100 %) 
and xylol and mounted in hydrophobic mounting medium (DePex). Sections were 
analyzed under the light microscope.  
2.2.7.3. CD31 staining 
Paraffin-embedded tumor sections (2.5 µm thickness) were stained with the anti-
endothelial cell marker cluster of differentiation 31 (CD31) antibody after being 
deparaffinized as described in section 2.2.7.2. Prior to antibody treatment, sections 
were incubated for 20 min in target retrieval solution at 98 °C in a steamer. After 
cooling down, the sections were washed twice with TRIS buffer. The endogenous 
peroxidase was blocked with 3 % hydrogen peroxid in PBS for 10 min at RT. 
Afterwards unspecific binding sites were blocked with commercial blocking buffer 
from fish for 15 min at RT. Incubation of tissue with anti-mouse CD31 antibody at a 
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1:100 dilution was carried out in commercial background reducing antibody diluent 
over night at 4 °C. Afterwards, the sections were washed twice with TRIS buffer and 
incubated with the secondary HRP-coupled anti-rat antibody at a 1:200 dilution in 
TRIS-buffer for 1 h at RT. Sections were washed twice with TRIS buffer followed by 
incubation with peroxidase substrate, 3-amino-9-ethylcarbazole (AEC) for 30 min at 
RT, and washed twice with water. Staining of cell nuclei was performed by incubation 
in Haematoxylin for 10-20 sec. The tumor sections were washed with water and 
mounted with aqueous mounting medium (Aquatex). CD31 staining was analyzed 
under the light microscope. 
 TRIS buffer 
 50 mM TRIS-HCl (pH 7.6) 
 150 mM NaCl 
2.2.7.4. Near-infrared (NIR)-microscopic analysis of tumor 
sections 
Tumors treated in vivo with fluorescent probes: 
Paraffin sections (2.5 µm thickness) of tumors of mice treated with Herceptin-
conjugates in vivo were deparaffinized as described in section 2.2.7.2. and mounted 
with hydrophobic mounting medium containing DAPI for counterstain of cell nuclei. 
Samples were allowed to dry for 24 h at 4 °C. Sections were analyzed under the 
fluorescence microscope as described in section 2.2.7.7. 
Ex vivo treatment with fluorescent probes: 
Paraffin embedded tumor sections (5 µm thickness) were deparaffinized as described 
in section 2.2.7.2. The sections were washed 3 times with TBS containing 1 % goat 
serum and blocked with TBS and 10 % goat serum for 1 h at RT. Tumor samples 
were incubated with Itrybe-loaded NPs in TBS and 10 % goat serum for 2 h at 4 °C. 
Afterwards, the sections were washed several times with TBST to remove unbound 
NPs. The cells were mounted with an antifade reagent supplemented with DAPI for 
counter stain of cell nuclei and allowed to dry for 24 h at 4 °C. Sections were 
analyzed under the fluorescence microscope as described in section 2.2.7.7. 
2.2.7.5. Spectrofluorometer 
Excitation and emission spectra of fluorescence probes and dye-loaded NPs were 
recorded in a Spectrofluorometer QuantaMaster equipped with a xenon lamp as 
excitation source and two fluorescence detectors. The solutions were measured in a 
quartz glass precision cuvette with a light pass of 3 x 3 mm. Spectra were recorded 
with a step size of 1 nm and an integration time of 1 sec. Wavelengths settings used 
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for recording of spectra are listed in Table 5. Analysis of spectroscopic measurements 
was performed with the software FeliX32 Analysis 1.0. Measurements are quantified 
as the mean of signals recorded from both detectors. 
 
Table 5. Settings used for recording of spectra of fluorescent probes 
excitation scan emission scan 
probe 




conjugates not analyzed not analyzed 635 610 - 750 
Itrybe-loaded NPs 740 - 770*  450 - 740 590 650 - 875 
λem: excitation wavelength; λex: emission wavelength 
* λem was chosen according to the absorption maximum of the NPs with different sizes, which was 740 nm 
for 15 nm NPs, 750 nm for the 25 nm NPs, and 770 nm for the 100 nm NPs. 
 
 
2.2.7.6. Odyssey infrared imaging system 
Functionality of bioconjugated Itrybe-loaded NPs was evaluated in the Odyssey 
infrared imaging system (see section 2.2.3.3 for production of NPs) by exciting the 
probes with a 685 nm laser diode. Fluorescence intensity was detected in a raster 
mode with a resolution of 84 µm. Analysis of fluorescence measurements was 
performed with the Odyssey Application Software, Version 2.1.  
Average fluorescence intensity was calculated as the sum of the intensity in an area 
set in the respective well divided by the number of measurement points in the area. 
2.2.7.7. Fluorescence microscope 
For examination of fluorescence stained human KPL-4 and MDA-MB-231 breast tumor 
cells, the fluorescence microscope Axiovert 200M equipped with a NIR-sensitive 
ORCA-ER digital camera was used. Filter settings are illustrated in Table 6. 
 
Table 6. Microscopy filter settings used for detection of fluorophores 
probe λex [nm] beam splitter [nm] λem [nm] 
fluorescence probes 640 ± 15 660 690 ± 25 
Itrybe-loaded NPs 620 ± 30 662 809 ± 45.5 
DAPI, Hoechst  365 ± 12.5 395 445 ± 25 
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Image generation and processing were performed with the software systems 
AxioVision Rel.4.6. and ImageJ, respectively. 
2.2.7.8. In vivo NIRF imager, Optix MX2 
The Optix MX2 system13 was used for characterization, quantification and illustration 
of NIRF probes in vitro and their localization in living animals. The system is a 
fluorescence imager working in reflectance mode and scanning in a raster scheme 
with a minimal step size of 0.5 mm. During the scan each raster point is irradiated 
with 9 ps laser impulses with a repetition rate of 80 MHz. The system utilizes a single 
photon counting detector, measuring the time between an excitation pulse and the 
detection of the first fluorescence photon. As illustrated in Figure 9, the generated 
temporal point spread function (TPSF) is a curve representing the distribution of the 
number of photons coming from a raster scan point on the sample over time. Under 
the assumption of a mono exponential decay of the measured intensity the 
fluorescence LT is calculated by linear regression in the slope of the logarithmic TPSF 
(Figure 9). Thus, the TPSF provides information about the fluorescence intensity and 
LT of the fluorescence transition. 
 
Figure 9. TPSF of one raster 
scan point 
Logarithmic photon time of 
flight histogram (TPSF) 
exemplarily shown for one 
scan point taken from a scan 
of a mouse injected with a 
fluorophore. The time between 
excitation pulse and detection 
of fluorescence photons is 
depicted on the x-axis. The 
fluorescence intensity in a log10 scale is illustrated on the y-axis. The fluorescence intensity is determined 
by the area under the curve. From the decay of the curve the fluorescence LT is calculated.      
 
For scanning mice were placed inside the imaging device on a table preheated to 37 °C 
and anesthetized with vaporized isoflurane at 0.8 to 1 % concentration throughout 
the imaging session.  
The excitation lasers (λex) and emission filters (λem) selected for detection of the 
fluorescence conjugates, free fluorescence dyes and Itrybe-loaded NPs are shown in 
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Table 7. Laser and filter settings used for detection of fluorophores in the Optix MX2 
probe λex [nm] λem [nm] 
fluorescence conjugates 635 670 ± 20 
Itrybe-loaded NPs 635/670* 700 long pass 
* Due to the very bright absorption spectrum of Itrybe, excitation was possible with the 635 and 670 nm 
laser. 
 
Table 8 shows the measurement time per raster position (integration time) and step 
size generally used for the different scans in the Optix MX2.  
 
Table 8. Integration time and step sizes used for fluorescence measurements in the Optix MX2 
situation: in vivo ex vivo in vitro 





1 0.7/0.2* 1 0.7 1 
step size 
[mm] 
1 1.5 1 1.5 0.5 
* Biodistribution experiments in healthy mice were performed with an integration time of 0.2 for whole 
body scans. 
 
The laser power was adapted automatically for optimal detection of the fluorescence 
yield. Analysis of the fluorescence measurements was performed with the software 
optiview 1.00.00 (ART). 
The following parameters were calculated for data analysis: 
Normalized counts (NC): 
The measured fluorescence signals (counts) were normalized for varying laser power 
and integration times, thus allowing comparison of measurements with different 
settings. 
Average fluorescence intensity: 
The average fluorescence intensity over a certain area was determined as the sum of 
the NC in the area divided by the number of measurement points in the area. 
Subtraction of autofluorescence: 
In order to eliminate unspecific signals deriving from endogenous particles of the 
mouse, subtraction of autofluorescence was performed. For this purpose, the average 
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fluorescence intensity in a region of the prescan of the mouse (e.g. the tumor area) 
was calculated and subtracted from the intensity maps after probe application. 
Contrast to noise ratio (CNR): 
To consider the signal difference from the average intensity over a certain area and 
those over the background, the contrast to noise ratio (CNR) was calculated. This 
ratio provides information about the level of signal differences and the affection of 





Fluorescence LT is the average time an atom stays in the meta-stable state before its 
transition to the ground state under emission of a fluorescent photon. Thus the LT of 
the fluorescence transition is the characteristic value of a fluorescent probe. 
Fluorescence LT measurements enable a differentiation between fluorescence signals 
originating from the fluorescence probe and unspecific- or autofluorescence. 
Average fluorescence LT: 
The average fluorescence LT over a certain area was determined as the sum of the 
LTs in the area divided by the number of measurement points in the area. 
LT goodness of fit: 
For determination of the quality of the measured LT, the LT goodness of fit was 
calculated. Since, the decay of the fluorscence over a certain point is modeled with a 
mono exponential decay function, a signal derived from two or more fluorescence 
sources would no longer show a mono exponential decrease but an overlay of several 
signal decreases. Thus, the determined LT would arise from two or more fluorescent 
species leading to a high LT error and a poor accuracy of the LT estimation. A LT-




3.1. Characterization of tumor model organisms 
Fluorescent probes evaluated in this study were coupled to Herceptin in order to 
achieve specific binding of probes to HER2-positive breast tumor cells in vitro and in 
vivo. Therefore, HER2-positive, KPL-4101 as well as HER2-negative, MDA-MB-231102 
tumor models were established. Prior to evaluation of fluorescence probes in vivo, 
tumor cells were analyzed for HER2 expression levels and their suitability to bind 
Herceptin-conjugated probes. 
3.1.1. Orthotopic breast tumor models in nude mice 
Tumor-bearing mice were generated by orthotopic implantation of KPL-4 or MDA-MB-
231 tumor cells in the right abdominal mammary fat pad of female nude mice at the 
age of 6-12 weeks. Imaging of mice bearing KPL-4 tumors started 8.3 ± 4.6 weeks 
after implantation when the tumors reached a mean size of 0.28 ± 0.19 cm3 (n = 
24). MDA-MB-231 tumor-bearing mice were scanned after 9.9 ± 9.2 weeks, when 
tumors had a mean size of 0.25 ± 0.07 cm3 (n = 16). In Figure 10, representative 
KPL-4 (Figure 10A) and MDA-MB-231 (Figure 10B) tumor-bearing mice are shown. 
Due to the lack of fur in nude mice, the tumor is clearly visible in vivo (Figure 10A,B; 
upper part) and the growth rate can be assessed by caliper measurements easily. 
Section through the excised tumors show necrotic areas, which have been already 
developed at the described tumor size in both models (Figure 10A,B; lower part). In 
addition, for the KPL-4 tumors, a soft consistency at the tumor center was noted 
(Figure 10A, lower, right picture). No invasive growth and metastases were detected 





Figure 10. Macroscopic appearance of orthotopic breast tumor xenografts in nude mice 
Human tumor cells were implanted orthotopically in the right abdominal mammary fat pad of female nude 
mice. A,B. Representative ex vivo picture of (A) a nude mouse bearing a KPL-4 tumor (T) with a size of 
0.22 cm3 and (B) a nude mouse bearing a MDA-MB-231 tumor (T) with a size of 0.36 cm3. (A,B) Both 
tumors are supplied by large-diameter blood vessels (V; lower part, left). A section through the excised 
tumors (lower part, right) illustrates inhomogeneous tissue with necrotic areas. 
 
Morphology of KPL-4- and MDA-MB-231 tumors was evaluated on sections stained 
with HE or with a CD-31 antibody for assessment of tumor blood vessels. For both 
tumor types, KPL-4 (Figure 11A-C; n = 12) and MDA-MB-231 (Figure 11D-F; n = 8) 
cancerous cells and also vital tumor tissue, such as mammary glands and ducts can 
be observed (Figure 11A,D; black arrow). Both tumors are supplied by several small-
diameter capillaries (Figure 11C,F; red stars). Towards the tumor border a network 
of microvessels is observed whereas the vessel density seems to be lower towards 
the center (data not shown). Moreover, necrotic areas can be seen between vital 
tumor tissue (Figure 11A,B,D,E; white arrow). Here, less necrosis is observed for the 
MDA-MB-231 tumors (Figure 11A,B; white arrow) that is, in comparison to the KPL-4 






Figure 11. Histology of breast tumor xenografts 
A-C. Sections of a representative KPL-4 tumor (n = 12). A. HE staining shows several necrotic areas 
(white arrows) between vital tumor tissue and normal breast tissue (black arrow). B. HE staining at a 
higher magnification illustrates a necrotic area in detail (white arrow). C. CD31 staining marks endothelial 
cells (red stars).  D-E. Sections of a representative MDA-MB-231 tumor (n = 8). D. HE staining shows 
some necrotic areas (white arrows) between vital tumor tissue (black arrow). E. HE staining at a higher 
magnification illustrates a necrotic area in detail (white arrow). F. CD31 staining marks endothelial cells 
(red stars). Images A,D. were taken with a x 2.5 objective and images B,C,E,F. were taken with a x 10 
objective. 
 
Taken together, KPL-4 and MDA-MB-231 tumor cells developed orthotopic breast 
tumors in nude mice that are partly necrotic but well vascularized. 
3.1.2. HER2 expression in breast tumors 
Tumors used in this study were analyzed for HER2 mRNA expression levels via 
quantitative real-time PCR. In Figure 12, the normalized expression ratio of HER2 in 
KPL-4 and MDA-MB-231 cells as well as in a corresponding tumor, are illustrated. 
High expression ratios were found in a KPL-4 tumor (sample no. 3383) and in KPL-4 
cells whereas a MDA-MB-231 tumor (sample no.3450) and MDA-MB-231 cells show a 






os are shown. 
Figure 12. Expression 
levels of HER2 mRNA in 
KPL-4 and MDA-MB-231 
cell lines and tumors 
Representative results of 
a quantitative real-time 
PCR (n = 2). Expression 
levels of HER2 are 
normalized to the amount 
of human transferrin. The 
highest normalized ratio 
detected in the KPL-4 
tumor (sample no. 3383) 
was set to 100 %. All measurements were performed in tripl
 
In addition, the expression levels of the HER2 protein were determined. For this 
purpose, 50 µg of total protein amount of KPL-4 and MDA-MB-231 cells as well as of 
two tumors, from each cell type were separated via SDS-PAGE and analyzed for the 
presence of HER2 protein by Western blot. As illustrated in Figure 13, KPL-4 cells and 
-tumors both show high expression of HER2 whereas MDA-MB-231 cells and tumors 
show a very weak protein band at the size of HER2 (185 kDa) after incubation with 
the anti-HER2 antibody. Staining for actin revealed that for all samples a comparable 
amount of protein was used. (The Western blot experiments were performed by Dr. 
Fernanda Ramos.)  
 
 
Figure 13. HER2 
protein levels in KPL-4 
and MDA-MB-231 cell 
lines and tumors 
Western blot analysis 
revealed that KPL-4 
cells (left) and tumors 
(right; samples no. 
3383 and 3380) express 
HER2 protein showing a 
band with the size of 
185 kDa after 
incubation with an anti-
HER2 antibody (upper 
panel). In contrary, 
almost no staining can be observed in the MDA-MB-231 cells (left) and tumors (right; samples no. 3444 
and 3450). Staining of actin reveals comparable amounts of total protein in all samples (lower panel). 
Representative results of three independent experiments performed by Dr. Fernanda Ram
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Taken together, KPL-4 cells as well as tumors developed from these cells express 
HER2, on the mRNA and protein level. In contrary, MDA-MB-231 cells and tumors 
show a very low expression of HER2. Therefore, KPL-4 cells (defined as HER2-
positive) provide an excellent model for the evaluation of Herceptin-conjugated 
fluorescence probes whereas MDA-MB-231 cells (defined as HER2-negative) were 
used as negative controls. 
3.1.3. Validation of tumor models for evaluation of fluorescence 
probes 
To evaluate the suitability of KPL-4 and MDA-MB-231 tumors, to be applied for 
evaluation of novel fluorescent conjugates in vivo, it is important to ensure that the 
dye-coupled Herceptin binds to HER2-expressing tumors that developed in mice. In 
order to enable a high sensitivity of signal detection, fluorescence distribution in the 
tumor was investigated by using an always-on fluorescent Herceptin-conjugate with 
high amounts of dyes per antibody. 24 h after i.v. injection of Alexa-Her at a DP ratio 
of 3.4, one KPL-4- and one MDA-MB-231 breast tumor were examined under a 
fluorescence microscope. As shown in Figure 14A, Alexa-Her-derived fluorescence 
can be detected inside the KPL-4 tumor, located around vital tumor cells. The 
antibody seems to be not equally distributed in the tumor tissue: Stronger 
fluorescence is observed in some clustered regions whereas signals in other areas are 
comparable weak. In contrary, as illustrated in Figure 14B, almost no Herceptin 






Figure 14. Herceptin-conjugates bind to HER2-expressing tumors in vivo 
Sections of paraffin fixed tumors were examined under a fluorescence microscope with a x 40 objective. A 
KPL-4 and a MDA-MB-231 tumor excised from mice 24 h after receiving i.v. injections of 25 µg Alexa-Her 
at a DP ratio of 3.4 is shown. For each box, on the left upper side, counter stain of cell nuclei with DAPI 
and on the left lower side, probe-derived signals are illustrated. Merged images of the cell nuclei (blue) 
and the probe (red) are shown on the right. A. The Herceptin-conjugates are detected inside the KPL-4 
tumor. Some tumor areas show stronger accumulation of the conjugates then others. B. In the MDA-MB-
231 tumor almost no Alexa-Her derived fluorescence is detected. The exposure time for detection of Alexa-
Her was 300 ms. Bars represent 50 µm. 
 
Here, we confirmed that breast tumors of HER2-positive, KPL-4 and HER2-negative, 
MDA-MB-231 cells can be used for the evaluation of Herceptin-conjugated 




3.2. Improvement of tumor detection via pH-sensitive 
NIRF probes 
There is a high demand for innovative probes with improved fluorescent properties to 
increase the sensitivity of tumor detection in vivo. In this context, functional 
fluorescence dyes that selectively activate at the targeted tumor site are promising 
tools to reduce unspecific signals in the background deriving from circulating and 
unbound fluorescence probes. 
In this part of the work, the functionality and sensitivity of the pH-sensitive tumor 
specific probe, pH-Her was examined and compared to the always-on fluorescence 
conjugate Alexa-Her.  
3.2.1. pH-Her conjugates at different DP ratios increase 
fluorescence in an acidic environment 
In order to investigate the spectroscopic properties of different fluorescence probes 
with distinct dye to protein (DP) ratios, ranging from statistically 0.5 up to 6.4 dye 
molecules per Herceptin, fluorescence emission spectra of Herceptin-conjuates were 
recorded. To illustrate influences of pH on fluorescence emission, the spectra of all 
probes were measured in a neutral pH of 7.5 and an acidic pH of 5.5.  
As illustrated in Figure 15, the shapes of the emission spectra of the pH-sensitive 
antibody-dye conjugates, pH-Her and always-on control conjugates, Alexa-Her are 
comparable to those of the free fluorescence dyes (CypHer5E and Alexa Fluor 647) 
showing an emission maximum at about 665 nm for pH-Her and about 668 nm for 
Alexa-Her (for details see section 2.2.3.1, Figure 7). In an acidic environment (pH of 
5.5; n = 3), all pH-Her probes increase their fluorescence compared to 
measurements at a neutral pH (of 7.5; n = 3). In contrast, the always-on Alexa-Her 







Figure 15. Fluorescence emission spectra of probes at different pH 
Representative fluorescence emission spectra of pH-Her and Alexa-Her probes recorded from 620 to 750 
nm at λex of 635 nm in a spectrofluorometer (n = 3). Probes were measured in PBS at a pH of 7.5 (blue 
curve) and of 5.5 (red curve). A-F. Fluorescence of pH-Her with different DP ratios (from 0.5 to 6.4) 
remarkably increases in a pH of 5.5 compared to a pH of 7.5. G,H. No remarkable change in fluorescence 





Table 9, summarizes the fluorescence intensities of all probes calculated from the λem 
maximum of the spectra illustrated in Figure 15. The pH-Her and Alexa-Her 
conjugates both show a clear tendency of higher fluorescence with an increase in DP 
ratio. The later probe also demonstrates much higher intensity when compared to 
pH-Her at comparable DP ratios. For example, the mean intensity of pH-Her with a 
DP ratio of 1.2 at a pH of 5.5 is 44,446 counts/s whereas Alexa-Her with a DP ratio of 
1.3 has an almost 4-fold higher mean fluorescence of 169,582 counts/s, under the 
same experimental conditions. pH-Her conjugates reveal a slightly less pH-sensitivity 
with increasing DP ratios. For example, pH-Her with a DP ratio of 5.0 shows a 3.9-
fold increase in fluorescence when measured in a neutral pH in correspondence to a 
pH of 5.5 (factor). In comparison, pH-Her with a DP ratio of 1.6 shows the highest 
increase in fluorescence with a factor of 5.6. In contrast, both Alexa-Her conjugates 
do not change fluorescence in a low pH.   
 
Table 9. Fluorescence intensities of Herceptin-conjugates in dependence of pH 
Fluorescence of 0.07 g/l conjugates was recorded in a spectrofluorometer at λem of 665 nm for pH-Her and 
668 nm for Alexa-Her. Measurements were performed in PBS at a pH of either 7.5 or 5.5. The fluorescence 
counts/s of three independently performed experiments (1 to 3) as well as the mean values are illustrated. 
The pH-sensitivity of the conjugates is shown as the factor of the mean fluorescence at a pH of 5.5 divided 
by the mean fluorescence at pH 7.5. 













1 4,311  23,624  1 8,415  38,205 
2 3,445  24,161  2 9,186  52,740 
3 5,202  23,457  3 9,048  42,393 
mean    
 
4,319       
± 879  
23,747      
± 368  
mean 
 
8,883      
± 411  
44,446      
± 7,482 
factor  5.5   factor  5.0  













1 11,890  67,832  1 12,963  58,480 
2 10,411  59,381  2 11,534  56,458 
3 9,751  51,224  3 13,136  52,796 
mean 
 
10,684   ± 
1,095  
59,479      
± 8,305  
mean 
 
12,544  ± 
879  
55,912      
± 2,881 


















1 28,155  109,445  1 32,622  120,354 
2 23,283  97,068  2 40,924  174,290 
3 21,818  80,698  3 20,990  82,792 
mean 
 
24,418   ± 
3,318  
95,737      
± 14,419  
mean 
 
31,512   ± 
10,013  
125,812     
± 45,992 
factor  3.9   factor  4.0  
 













1 157,824  152,775  1 317,535  264,915 
2 152,639  163,651  2 332,074  302,574 





169,582     





292,819     
± 24, 528 
factor  1.1   factor  0.9  
 
After spectroscopic characterization, two pH-Her conjugates with distinct properties 
were chosen for further analysis: pH-Her with a low DP ratio of 1.6 (pH-Her DP 1.6) 
due to its high pH-sensitivity (5.6-fold increase in fluorescence from pH 7.5 to pH 
5.5) and pH-Her with a high DP ratio of 5.0 (pH-Her DP 5.0) due to its relatively high 
fluorescence intensity (96,000 counts of 0.07 g/l probe at a pH of 5.5). As controls, 
the always-on conjugates Alexa-Her with a DP ratio of 1.3 (Alexa-Her DP 1.3) and 
Alexa-Her with a DP ratio of 3.4 (Alexa-Her DP 3.4) were used for further 
experiments in order to have probes with low and high DP ratios, comparable to the 
selected pH-Her probes.   
3.2.2. LTs of fluorescence probes are influenced by the 
environment 
Due to its comparable high pH-sensitivity, pH-Her DP 1.6 was applied for LT-gated 
analysis in vivo. Therefore, LTs of pH-Her DP 1.6 and of the control conjugate Alexa-
Her DP 1.3 were analyzed in detail and compared to LTs of the respective free 
fluorescence dyes pH-OH and Alexa-OH. 
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The influence of the environment on the LT of pH-sensitive- and control-probes was 
analyzed by examination of the probes under different conditions that are known to 
influence LTs, like pH (pH of 7.5 and 5.5) or presence of proteins (PBS/BSA 
5%)2,108,109. Here, BSA was chosen as serum albumin presents the main plasma 
protein (60 %) in humans110. In addition, LTs were also determined under in vivo 
conditions after s.c. injection of probes in mice. The mean LT of all measurements for 
each probe was defined as the predicted LT and used for probe identification in in 
vivo LT-imaging.  
As summarized in Table 10, pH-Her DP 1.6 has a mean LT of 1.3 ns and shows low 
variation upon changes in pH, in the presence of proteins, or after s.c. injection. 
Alexa-Her DP 1.3 has a mean LT of 1.5 ns and reveals slightly longer LTs in the 
presence of proteins (BSA). The respective free hydrolyzed fluorophores pH-OH and 
Alexa-OH, both have shorter mean LTs (of 1.1 and 1.3 ns) compared to the 
corresponding Herceptin-conjugated flurophores, pH-Her and Alexa-Her. Moreover, 
LTs of both free dyes increase in the presence of proteins, especially at a low pH as 
well as after s.c. injection in mice.  
 
Table 10. Determination of the probes’ LT under different conditions 
LTs of pH-sensitive- and control-probes were determined in PBS and PBS/BSA 5 % with a pH of 7.5 and 
5.5, respectively as well as after s.c. injection in mice. Measurements were performed in triplicates in the 
Optix MX2. The mean LT of all measurements for each probe was defined as the predicted LT. 
 








PBS 1.25 ± 0.01  1.26 ± 0.01 
PBS/BSA 5% 1.29 ± 0.03  1.33 ± 0.01 
in vivo s.c.  1.23 ± 0.01  











PBS 0.81 ± 0.01  0.83 ± 0.00 
PBS/BSA 5% 1.00 ± 0.01  1.55 ± 0.02 
in vivo s.c.  1.14 ± 0.02  













PBS 1.43 ± 0.03  1.4 ± 0.03 
PBS/BSA 5% 1.53 ± 0.02  1.63 ± 0.07
in vivo s.c.  1.36 ± 0.01  
predicted LT  1.5 ns  










PBS 1.17 ± 0.00  1.14 ± 0.00
PBS/BSA 5% 1.20 ± 0.02  1.57 ± 0.02
in vivo s.c.  1.27 ± 0.02  
predicted LT  1.3 ns   
 
Taken together, the influences of a changing environment on the probes’ LTs are 
relatively small. However, the LTs of all probes show a tendency to increase in the 
presence of proteins. This increase is most prominent for the free dyes measured in 
BSA-containing solution with a low pH. Furthermore, probes’ LTs become longer for 
both dyes after their conjugation to Herceptin.  
3.2.3. pH-sensitive conjugates are functional in vitro 
In order to test the functionality of the pH-sensitive probes of low and high DP ratios 
in vitro, fluorescence microscopy with HER2-positive (KPL-4) and HER2-negative 
(MDA-MB-231) breast cancer cells was performed after incubation with different 
probes. Herceptin conjugates are known to internalize and localize in the acidic 
endosomes and lysosomes within 8 h of incubation at 37 °C7,38,92 whereas at 4 °C 
internalization is strongly reduced5. Therefore, cells were incubated with Herceptin 
conjugates for 8 h at 37 °C and at 4 °C as a control, in order to measure only 
fluorescence of membrane bound probes, when located in an approximately neutral 
pH.  
The pH-sensitive probe, pH-Her DP 1.6 shows fluorescence only after receptor-
mediated internalization into KPL-4 cells (Figure 16A) whereas no signals are 
detected of membrane bound pH-Her (Figure 16B). In contrast, the always-on probe 
Alexa-Her DP 1.3, shows fluorescence after internalization (Figure 16C) as well as 
when bound to the cell membrane (Figure 16C,D). No fluorescence signals are 
detected on HER2-negative MDA-MB-231 cells after incubation with all probes (Figure 
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Figure 16. In vitro fluorescence microscopy demonstrates functionality of pH-sensitive probes 
with low DP ratio 
Cells grown on culture slides were examined under a fluorescence microscope with an x 40 objective. For 
this purpose breast cancer cells were seeded on chambered coverglasses and incubated for 8 h with the 
fluorescent probes pH-Her or Alexa-Her (5 µg IgG) with a low-DP ratio. On the left, counter stain of cell 
nuclei with Hoechst 33342, in the middle, probe-derived signals, and on the right, merged images of the 
cell nuclei (blue) and the probe (red) are illustrated. For detection of pH-Her an exposure time of 1500 ms 
and for detection of Alexa-Her an exposure time of 200 ms was used. A. When incubated with KPL-4 cells 
at 37 °C, pH-Her DP 1.6 shows fluorescence only after receptor-mediated internalization (green arrow). B. 
No signals from the membrane-bound probes are observed, as can be seen by incubation of cells at 4 °C. 
C,D. In contrast, Alexa-Her DP 1.3 shows fluorescence from the internalized probe (green arrow) but also 
membrane-derived fluorescence after 8 h of incubation at (C) 37 °C and at (D) 4 °C (yellow arrow). E-H. 
No fluorescence signals can be detected after 8 h incubation of MDA-MB-231 cells with pH-Her at (E) 37 °C 
or (F) 4 °C as well as after incubation with Alexa-Her at (G) 37 °C and (H) 4 °C. Representative images of 
three independently performed experiments are presented. Bars represent 50 µm. 
 
Incubation of breast cancer cells with pH-Her and Alexa-Her conjugates of high DP 
ratios (Figure 17) revealed similar results as the cell experiments performed with 
probes with low DP ratios (Figure 16). In KPL-4 cells pH-Her DP 5.0 shows 
fluorescence only after internalization (Figure 17A) but not when bound to the 
membrane (Figure 17B) whereas fluorescence of Alexa-Her DP 3.4 is independent on 
internalization (Figure 17C,D). MDA-MB-231 cells show no fluorescence signals upon 
incubation with probes with high DP ratios (Figure 17E-H). 
In order to prove that fluorescence signals on the KPL-4 cells after incubation with 
pH-Her and Alexa-Her conjugates (Figure 16 and 17) do derive from specifically 
membrane-bound or internalized Herceptin, control experiments with the free 
fluorophores were carried out. No fluorescence signals are detected on HER2-positive 
KPL-4 cells after incubation with pH-OH neither at 37 °C nor at 4 °C (Figure 18A,B) 
or with Alexa-OH at 4 °C or at 37 °C (Figure 18C,D). MDA-MB-231 cells also show no 













Figure 17. In vitro fluorescence microscopy demonstrates functionality of pH-sensitive probes 
with high DP ratio 
Cells grown on culture slides were examined under a fluorescence microscope with an x 40 objective. For 
this purpose cells were incubated for 8 h with pH-Her or Alexa-Her fluorescent probes (5 µg IgG) with a 
high DP ratio. On the left, counter stain of cell nuclei with Hoechst 33342, in the middle, probe-derived 
signals, and on the right, merged images of the cell nuclei (blue) and the probe (red) are illustrated. For 
detection of pH-Her an exposure time of 1000 ms and for detection of Alexa-Her an exposure time of 100 
ms was used. A. When incubated with KPL-4 cells at 37 °C, pH-Her DP 5.0 shows fluorescence only after 
receptor-mediated internalization (green arrow). B. No signals from the membrane-bound probes are 
observed at 4 °C. C,D. Alexa-Her DP 3.4 shows fluorescence from the internalized probe (green arrow) but 
also membrane-derived signals after 8 h of incubation at (C) 37 °C and at (D) 4 °C (yellow arrow). E-H. 
No fluorescence signals can be detected after 8 h incubation of MDA-MB-231 cells with pH-Her at (E) 37 °C 
or (F) 4 °C as well as after incubation with Alexa-Her at (G) 37 °C and (H) 4 °C. Representative results of 




Figure 18. In vitro fluorescence microscopy reveals no unspecific binding of free fluorescence 
dyes 
Cells grown on culture slides were examined under a fluorescence microscope at with an x 40 objective. 
For this purpose cells were incubated for 8 h with 0.2 nmol of pH-OH or Alexa-OH. On the left, counter 
stain of cell nuclei with Hoechst 33342, in the middle, probe-derived signals, and on the right, merged 
images of the cell nuclei (blue) and the probe (red) are illustrated. For pH-OH an exposure time of 1500 
ms and for Alexa-OH an exposure time of 200 ms was used, according to the exposure times used for 
Herceptin-conjugates with low DP ratios (Figure 16). A.-H. No fluorescence can be detected on KPL-4 cells 
after 8 h of incubation with pH-OH at (A) 37 °C and (B) 4 °C or with Alexa-OH at (C) 37 °C and (D) 4 °C. 
Incubation of MDA-MB-231 cells with pH-OH at (E) 37 °C or (F) 4 °C as well as with Alexa-OH at (G) 
37 °C and (H) 4 °C also does not result in the detection of fluorescence signals. Representative results of 
three independently performed experiments are shown. Bars represent 50 µm. 
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The functionality of pH-Her was confirmed by showing pH-Her-derived fluorescence 
only after internalization in HER2-positive breast cancer cells presumably due to 
localization in acidic cell compartments. In contrast to that, fluorescence intensity of 
the always-on control probes, Alexa-Her was independent on pH and internalization.  
3.2.4. Improved detection sensitivity of tumors by the combined 
use of pH-sensitive probes and subtraction of autofluorescence 
pH-probes were tested for their ability to improve tumor detection-sensitivity in 
tumor-bearing mice. A further aim of this study was to eliminate autofluorescence 
signals deriving from the mouse itself, hampering the detection sensitivity of specific, 
probe-derived signals. Consequently, imaging data were processed by the use of two 
different techniques for background suppression, subtraction of autofluorescence and 
LT-gated imaging. 
For this purpose, KPL-4 and MDA-MB-231 breast tumor-bearing nude mice were 
imaged before (prescan) and at different times up to 72 h after i.v. injection of 25 µg 
IgG of the respective probe in the Optix MX2.  
3.2.4.1. Background suppression via subtraction of 
autofluorescence in combination with pH-Her improves tumor 
detection sensitivity  
In order to eliminate autofluorescence of mice and thus to only illustrate signals 
deriving from the injected probes, subtraction of autofluorescence was performed. 
For this purpose, the average fluorescence intensity over the tumor area of the 
untreated mouse (prescan) was subtracted from all scans of the same mouse. In 
Figure 19, representative fluorescence intensity maps of KPL-4 tumor-bearing mice 
before and 1 to 72 h after injection of the probes are demonstrated. After i.v. 
application of pH-Her DP 1.6 (Figure 19A; n = 3) fluorescence in the tumor (white 
circle, shown at 24 h) can be clearly detected. The background fluorescence (white 
circle, shown at 24 h) is low and comparable to the fluorescence of the prescan, with 
exception of some signals deriving from the gastrointestinal (GI) tract of the mouse. 
In contrast, after injection of Alexa-Her DP 1.3 (Figure 19B; n = 3), fluorescence in 
the tumor (white circle, shown at 24 h) is also clearly visible but background signals 
(white circle, shown at 24 h) are high compared to signals of the prescan. Note also, 
that fluorescence intensities after injection of Alexa-Her in mice (Figure 19B) are 
much higher compared to signals after injection of pH-Her (Figure 19A) as indicated 





Figure 19. Intensity maps after subtraction of autofluorescence after probe application in vivo 
KPL-4 breast tumor-bearing mice were imaged before and at different times up to 72 h after probe 
injection (25 µg IgG) in the Optix MX2 in a ventral position. Representative examples (n = 3) of 
fluorescence intensity images after subtraction of the mean autofluorescence, calculated over the tumor 
area of the respective untreated mouse (prescan) are shown. A. Images of a mouse receiving pH-Her DP 
1.6 are illustrated. Probe-derived signals are mainly detected in the tumor. B. Images of a mouse 
receiving Alexa-Her DP 1.3 are illustrated. Probe-derived signals are detected in the tumor and in the 
background. Background- and tumor area are indicated with white circles. Note, that fluorescence 
intensities in B. are much higher than in A., as indicated by the different scale bars. 
 
In summary, use of the pH-sensitive probe, pH-Her at a low DP ratio in combination 
with subtraction of autofluorescence resulted in elimination of major parts of 
background fluorescence in scans of tumor-bearing mice. In contrast, the intensity of 
the background strongly increased after injection of the always-on probe, Alexa-Her 
and could not be eliminated by subtraction of autofluorescence.  
 
Contrast to noise ratios (CNRs) were calculated to quantify signal detection 
sensitivity of the tumor in in vivo scans after background subtraction. The CNR 
provides information about the level of signal difference in the tumor and background 
and the affection of the signal by the background noise (see 2.2.7.8). CNRs were 
calculated in scans of KPL-4 tumor-bearing mice after treatment with Herceptin 
conjugates. As controls, CNRs were also determined in scans of MDA-MB-231 tumor-
bearing mice injected with Herceptin conjugates and of KPL-4 tumor-bearing mice 
receiving the free fluorophores. As shown in Figure 20, i.v. injection of pH-Her DP 1.6 
(Figure 20A) in HER2-positive KPL-4 tumor-bearing mice (n = 5) resulted in an 
continuous increase of CNRs within 24 h to a ratio of 171 that stays comparable high 
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up to 72 h. In contrast, Alexa-Her DP 1.3 (Figure 20B; n = 5) shows an increase in 
CNRs in these mice over time but only to a maximum CNR of 82 after 72 h. The 
average CNR over all times in KPL-4 mice treated with pH-Her DP 1.6 was about 2.5-
fold higher than for mice treated with Alexa-Her.  
Control experiments performed in HER2-negative MDA-MB-231 tumor-bearing mice 
injected with pH-Her DP 1.6 (Figure 20A; n = 3) or Alexa-Her DP 1.3 (Figure 20B; n 
= 3) revealed much lower CNRs, with an average of about 18, that is 9-times lower 
than in KPL-4 tumor-bearing mice treated with pH-Her. In contrast to that, for the 
same times, the average CNR after application of Alexa-Her DP 1.3 is only 4-times 
higher in KPL-4 tumor-bearing mice compared to MDA-MB-231 tumor-bearing mice. 
This illustrates that the differences of signals deriving from HER2-positive- and HER2-




Figure 20. Improved tumor detection sensitivity in vivo by use of a pH-sensitive tumor-specific 
probe at a low DP ratio 
A,B. CNRs calculated from in vivo intensity scans after subtraction of autofluorescence are shown. For 
calculation, the average intensity of the background was measured in the area over the lung. CNRs were 
calculated in scans of KPL-4 tumor-bearing mice before (0 h) and 1, 2, 4 (n = 3), 24, 28, and 72 h (n = 5) 
after injection of (A) pH-Her DP 1.6 or (B) Alexa-Her DP 1.3. As controls, CNRs were also calculated from 
scans of KPL-4 tumor-bearing mice 0 to 72 h after injection of the free fluorescence dyes (0.8 nmol; n = 
3), (A) pH-OH and (B) Alexa-OH as well as from scans of MDA-MB-231 tumor-bearing mice 0, 24, 48, and 
72 h (n = 3) after injection of (A) pH-Her DP 1.6 or (B) Alexa-Her DP 1.3. Standard deviations are 
indicated as black bars. 
 
Further control experiments in KPL-4 tumor-bearing mice revealed that after 
injection of the free dyes, CNRs also are low after 24 to 72 h with a maximum ratio 
for pH-OH of 21 (Figure 20A; n = 3) and of 20 for Alexa-OH (Figure 20B; n =3). 
These findings further suggest that signals after application of both Herceptin-
conjugates, pH-Her and Alexa-Her to mice with KPL-4 tumors are deriving from 
specific interaction of the antibody with tumor cells, as here much higher CNRs were 
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calculated. Moreover, the fact that CNRs calculated for mice with MDA-MB-231 
tumors after injection of pH-Her and Alexa-Her are comparable to the CNRs in mice 
that received free fluorophores, indicates that tumor signals in MDA-MB-231 tumor-
bearing mice are deriving from unspecific accumulation of the Herceptin probe. 
Surprisingly, for Alexa-OH administered to KPL-4 tumor-bearing mice, relatively high 
CNRs, of 72 were calculated 1 h after injection (Figure 20B). Furthermore, for both 
free dyes, pH-OH and Alexa-OH high intensity signals were observed over the 
bladder at early (1 and 4 h) times after probe injection, very likely deriving from a 
rapid excretion of the low molecular weight (~1000 Da) molecules via the urinary 
system. 
In addition, to analyze in more detail whether the fluorescence probes unspecifically 
accumulate in any other organ than the tumor, KPL-4 and MDA-MB-231 tumor-
bearing mice were sacrificed 72 h after injection of pH-Her, Alexa-Her, or the free 
fluorescence dyes and organs were scanned ex vivo. When compared to organs of 
untreated mice (n = 4), no remarkable fluorescence signals could be detected in 
liver, kidneys, lung, heart, spleen, stomach, and gut (data not shown). 
Taken together, subtraction of autofluorescence in vivo in combination with 
application of pH-Her at a low DP ratio led to an efficient elimination of background 
fluorescence in breast tumor-bearing mice and clearly improved tumor detection 
sensitivity compared to injection of Alexa-Her.  
3.2.4.2. Background suppression via LT-gating does not improve 
tumor-detection sensitivity in vivo 
LT imaging in vivo not only illustrates specific signals deriving from the applied probe 
but can depict signals occurring from autofluorescence of the tissue and from 
unspecific fluorescence, e.g. from the food in the GI tract. First, in order to 
characterize this fluorescence from different origin, the LTs were analyzed in distinct 
areas of whole body scans of tumor-bearing mice prior to probe application. The 
representative histogram in Figure 21, on the left side shows the frequency of 
occurrence of different LTs measured in an untreated KPL-4 tumor-bearing mouse (n 
= 10). The most frequently detected LTs are shorter than 1 ns or longer than 2 ns. 
The corresponding color-coded LT map (Figure 21, right side) illustrates that the 
short LTs are deriving from autofluorescence in the background, which has a mean 
LT of 1.0 ns (n = 10) whereas the longer LTs correspond likely to the food in the GI 
tract, with a mean LT of 2.0 ns (n = 10). The LT of the autofluorescence in the tumor 




Figure 21. LTs of 
fluorescence signals in 
certain areas of untreated 
tumor-bearing mice  
On the left side, a 
representative histogram 
shows the frequency of 
occurrence of different 
LTs measured in an 
untreated KPL-4 tumor-
bearing mouse (n = 10) 
in the Optix MX2. The 
most frequently 
measured LTs are shorter 
than 1 ns or longer than 2 ns. On the right side, the corresponding color-coded LT map of an untreated 
mouse is shown. The autofluorescence in the background has a mean LT of 1.0 ns (arrow; n = 10). In 
contrary, the GI tract (GI) has a mean LT of 2.0 ns (arrow; n = 10). The mean LT of the autofluorescence 
in the tumor is 1.6 ns (arrow). 
 
With the aim to only illustrate fluorescence signals in vivo, that are deriving from the 
applied probe, intensity maps of mice were gated to the predicted LT of the applied 
probe ± 0.2 ns in order to decouple them from unspecific background fluorescence. 
The predicted LT was calculated as the mean from the LTs of the respective probe 
determined in vitro under different conditions and after s.c. injection in mice (see 
section 3.2.2, Table 10). In Figure 22A, representative fluorescence intensity maps of 
a mouse bearing a KPL-4 tumor in the right abdominal mammary gland are 
illustrated at different times after receiving pH-Her DP 1.6 (n = 5). Only signals with 
LTs of 1.3 ns ± 0.2 ns are shown, according to the predicted LT for pH-Her (Table 
10). When comparing these LT-gated images to the ones after subtraction of 
background fluorescence of the same mice, in Figure 19A, some fluorescence is still 
visible in the background (white circle, shown at 24 h) whereas unspecific 
fluorescence from the GI tract of mice could be completely eliminated. Unexpectedly, 
the fluorescence signals of high intensity from pH-Her in the tumor (white circle, 
shown at 24 h) are also eliminated at most times (e.g. at 48 and 72 h). Figure 22B, 
shows representative fluorescence intensity maps of a mouse with a KPL-4 tumor 
receiving Alexa-Her DP 1.3 (n = 5). Only signals with LTs of 1.5 ns ± 0.2 ns are 
shown, according to the predicted LT for Alexa-Her (Table 10). In contrary to LT-
gating after application of pH-Her, the major part of the background fluorescence is 
still visible (white circle, shown at 24 h) whereas fluorescence signals from Alexa-Her 
in the tumor (white circle, shown at 24h) are also partly eliminated at some time 






Figure 22. LT-gated intensity maps after probe application in vivo 
KPL-4 breast-tumor bearing mice were imaged before and from 1 to 72 h after probe injection (25 µg IgG) 
in the Optix MX2 in a ventral position. Representative examples of LT-gated in vivo intensity maps are 
shown. The LT-gates were set according to the predicted LT of the respective probe ± 0.2 ns. A. A 
representative mouse receiving pH-Her DP 1.6 is illustrated (n = 3). After LT-gating (LT: 1.3 ± 0.2 ns) 
remaining background fluorescence and partial elimination of the tumor signals are observed at most 
points of time (e.g. after 48h). B. A representative mouse receiving Alexa-Her DP 1.3 is illustrated (n = 3). 
After LT-gating (LT 1.5 ± 0.2 ns) a high amount of background fluorescence remains and part of the tumor 
signal is eliminated at some time points (e.g. after 4 and 48 h). Background- and tumor area are indicated 
with white circles at 24 h after probe injection. Note, that fluorescence intensities in B. are much higher 
than in A., as indicated by the different scale bars. 
 
Here, LT-gating does not lead to an improved tumor detection sensitivity in vivo as 
probe-derived signals in the tumor are eliminated, especially those of pH-Her. In 
addition, LT-gating does not reduce fluorescence in the background after injection of 
the always-on fluorescent probe, Alexa-Her. 
The average LTs in the tumor at each time point were analyzed more precisely in 
order to evaluate why part of tumor signals was eliminated after LT-gating, although 
high intensities in the tumor were very likely deriving from the applied fluorescence 
probes. Figure 23, shows that the average LTs in the tumor area of KPL-4 tumor-
bearing mice (M1 to M5), each treated with either pH-Her DP 1.6 (Figure 23A) or 
Alexa-Her DP 1.3 (Figure 23B) vary over time and in the different mice. Moreover, 
after application of pH-Her (Figure 23A) tumor LTs are clearly longer than the 
predicted LTs (black dashed line; Table 10) and are also partly outside the LT-range 
used for gating (1.3 ± 0.2 ns, grey area) of pH-Her signals. The mean LT in the KPL-
4 tumor area of all mice treated with pH-Her and at all times is 1.49 ± 0.06 ns (n = 
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24). Ex vivo LT analyses of the excised tumors 72 h after injection of pH-Her reveal 
an even higher mean LT of 1.57 ± 0.13 ns (n = 5; data not shown). In contrary, the 
average LTs after injection of Alexa-Her (Figure 23B) are close to the predicted LT 
(black dashed line; Table 10) and are within the LT-gate (1.5 ± 0.2 ns, grey area) 
determined for Alexa-Her. Here, the mean LT in the tumor area over time of all mice 
is 1.48 ± 0.04 ns (n = 24). Ex vivo LT analyses of the tumors 72 h after injection of 
Alexa-Her also reveal a higher mean LT of 1.65 ± 0.05 ns (n = 5; data not shown). 
This demonstrates that for both Herceptin probes the LT does further increase when 
the tumor is measured ex vivo where its fluorescence signal is not overlayed with 




Figure 23. Variations of LTs in the tumor area after probe application 
In vivo average LTs in KPL-4 tumors of mice (M1 – M5) are shown. Tumor LTs were analyzed 1, 2, 4 (n = 
3), 24, 48, and 72 h (n = 5) after i.v. injection of fluorescence probes. A,B. The predicted LT of the probe 
(determined in in vitro measurements and after s.c. injection) is indicated as a black dashed line and the 
LT-ranges used for LT-gating of in vivo intensity images are shown in grey. LTs after application of (A) pH-
Her DP 1.6 and (B) Alexa-Her DP 1.3 are shown. LTs vary over time as well as between mice. Note, that 
tumor LTs after application of (A) pH-Her are partly longer than the predicted LT. Standard deviations are 
indicated as bars.  
 
In summary, LT-analyses of tumor signals over time in vivo and ex vivo show that 
the predicted LT for pH-Her differs from the LT of the probe in the tumor. Therefore, 
a clear prediction of the in vivo LT of the probe in the KPL-4 tumor environment and 
thus an identification of probe derived signals via LT-gating is not possible.  
In order to examine the reliability of the LT calculations in the tumor, the LT 
goodness of fit was determined. This parameter determines the quality of the mean 
LTs calculated over the tumor area of the respective mice. A LT-calculation with a 
high accuracy is considered to have a LT goodness of fit between 0.8 and 1.2 (see 
also section 2.2.7.8 in Material and Methods). As can be seen in Figure 24, the LT 
goodness of fit does not significantly increase or decrease from 1 to 72 h after probe 
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application or between the mice. For tumor LTs after injection of pH-Her (Figure 24A) 
as well as of Alexa-Her (Figure 24B) the mean goodness of fit is 0.8 (n = 24) 
indicating that the LT calculations have a high accuracy. 
 
 
Figure 24. Analysis of reliability of in vivo LT calculations 
The LT goodness of fit of the in vivo LT calculation in the KPL-4 tumor area in mice (M1 – M5) at different 
times after injection of (A) pH-Her DP 1.6 and (B) Alexa-Her DP 1.3 shows slight variations over time as 
well as between the mice. The mean LT goodness of fit for the LT calculations of both probes is 0.8. 
Standard deviations are indicated as bars. 
 
These results demonstrate that the in vivo LT calculations of the tumor area are 
reliable, even at early (1 h) and late (72 h) times after injection of the respective 
probe when the concentration of the fluorescent probe in the tumor might be low. 
In summary, tumor detection sensitivity in vivo was not enhanced after injection of 
Herceptin-conjugates in combination with LT-gating. As prediction of the pH-Her LT 
was not precise and background signals deriving from unbound Alexa-Her could not 
be efficiently eliminated, tumor derived fluorescence was not effectively separated 
from background fluorescence. 
3.2.5. pH-Her conjugates at high DP ratios are less suitable for in 
vivo imaging 
Fluorescence probes with high DP ratios, pH-Her DP 5.0 and Alexa-Her DP 3.4 were 
injected in KPL-4 tumor-bearing mice (n = 3) to evaluate their tumor detection 
sensitivity in vivo in comparison to fluorescence probes with low DP ratios. For this 
purpose, CNRs were calculated from in vivo fluorescence intensity scans of KPL-4 
tumor-bearing mice receiving probes at high DP-ratios after background subtraction. 
As depicted in Figure 25, after injection of pH-Her DP 5.0, CNRs over time stay very 
low with a maximum ratio of 7 after 72 h (Figure 25A). In addition, during in vivo 
scans we could detect only weak tumor signals but interestingly strong fluorescence 
in the bladder of the mice especially at early times (1 to 4 h) after application of pH-
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Her DP 5.0 (n = 3; data not shown). This was also observed after injection of pH-Her 
DP 6.4 (data not shown; n = 2) and after application of the free fluorescence dyes, 
pH-OH and Alexa-OH (see 3.2.4.1) in tumor-bearing mice.  
CNRs after injection of Alexa-Her DP 3.4 in KPL-4 tumor-bearing mice increased over 
time to a maximum ratio of 47. However, the average CNR at all times was ~1.7 fold 
lower compared to the average CNRs in the same mice model after injection of the 
Alexa-Her conjugate with a low DP ratio (see 3.2.4.1, Figure 20B).  
Human IgG has a hydrodynamic diameter (HD) of 10 nm and usually gets excreted 
via the liver75. The observation of a rapid excretion of the pH-Her probe at high DP 
ratio via the kidneys and bladder which is usually the case for smaller molecules of 5 
to 6 nm in HD75 pointed already to a structural degradation of the Herceptin 
conjugates into smaller fragments. As CNRs were low for Herceptin conjugates with 
high DP ratios, when compared to CNRs of conjugates with low DP ratios, control 





Figure 25. Fluorescence probes with high DP ratios reveal no improvement in tumor detection 
sensitivity  
CNRs were calculated from fluorescence intensity scans of KPL-4 tumor-bearing mice after background 
subtraction before (0 h) and 1 to 72 h (n = 3) after injection of probes (25 µg IgG) at high DP ratios. CNRs 
after application of (A) pH-Her DP 5.0 and (B) Alexa-Her DP 3.4 are shown. For CNR-calculation the 
average intensity of the background was measured in the area of the lung. Standard deviations are 
indicated as black bars. 
 
Taken together, the application of fluorescent probes with high DP ratios 
unexpectedly did not lead to an improved sensitivity of tumor detection in vivo, when 




In the following it was assessed, whether pH-Her at high DP ratios might have been 
decomposed to nonfunctional fragments at the time of in vivo application in tumor-
baring mice, in comparison to their application in vitro on cells (see section 3.2.3, 
Figure 16 and 17). 
For this purpose, first fluorescence probes were separated according to their size by 
SDS-PAGE under non-reducing conditions as shown in Figure 26. As a control, 
unlabeled Herceptin in its reduced and unreduced form was used. In order to 
separate the heavy (~50 kDa) and the light chain (~25 kDa) of the antibody, 
Herceptin was incubated with reducing agent and heated at 70 °C for 10 min (line A). 
Herceptin in its unreduced form has a size of ~146 kDa (line B). Compared to the 
size of this antibody, the CypHer5E- and Alexa Fluor 647 fluorophores are small (750 
to 1200 Da) so that the size of the fluorescence conjugates does not significantly 
differ from that of the free IgG. Alexa-Her DP 1.3 (line C) and DP 3.4 (line D) as well 
as pH-Her DP 1.6 (line E) reveal a comparable strong band with the size of 
unreduced Herceptin. pH-Her DP 1.6 additionally shows two bands with the size of 
250 kDa and larger which are likely to be deriving from agglomerates of the 
conjugates. In contrast, pH-Her DP 5.0 (line F) and DP 6.4 (line G), both show no 
bands at the size of unreduced Herceptin and only some very weak bands between 
25 and 45 kDa, indicating that pH-Her at high DP ratios has been decomposed into 
smaller fragments.  
 
 
Figure 26. Detection of 
conjugates in a non-
reducing protein gel 
Herceptin-dye conjugates (5 
µg IgG) were separated 
according to their size via 
SDS-PAGE under non-
denaturating conditions and 
stained with Coomassie (n = 
1). (A) As a control, unlabeled 
Herceptin was treated with 
reducing agent and heated to 
70 °C for 10 min. Heavy and 
light chains of the antibody 
can be seen. (B) Unlabeled 
Herceptin in its non-reduced 
form.  (C) Alexa-Her DP 1.3 
and (D) DP 3.4 as well as (E) 
pH-Her DP 1.6 have a size comparable to the unlabeled Herceptin. (F) pH-Her DP 5.0 and (G) DP 6.4 show 




To verify whether the Herceptin conjugates were destructed into smaller fragments, 
the protein content of the probes was determined in a BCA assay (n = 2; data not 
shown) revealing that pH-Her DP 5.0 (line F) and pH-Her DP 6.4 (line G) had an 
approximately 3- and 5-times lower protein content, respectively when compared to 
the other probes (line B-E). Via this method, proteins decomposed to very small 
peptides containing three or more aminoacid residues are still detectable. Therefore, 
it can be assumed that the low functionality of the pH-Her conjugates with high DP 
ratios in vivo might not solely been caused by a degradation of the antibody 
conjugates into smaller fragments, detected in vivo in the bladder but also by a 
partial precipitation, presumably caused by probe aggregation. 
In general, fluorescence conjugates with low DP ratios tend to be more stable over 





3.3. Evaluation of Itrybe-loaded NPs as in vivo NIRF 
imaging agents 
Nanosized carrier systems are promising imaging tools as they exhibit several 
advantages, such as loading with multiple fluorophores resulting in highly intense 
and stable fluorescent labels. Furthermore, they enable surface conjugation with 
multiple target-specific ligands, which compared to the commonly used single 
antibody-fluorophore units may be especially favorable for in vivo imaging 
applications.  
In this context, NPs with a diameter of 100 nm, 25 nm, and 15 nm, loaded with the 
NIR fluorophore Itrybe were evaluated for their capacity to be used for in vivo 
monitoring of tumors. These particles were either unmodified, bearing NH2 groups or 
PEG chains of 1.5 or 10 kDa, linked to the NPs via the NH2 groups. In addition, 
Herceptin-modified (Her) NPs were examined, at which the antibody was conjugated 
to the particle surface via the PEG chains (dye-loading and surface conjugation were 
performed by Thomas Behnke, BAM I.5, Berlin, see section 2.2.3.3). 
3.3.1. Characterization of Itrybe-loaded NPs 
Fluorescence excitation and emission spectra of different Itrybe-loaded NPs were 
recorded, to analyze whether the different sizes (100, 25, and 15 nm) and surface 
modifications (NH2, PEG, Her) influence their spectral behavior.  
Figure 27A-C illustrates no remarkable spectral differences of NPs with the same size 
but different surface-modifications. However, the excitation and emission spectra of 
the 100 nm particles (blue line) are slightly right shifted compared to the spectra of 
the smaller sized NPs (25 nm and 15 nm), as exemplarily shown for NH2-modified 
probes in Figure 27. All spectra appear noisy which might be caused by a decreased 
emission intensity due to scattering effects of the NPs itself. Scattering of the NPs 
can lead to a size-dependent decrease of excitation intensity and to interreflections of 
emitted photons and subsequently to a stronger reabsorption by the dye. This may 
cause the slight right shifts in the spectra of the 100 nm NPs (Figure 1D) compared 
to the smaller sized 15 nm and 25 nm NPs. With an increase in NP size, scattering 






Figure 27. Fluorescence excitation and emission spectra of NPs 
Representative normalized fluorescence spectra of Itrybe-loaded NPs of different sizes and surface 
modifications were measured in a spectrofluorometer. The excitation spectra range from ~450 to 750 nm. 
The emission spectra range from ~650 to 850 nm. Fluorescence spectra of (A) 100 nm (n = 3), (B) 25 nm 
(n = 3), and (C) 15 nm (n = 2) NPs are illustrated. No remarkable spectral changes are observed for the 
different surface-modifications of NPs (NH2, PEG, and Her). D. Spectra of all three sizes of NPs with NH2 
groups are illustrated. Note that, excitation and emission spectra of 100 nm particles (blue line) are 
slightly right shifted compared to the 25 nm and 15 nm NPs (green and red line). 
 
Taken together, spectral differences of NPs of the same size but with various surface 
modifications are only small showing that the surface moiety has no relevant impact 
on the detection of Itrybe-derived fluorescence using the same excitation and 
emission settings. As fluorescence intensities from differently sized particles were not 
directly compared, the slight spectral variations of NPs of different sizes were not of 
relevance for the results of the study.  
 
The encapsulation of the NIR fluorescence dye, Itrybe in NPs provides a cover of the 
dye towards the environment. Common factors influencing the fluorescence 
properties of fluorophores are, among others, proteins and ions2,20,108. Therefore, the 
influences of changes in the environment on Itrybe loaded in NPs were analyzed 
exemplarily for the different sizes of the NH2-modified particles (n = 2, for each size 
and each condition). As depicted in Figure 28, a decrease in pH from 7.5 to 5.5 has 
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no influence on fluorescence properties of the dye enclosed in NPs of all sizes; 
however a slight (1.3-fold) increase was observed for the 100 and 25 nm NPs when 5 % 
BSA is added to the measurement solution (PBS), independent on pH. In contrary, as 
can be seen in Figure 28C, Itrybe loaded in the smallest, 15 nm particles shows a 
stronger, 5-fold increase in fluorescence in the presence of 5 % BSA at a neutral pH. 
At an acidic pH of 5.5 the fluorescence is still 4-fold higher compared to fluorescence 




Figure 28. Sensitivity of NP-encapsulated Itrybe to changes in environment 
The relative increase in fluorescence intensity of Itrybe-loaded NH2 NPs of different sizes in dependence on 
environmental factors was analyzed in the Optix MX2. For this purpose, NPs were measured in PBS with a 
pH of 7.5 and 5.5 as well as in the presence of proteins (5 % BSA). For relativization, the lowest mean 
intensity for each NP size was set to 1. A. 100 and B. 25 nm particles show no influence on fluorescence 
intensity with a change in pH but a slight (1.3-fold) increase in fluorescence in the presence of proteins. C. 
In contrary, 15 nm NPs revealed a high (5.3-fold) increase in fluorescence in the presence of proteins at a 
pH 7.5 that is slightly lower (4-fold) at a pH of 5.5. The mean of two measurements is illustrated for each 
probe and each condition.  
 
In summary, the influence of proteins on Itrybe-derived fluorescence are relatively 
small in 100 nm and 25 nm particles but increase in the small, 15 nm NPs. Moreover, 
the pH shows no strong influence on fluorescence of Itrybe. 
3.3.2. Functionality of bioconjugated NPs 
Itrybe-loaded NPs were designed to specifically bind to tumor cells. For this purpose, 
Herceptin, which recognizes HER2, was bioconjugated to the 100, 25, and 15 nm 
NPs. Immunoassays were performed to evaluate whether 1.) bioconjugation of NPs 
was successful and 2.) Herceptin-conjugated NPs bind to the HER2 antigen, as well 
3.) NH2-modified and PEGylated particles unspecifically bind to HER2 antigen coated 
surfaces.  
Figure 29 shows the ratio of fluorescence detected after incubation of HER2-coated 
and -uncoated wells with 15 nm particles. A ratio of 1.0 is determined for the control 
experiment in which coated and uncoated wells were incubated with TBS only. 
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Particles with NH2 groups and PEG 10 kDa chains show no specific binding to antigen 
coated wells. To achieve a high conjugation efficiency of Herceptin to the relatively 
small 15 nm NPs und thus to specific binding to HER2, a 5-fold amount of Herceptin 
(Her x5; 2.4 nmol/mg PS; see section 2.2.3.3, Table 2) was used for coupling 
procedure. After Herceptin-conjugation (Her x5), NPs with 10 and 1.5 kDa PEG 
chains show a slightly increased binding ratio of 1.1 and 1.2, respectively. To further 
increase specific binding of 15 nm NPs by Herceptin, in a next step the amount of 
PEG for coupling procedure was reduced to 1/10 (PEG 1.5 kDa 1/10; 50 nmol/mg PS; 
see section 2.2.3.3, Table 2) of the original amount. This was done, as a too high 
density of PEG chains might probably lead to steric hindrances during antibody 
conjugation. In addition, a “blockade” of the already conjugated antibodies on the 
particle surface can occur, thereby hampering interaction of the antibody with its 
target. However, when reducing the PEG amount for coupling procedure, after 
conjugation to Herceptin (Her x5) again no specific binding to the HER2 antigen is 
observed (ratio 1.0). 
 
 
Figure 29. Binding specificity of 
bioconjugated 15 nm NPs 
Signals from immunoassays with 
15 nm NPs were measured in the 
Odyssey infrared imaging system. 
The ratio of fluorescence detected 
after incubation with 0.2 g/l NPs 
on HER2 antigen-coated and -
uncoated wells, is illustrated. The 
control experiments, after 
incubation with only TBS buffer or 
NH2 and PEG 10 kDa NPs all show a ratio of 1.0. After Herceptin conjugation (Her x5), NPs with 10 and 1.5 
kDa PEG chains have a slightly increased ratio of 1.1 and 1.2, respectively. No binding of Herceptin-
conjugated NPs (Her x5) is observed for NPs with PEG 1.5 kDa chains when lower amounts of PEG (1/10) 
were used for coupling (ratio of 1.0). The number of independently done experiments is listed under the 
probes. Standard errors are illustrated as black bars. Each experiment was performed in triplicate. 
 
Further it was tested whether bioconjugation of 25 nm particles with Herceptin was 
successful and thus specific binding of these probes to HER2 occurs. As can be seen 
in Figure 30A, the controls, NH2- or PEGylated NPs (PEG 1.5 kDa, and PEG 10 kDa) 
do not specifically bind to antigen coated wells. A weak binding to antigen coated 
wells is observed after coupling of Herceptin to 25 nm particles with PEG 1.5 kDa 
chains (ratio of 1.7) that cannot be further enhanced when the amount of antibody 
was increased 5-fold for coupling procedure (Her x5; 2.4 nmol/mg PS, see section 
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2.2.3.3, Table 2; ratio of 1.7). The use of PEG 10 kDa chains leads to a reduced 
antigen binding after Herceptin conjugation, with a ratio of 1.4. The bioconjugated 
NPs with the highest ratio and therefore best HER2 binding, PEG 1.5 kDa-Her and 
PEG 1.5 kDa-Her x5 were selected for further analysis. Figure 30B, illustrates that 
binding of these probes to HER2-coated wells is saturated at concentrations of 1 g/l 
whereas binding to uncoated wells further increases up to 2 g/l (n = 1). The ratios of 
binding to coated and uncoated wells for both 25 nm-Her probes (Figure 30C) are 
comparable high at 0.2 to 1 g/l (ratios between 1.6 and 1.8). Therefore, a 
concentration of 0.2 g/l was chosen for further analysis of binding specificity of NPs 




Figure 30. Binding specificity of bioconjugated 25 nm NPs 
Signals from immunoassays with 25 nm NPs were measured in the Odyssey infrared imaging system. A. 
The ratios of signals from HER2-coated and -uncoated wells incubated with 0.2 g/l of NPs are illustrated. 
The control experiments, after incubation with only TBS buffer or NH2, PEG 1.5 kDa, and 10 kDa NPs all 
show low ratios (of 1.1 and 1.0). Slightly higher ratios are observed for the Herceptin-conjugated NPs PEG 
1.5 kDa-Her and –Her x5 (ratio of 1.7), and PEG 10 kDa-Her (ratio of 1.4). The number of independently 
done experiments is listed under the probes. B. Relative intensities of 25 nm PEG 1.5 kDa-Her and -Her x5 
NPs incubated on HER2-coated and -uncoated wells at concentrations of 0.02 to 2 g/l are shown. C. The 
respective ratios of signals from coated and uncoated wells for both probes are illustrated. D. Relative 
intensities of 25 nm PEG 1.5 kDa-Her x5 NPs (n = 2) incubated on HER2-coated and -uncoated wells at 
concentrations of 0.2 g/l. Free Herceptin was added in increasing amounts (0.005 to 1 µg) to the wells. 
Black bars indicate standard errors in A,C. and standard deviations in B,D. Each experiment was 
performed in triplicate. 
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Figure 30D shows, that binding of the probe to HER2 is specifically occurring via 
interaction of Herceptin and the antigen as this binding can be “blocked” by addition 
of increasing amounts of free Herceptin (n = 2). After co-incubation with 0.5 µg 
Herceptin per well, binding of 25 nm PEG 1.5 kDa-Her x5 NPs can be completely 
reduced to the level of unspecific binding to uncoated wells. 
 
In Figure 31A, the ratios of signals from antigen-coated and -uncoated wells after 
incubation with 100 nm particles are illustrated. NPs without bioconjugation show no 
binding to the antigen (NH2, ratio of 1.0 and PEG 1.5 kDa, ratio of 1.1). In contrary, 
the Herceptin-conjugated NPs with PEG 1.5 kDa chains show a 4.7-fold increased 
ratio which is even slightly higher (ratio of 4.8) when the double amount of Herceptin 
was used for bioconjugation (Her x2; 0.96 nmol/mg PS, see section 2.2.3.3, Table 
2). Antigen binding is reduced when PEG 10 kDa chains were used as a linker for 
Herceptin to the NPs, which is in agreement with the results observed for the 25 nm 
NPs (see Figure 30A). Here, a ratio of 2.9 and 2.7 was calculated for two 
independently produced 100 nm-PEG 10 kDa-Her probes. This effect can be 
explained by the differences in number of Herceptin molecules per 100 nm particle 
(listed in section 2.2.3.3., Table 3): The 100-PEG 1.5 kDa-Her and –Her x2 probes 
bear ~70 and 100 Herceptin molecules on the surface of one particle, whereas the 
100-PEG 10 kDa-Her probes bear only ~10 antibodies per NP. Therefore, the 100 
nm-PEG 1.5 kDa-Her and –Her x2 NPs, showing the highest ratios, were selected for 
further studies. As illustrated in Figure 31B, the binding of PEG 1.5 kDa-Her to the 
antigen is saturated at 0.2 g/l whereas binding of PEG 1.5 kDa-Her x2 increases up 
to 1 g/l as does the unspecific binding for both probes to the uncoated wells (n = 1). 
Analysis of the ratio of signals from coated and uncoated wells (Figure 31C) reveals 
best ratios for the PEG 1.5 kDa-Her and –Her x2 probes at 0.1 g/l (ratio of 4.8 and 
4.1) and 0.2 g/l (ratio of 4.6 and 4.2). Exemplarily, the binding specificity is shown 
for the PEG 1.5 kDa-Her NPs at 0.2 g/l in Figure 31D. Binding of NPs to HER2 can be 
decreased via addition of increasing amounts of free Herceptin (n = 2). After co-
incubation with 0.5 µg Herceptin per well the signal from bound NPs is comparable 
low to the unspecific signal deriving from uncoated wells. 
In summary, the highest binding specificity to HER2 was achieved after Herceptin-
conjugation to the 100 nm NPs, whereas bioconjugated 25 and 15 nm NPs showed 
weak or almost no binding to HER2, respectively. For the bioconjugated 25 nm as 
well as 100 nm particles stronger binding to HER2 was observed when short PEG 






Figure 31. Binding specificity of bioconjugated 100 nm NPs 
Signals from immunoassays with 100 nm NPs were measured in the Odyssey infrared imaging system. A. 
The ratios of signals from HER2-coated and -uncoated wells incubated with 0.2 g/l of NPs are illustrated. 
The control experiments, after incubation with only TBS buffer or NH2, and PEG 1.5 kDa NPs, all show low 
ratios (of 1.1 and 1.0). An increase in specific binding can be observed for 1.5 kDa PEG-Her and -Her x2 
(ratio of 4.7 and 4.8, respectively). Use of 10 kDa PEG chains reduces binding of Herceptin-conjugated 
NPs to HER2 (ratio of 2.9 and 2.7 for two independently generated probes). The number of independently 
done experiments is listed under the respective probes. B. Relative intensities of 100 nm-1.5 kDa-Her and 
-Her x2 NPs incubated on coated and uncoated wells at concentrations of 0.02 to 1 g/l are shown. C. The 
respective ratios of signals from coated and uncoated wells for both probes are illustrated. D. Relative 
intensities of 100 nm-PEG 1.5 kDa-Her NPs (n = 2) incubated on HER2-coated and -uncoated wells at 
concentrations of 0.2 g/l. Free Herceptin was added in increasing amounts (0.005 to 1 µg) to the wells. 
Black bars indicate standard errors in A,C. and standard deviations in B,D. Each experiment was 
performed in triplicate. 
 
3.3.3. NPs show no influence on cell viability  
As 100-PEG 1.5 kDa-Her and –Her x2 NPs showed the highest binding specificity to 
HER2, these probes were selected for further analyses of tumor cell binding 
specificity in vitro and in vivo.  
Since, potentially cytotoxic effects of NPs, especially to non-cancerous cells had to be 
excluded, a cell viability assay was performed on 3T3 mouse fibroblasts. Fibroblasts 
were incubated for 24 h with 0.01 to 2 g/l 100 nm NPs and the amount of viable 
cells, proportional to the amount of formazan was measured by absorption at 450 
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nm. Figure 32 shows that 100 nm-NH2 NPs (blue columns; n = 3) as well as 
Herceptin-conjugated NPs (PEG 1.5 kDa-Her, green columns, n = 2; PEG 1.5 kDa-
Her x2, red columns, n = 1) had no effect on cell viability when compared to 
untreated cells (0 g/l, grey column, n = 3) with a confidence of 90 % (red lines). As 
controls, samples without cells, containing only medium (medium, grey column; n = 1) 





Figure 32. NPs do not decrease cell viability 
3T3 mouse fibroblasts were incubated with 0.01 to 2 g/l of 100 nm NPs for 24 h and cell viability was 
analyzed via WST-1 assay and measurement of absorption at 450 nm. To exclude absorption effects by 
the Itrybe-loaded NPs, absorption was measured before addition of WST-1 and subtracted from absorption 
after WST-1 treatment. The mean values of the absorption by formazan are illustrated for untreated cells 
(0 g/l 100 nm PS; n = 3) and for medium only (grey column; n = 1) as well as for cells incubated with 100 
nm NPs. Incubation with NPs is shown in blue columns for 100 nm-NH2 (n = 3), in green columns for 100 
nm-PEG 1.5 kDa-Her (n = 2), and in red columns for 100 nm-PEG 1.5 kDa-Her x2 (n = 1). All experiments 
were performed in triplicate. The 90 % confidence interval of untreated cells is depicted in red lines. 
 
In summary, NPs at concentrations up to 2g/l incubated for 24 h do not affect cell 







3.3.4. Binding specificity of bioconjugated NPs to breast tumor cells 
in vitro 
As 100-PEG 1.5 kDa-Her and –Her x2 NPs showed strong binding to the HER2 
antigen in immunoassays (see section 3.3.2, Figure 31), they were analyzed for their 
binding capacity to KPL-4 and MDA-MB-231 tumor cells by fluorescence microscopy, 
in comparison to controls, the 100-NH2 and -PEG 1.5 kDa NPs.  
Specific binding of Herceptin-conjugated NPs to HER2-positive KPL-4 cells was 
observed, whereas the controls revealed also some unspecific binding. Figure 33 
shows, that strongest fluorescence is detected from HER2-positive, KPL-4 cells after 
incubation with 100 nm-PEG 1.5 kDa-Her NPs (Her) whereas signals are low after 
incubation of the same cell type with the unspecific probe, 100 nm- PEG 1.5 kDa NPs 
(PEG). Incubation of both probes with HER2-negative, MDA-MB-231 cells also 
revealed comparable low fluorescence (n = 3). The differences of specific and 
unspecific binding to cells decreased with increasing incubation times: Whereas the 
differences of fluorescence of KPL-4 cells incubated with Her to the control samples 
(PEG on KPL-4 as well as Her and PEG on MDA-MB-231 cells) are relatively high after 
30 min (Figure 33A) and 1 h (Figure 33B), unspecific uptake of the control samples 
in cells increased after 3 h (Figure 33C) and 5 h of incubation (Figure 33D).  
The binding and/or uptake of 100 nm-PEG 1.5 kDa-Her NPs on KPL-4 cells over time 
is illustrated in Figure 34. Itrybe-derived signals continuously increased from 30 min 
to 5 h after incubation of the probe at 37 °C (Figure 34A; n = 3). At 4 °C incubation 
(Figure 34B; n = 1), no fluorescence can be detected on cells using the same 
exposure time (10 ms). Nevertheless, an increase of Itrybe-derived fluorescence 
over time is also detected at 4 °C with a higher exposure time of 20 ms (Figure 34C), 
however, cell binding and/or uptake of NPs is lower compared to incubation at 37 °C. 
The distribution of NPs on cells incubated at 37 °C (Figure 34A) and at 4 °C (Figure 
34C) is relatively equal over time as no differences in location of NPs, e.g. 
predominantly membrane bound probe at early time points in comparison to 
internalized probe after longer incubation times, are observed. NPs seem to localize 







Figure 33. Increased binding/uptake of Herceptin-conjugated NPs to HER2-positive cells in 
vitro 
Cells were seeded on glass slides and incubated for 30 min, 1, 3, and 5 h at 37 °C with 1 g/l Itrybe-loaded 
100 nm NPs and examined under a fluorescence microscope with an x 40 objective. For each box, on the 
left, counter stain of cell nuclei with Hoechst 33342 and in the middle probe-derived signals are illustrated. 
Merged images of the cell nuclei (blue) and the probe (red) can be seen on the right. The exposure time 
used for detection of Itrybe was 30 ms after 30 min, 10 ms after 1 and 3 h, and 4 ms after 5 h of 
incubation.  A,B. After (A) 30 min and (B) 1 h of incubation strongest fluorescence is deriving from KPL-4 
cells treated with 100 nm-PEG 1.5 kDa-Her (Her). The control probe, PEG 1.5 kDa (PEG) on KPL-4 cells as 
well as both probes on MDA-MB-231 cells reveal low fluorescence signals. C,D. When incubated (C) for 3 h 
and (D) 5 h with 100 nm NPs, still strongest fluorescence is deriving from 100 nm-Her on KPL-4 cells but 
signals from 100 nm-PEG on KPL-4 cells and from both probes on MDA-MB-231 cells are slightly increased, 
compared to A. and B. Representative results of three independently performed experiments are shown. 







Figure 34. Increased binding/uptake of Herceptin-conjugated 100 nm NPs in HER2-positive 
cells over time at 37 and 4 °C  
KPL-4 cells were incubated for 30 min, 1, 3, and 5 h at 37 °C and 4 °C with 1 g/l Itrybe-loaded 100 nm-
PEG 1.5 kDa-Her NPs and examined under a fluorescence microscope with an x 40 objective. For each box, 
on the left, counter stain of cell nuclei with Hoechst 33342 and in the middle, probe-derived signals are 
illustrated. Merged images of the cell nuclei (blue) and the probe (red) can be seen on the right. A. Itrybe-
derived fluorescence on cells, detected with a constant exposure time of 10 ms, continuously increases 
over time at 37 °C. Representative results of three independently done experiments are shown. B. No 
fluorescence signals on cells can be detected after incubation at 4 °C (n = 1) at the same exposure time 
as in A., of 10 ms. C. When using a higher exposure time of 20 ms, increased Itrybe-derived signals on 
cells can be detected over time. Bars represent 50 µm. 
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The binding specificity of Herceptin-conjugated NPs was further verified on KPL-4 and 
MDA-MB-231 tumor sections (two tumors of each type) that were incubated with 
different 100 nm probes. As illustrated in Figure 35, 100 nm-PEG 1.5 kDa-Her x2 NPs 
(n = 2) show strong binding to KPL-4 tumors (Figure 35A; n = 2), compared to the 




Figure 35. Ex vivo fluorescence experiments demonstrate binding specificity of Herceptin-
conjugated NPs to HER2-positive tumors 
Paraffin fixed KPL-4 and MDA-MB-231 tumor sections were incubated with 0.1 g/l Itrybe-loaded NPs and 
examined under a fluorescence microscope with a x 40 objective. For each box, on the left upper side, 
counter stain of cell nuclei with DAPI and on the left lower side, probe-derived signals are illustrated. 
Merged images of the cell nuclei (blue) and the probe (red) can be seen on the right. A-C. Representative 
results of two different KPL-4 tumors incubated with (A) 100 nm-PEG 1.5 kDa-Her x2 (Her; n = 2) show 
strong fluorescence in comparison to KPL-4 tumors incubated with (B) 100 nm-PEG 1.5 kDa (PEG; n = 1), 
or (C) 100 nm-NH2 (NH2; n = 2). D-F. Representative results of two different MDA-MB-231 tumors 
incubated with (D) 100 nm-PEG 1.5 kDa-Her x2 (Her; n = 1), (E) 100 nm-PEG 1.5 kDa (PEG; n = 1), or 
(F) 100 nm-NH2 (NH2; n = 1) reveal lower fluorescence compared to A. The exposure time for detection of 





Weak fluorescence could be observed in MDA-MB-231 tumors treated with 100 nm-
PEG 1.5 kDa-Her x2 NPs (Figure 35D) that was slightly higher compared to both 
tumor types incubated with the control probes (Figure 35B-C,E-F). 
Taken together, Herceptin-conjugated 100 nm NPs are functional on breast tumor 
cells, as they showed increased binding/uptake to HER2-positive KPL-4 cells and -
tumors. In contrary, PEGylated or NH2-modified NPs showed lower binding to KPL-4 
cells and –tumors as did all NP probes to HER2-negative, MDA-MB-231 cells and –
tumors. 
3.3.5. In vivo detection of Itrybe-loaded NPs 
The suitability of fluorescence deriving from Itrybe-loaded NPs to be detected in vivo 
in tumor tissue and at other sites of the mice was investigated. For this purpose, 
KPL-4 and MDA-MB-231 tumor-bearing nude mice received i.v. injections of different 
Itrybe-loaded NPs and were imaged in vivo and ex vivo at diverse time points. Due to 
the broad absorption spectra of Itrybe-loaded NPs (see section 3.3.1, Figure 27), 
imaging was performed at two different λex of 635 and 670 nm and fluorescence was 
detected at λem above 700 nm (n = 9).  
Figure 36A, shows representative in vivo images of a KPL-4 tumor-bearing nude 
mouse before and 1 to 24 h after i.v. injection of 400 µg 100 nm-PEG 1.5 kDa-Her at 
λex 635 nm (n = 2). Autofluorescence (white circle) was assessed in prescans of mice 
before treatment. High fluorescence in the liver is seen shortly after NP-injection up 
to 24 h (white ellipse after 1 h). However, no tumor signals were detected within this 
time (white circle). The same mouse imaged at λex 670 nm, is illustrated in Figure 
36B. Here, autofluorescence is lower in the prescan but unspecific signals in the 
stomach (arrow) and gut (white ellipse) appear higher. NP-derived fluorescence in 
the liver was also observed but appears weaker than at λex 635 nm (Figure 36A). 
This can be explained by the better excitability of Itrybe at λex 635 nm, compared to 
λex 670 nm (see Figure 27 in section 3.3.1). Ex vivo scans of excised organs of the 
same mouse 24 h after probe injection are depicted in Figure 36C,D. Here, the 
highest signals can be seen in the liver at λex 635 nm (Figure 36C) as well as at λex 
670 nm (Figure 36D) compared to low signals at both wavelengths in the gut, 
stomach, kidneys, heart, spleen, lung, and tumor. In comparison to excitation at λex 
635 nm, Itrybe-derived fluorescence in the liver is weaker at λex 670 nm but 







Figure 36. In vivo and ex vivo detection of NP-derived fluorescence at different wavelengths 
Fluorescence intensity scans taken by the Optix MX2 before (prescan) and after i.v. injection of 400 µg 
100 nm-PEG 1.5 kDa-Her NPs in nude mice bearing KPL-4 tumors in the right abdominal mammary gland  
(n = 2). A. A representative mouse in a ventral position imaged before and 1, 4, and 24 h after probe 
application at λex 635 nm and λem above 700 nm. Autofluorescence in the prescan over the lung area is 
illustrated with a white circle. No accumulation of NPs in the tumor (white circle, 24 h) but high liver 
signals (white ellipse, 1 h) are observed after probe application. B. The same mouse shown in A. imaged 
at λex 670 nm and λem above 700 nm. In the prescan autofluorescence is lower compared to A. but 
unspecific signals from the stomach (arrow) and gut (white ellipse) are higher. C. Ex vivo scans of excised 
organs of the mouse shown in A. and B. at λex 635 nm, 24 h after NP-injection confirm in vivo 




In summary, Itrybe-loaded NPs can be excited at λex 635 nm but also at λex 670 nm 
and be detected well above λem 700 nm. Following injection of NPs, probe-derived 
fluorescence cannot be detected in the tumor, but strong signals are observed in the 
liver. Due to the higher fluorescence of Itrybe at λex 635 nm making autofluorescence 
appear negligible, this excitation wavelength was used for all following in vivo and ex 
vivo scans performed in the Optix MX2. 
 
In order to illustrate the brightness of Itrybe-loaded NPs and its detection limit for 
tumors in vivo, different concentrations (100 to 0.8 µg) of 15 nm-PEG 10 kDa NPs 
were injected s.c. in mice at different sites (n = 2). 15 nm particles were selected 
due to their lowest fluorescence intensity per mg PS compared to other NPs (see 
Table 11). As illustrated in Figure 37, fluorescence intensities of NPs after s.c. 
injection (Figure 37A,B; white circles) are well detectable even at an amount of 1.6 
µg, as NPs are still 4-times more fluorescent (Figure 37C; 1,200 NC) than the 
autofluorescence (Figure 37B,D; red circle; 327 NC). In comparison, fluorescence of 
1.6 µg of NPs injected in the MDA-MB-231 tumor (Figure 37C; 813 NC) is slightly 
weaker, as only 2.5-fold higher than the autofluorescence. 
As a result, Itrybe-derived fluorescence can be detected in very low amounts in vivo, 
although fluorescence is lower within the tumor compared to s.c. injections near the 
surface of the mouse. Therefore, Itrybe-loaded NPs are suitable for in vivo tumor 






Figure 37. In vivo detection of Itrybe-derived fluorescence  
Fluorescence intensity scans taken by the Optix MX2 directly after injection of different amounts of 15 nm-
PEG 10 kDa NPs solved in 30 µl NaCl. The areas of probe injections are indicated with white circles. A. 
Mouse in a dorsal view with s.c. injections of 100, 50, 25, and 12.5 µg NPs (n = 2). B. Mouse in a dorsal 
view with s.c. injections of 6.3, 3.1, 1.6, and 0.8 µg NPs (n = 2). Autofluorescence (red circle) was 
determined in an area outside the gut and stomach C. A MDA-MB-231 tumor-bearing mouse in a ventral 
position injected with 1.6 µg NPs i.t. (red arrow) and s.c. (red arrow). Note that different intensity scales 
are shown in A-C. D. The log of the average intensity after s.c. injection of 100 to 0.8 µg 15 nm NPs (A,B) 
and of the autofluorescence of the mouse (0.0 µg NPs) is illustrated.  
 
3.3.6. Biodistribution of NPs 
In order to compare the in vivo behavior of NPs depending on different sizes and 
surface modifications, biodistribution studies were performed in healthy nude mice. 
As NPs seem to be captured in the liver rapidly after injection (see section 3.3.5, 
Figure 36), mice were analyzed at early time points, from 6 min to 4 h after injection 
of NH2 and PEGylated NPs of different sizes (n = 28). 
As illustrated in Figure 38, exemplarily for a mouse injected with 25 nm-PEG 10 kDa 
(n = 4), NPs accumulate in the liver (white ellipse) already 6 min after injection. 
Therefore, fluorescence is especially analyzed over the liver and compared to 
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fluorescence measured in the background of mice, representing the amount of 
circulating unbound NPs in the blood. An area over the hindlimb of mice (in a ventral 
position) was selected as a background region (white circle), since no unspecific 
accumulation of NPs is expected here. After injection of NPs, only a marginal increase 
in fluorescence is detected in the background (white circle) indicating a fast 




Figure 38. Biodistribution of NPs in healthy mice over time 
Fluorescence intensity maps of healthy, tumor free, female nude mice scanned in vivo in the Optix MX2 
before (prescan) and 6 min to 4 h after injection of diverse NPs (n = 28). Exemplarily, a representative 
mouse before and after injection of 400 µg 25 nm-PEG 10 kDa NPs is illustrated (n = 4). High liver signals 
can be seen rapidly after probe application (white ellipse) whereas background fluorescence (white circle) 
remains low. 
 
In Figure 39 average fluorescence intensities in liver (Figure 39A-C) and background 
regions (Figure 39D-F) of healthy nude mice treated with different NPs are illustrated 
before and 6 min to 4 h after treatment (n = 4; see also Figure 38). In order to 
eliminate signals deriving from autofluorescence of the mouse, the average 
fluorescence in the liver and background of the prescans of each mouse was 
subtracted from the respective regions after probe injection.  
Note that intensities are not comparable between mice treated with NPs of varying 
sizes (15, 25, and 100 nm) since the fluorescence intensity of the injected probe 
varies dependent on the NP size. As illustrated in Table 11, per mg PS, the 25 nm 
NPs are 3-fold more fluorescent and the 15 nm particles are 5-fold less fluorescent 








Table 11. Fluorescence intensities of NPs of different sizes 
Total fluorescence intensities of NP probes in 200 µl NaCl were measured in the Optix MX2 prior to i.v. 
injection in mice. Measurements and calculations were performed for the PEGylated NPs (100 nm-PEG 1.5 
kDa, 25 nm-PEG 10 kDa, and 15 nm-PEG 10 kDa). 




PI [NC] 1,900,000  5,630,000  790,000 
relative* PI/mg 1.0  3.0  0.2 
PI = Total fluorescence intensity of the injected probe  
* relative to 100 nm NPs 
 
As summarized in Figure 39A-C, NPs with increasing size accumulate slower in the 
liver: Signals of 15 nm NPs already show a peak intensity ~6 min (Figure 39A), 
signals of 25 nm NPs peak ~30 min (Figure 39B), and fluorescence of 100 nm NPs 
peaks ~1 to 2 h after injection (Figure 39C). Furthermore, PEGylation of probes 
influences their accumulation in the liver, as 25 and 100 nm NPs demonstrate 
decreased liver signals after PEGylation whereas PEGylated 15 nm NPs show 
increased signals when compared to the NH2-modified particles (Figure 39A-C).  All 
probes show low fluorescence in the background with a maximal intensity within the 
first view minutes after injection of NPs that decreases over time (Figure 39D-F). 
Only the 100-PEG 1.5 kDa NPs (Figure 39F) revealed a well measurable and stable 
background signal over time (from 30 min to 4 h). In contrary, PEGylation of the 15 
and 25 nm NPs had no impact on the prolongation of their blood circulation time 
(Figure 39D,E). 
 
Healthy nude mice treated with NPs (see Figure 39) were sacrificed 4.5 h after 
injection and excised organs were scanned in the Optix MX2 ex vivo. Probe-derived 
fluorescence in the organs is displayed according to the presumable size of the 
injected NPs from the probe with the highest to the lowest diameter (100 nm-PEG 
1.5 kDa > 100 nm-NH2 > 25 nm-PEG 10 kDa > 25 nm-PEG 1.5 kDa > 25 nm-NH2 > 
15 nm-PEG 10 kDa > 15 nm-NH2). To exclusively illustrate NP-derived signals, the 
autofluorescence from untreated organs (n = 4) was subtracted from the respective 
organs from mice that received NPs. To allow comparability of intensities from 
different probes, the average fluorescence intensity in particular organs is illustrated 
relative to the total intensity of all organs (liver, lung, heart, spleen, and kidneys) of 






Figure 39. NP distribution in liver and background of healthy mice in vivo over time 
Average fluorescence intensities in liver (A-C) and background regions (D-F) of female healthy nude mice 
treated with distinct NPs are shown before and 6 min to 4 h after probe injection (n = 4). Mice received 
(A,D) 1 mg of 15 nm NPs, (B,E) 400 µg of 25 nm, or (C,F) 400 µg of 100 nm NPs. The average 
autofluorescence in the liver and background of the prescans of each mouse is subtracted from the 
respective regions after probe injection. Liver signals after injection of (A) 15 nm-NH2 and –PEG 10 kDa, 
(B) 25 nm-NH2, -PEG 1.5 kDa, and -10 kDa as well as (C) 100 nm-NH2 and –PEG 1.5 kDa are shown. 
Corresponding background signals after injection of (D) 15 nm-NH2 and –PEG 10 kDa, (E) 25 nm-NH2, -
PEG 1.5 kDa, and -10 kDa, as well as (F) 100 nm-NH2 and –PEG 1.5 kDa are illustrated. Mean values of 4 
mice are shown. Standard deviations are indicated as black bars. 
 
Figure 40A illustrates that all probes accumulate in the liver to a high extend after 
i.v. injection. For example, 25 nm NPs show highest liver uptake with up to 90 % (for 
the 25 nm-PEG 10 kDa probe) whereas lung, heart, spleen, and kidneys show 
comparable low fluorescence (Figure 40B). The second highest fluorescence after NP 
injection is seen in the spleen. Here, the 100 nm-NH2 particles show the strongest 
fluorescence, with 9 % and a slightly decreasing tendency with a decrease in size of 
NPs. In contrary, highest fluorescence in the kidneys was found for the smallest (15 
nm) NPs with 6 % whereas the larger probes show lower fluorescence of 2 to 3 %. 






Figure 40. Biodistribution of NPs by ex vivo analysis 
Healthy nude mice injected with different NPs were sacrificed after 4.5 h and organs were scanned in the 
Optix MX2 (n = 4). Mice received 1 mg of 15 nm or 400 µg of 25 or 100 nm NPs, with NH2 or PEG (1.5 and 
10 kDa) surface groups. Autofluorescence from the respective untreated organs (n = 4) is subtracted from 
the organs of treated mice. The relative fluorescence intensity of average signals over the respective 
organs is illustrated. This is calculated under the assumption that liver, lung, heart, spleen, and kidneys 
make up 100 % of the fluorescence. A. Relative fluorescence intensity in the liver is high compared to 
other organs. B. The spleen shows second highest uptake of NPs. In the kidneys, fluorescence increases 
after injection of 15 nm NPs. 
 
Taken together, biodistribution studies in mice illustrate a rapid and high 
accumulation of all probes in the liver compared to the spleen, kidneys, lung, and 
heart. Ex vivo, 15 nm NPs showed the lowest liver accumulation but the highest 
signals in the kidney. With an increase in NP size, liver uptake and excretion seems 
to be slower over time. Blood circulation times for all NPs were low, showing peak 
intensity rapidly after injection, but are slightly enhanced after applying the 
PEGylated 100 nm NPs.  
3.3.7. NPs accumulate in MDA-MB-231 breast tumors 
In KPL-4 or MDA-MB-231 tumor-bearing mice injected with Herceptin-conjugated or 
PEGylated 15, 25, and 100 nm particles no NP-derived fluorescence could be 
detected in the tumors in vivo in whole-body scans up to 24 h (see Figure 36A,B; n = 
19). Accumulation of NPs in a MDA-MB-231 tumor was not observed up to 96 h after 
injection of 400 µg 100 nm NPs with surface carboxyl-groups (-COOH) (data not 
shown). 
Furthermore, tumors of mice treated with 1 mg of 15 nm NPs or with 400 µg of 100 
and 25 nm NPs were excised 24 h after injection and scanned ex vivo (n = 2). Figure 
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41A,B shows the “total fluorescence intensities in the tumor normalized to the tumor 
volume” (TIV) of KPL-4 tumors from mice treated with NPs. Compared to the average 
TIV of untreated mice (red line), no increase in fluorescence after NP-injection is 
observed. In contrary, TIVs in MDA-MB-231 tumors of mice treated with PEGylated 
NP show a clear increase with decreasing particle size compared to tumors of 
untreated mice (Figure 41C,D). Note, that untreated KPL-4 tumors (Figure 41A,B) 
have more than twice as high autofluorescence compared to MDA-MB-231 tumors 




Figure 41. Passive accumulation of PEGylated NPs in MDA-MB-231 tumors ex vivo 
Ex vivo analysis of excised KPL-4 and MDA-MB-231 tumors of mice 24 h after i.v. injection of Herceptin-
conjugated and PEGylated 100, 25, and 15 nm NPs (n = 2) scanned in the Optix MX2. A. Total 
fluorescence intensities in the tumor normalized to the tumor volume (TIV) of KPL-4 tumors before 
(untreated, grey columns) and after treatment (white columns) with NPs are shown. From left to right: 
untreated, 100 nm-PEG 1.5 kDa-Her (100-Her), 100 nm-PEG 1.5 kDa (100-PEG), 25 nm-PEG 1.5 kDa-Her 
(25-Her), 25 nm-PEG 1.5 kDa (25-PEG), and 15 nm-PEG 10 kDa (15-PEG). The average TIV in untreated 
mice is indicated with a red line. No increase in fluorescence is observed in tumors after NP-treatment 
compared to tumors of untreated mice. B. Fluorescence intensity scans of KPL-4 tumors corresponding to 
A. are illustrated. C. TIV of MDA-MB-231 tumors before (untreated; grey columns) and after treatment 
(white columns) with NPs are shown. From left to right: untreated, 100-PEG, 25-PEG, and 15-PEG. The 
average TIV in untreated mice is indicated with a red line. Increased fluorescence is measured in tumors of 





In order to obtain only the fluorescence in the tumor deriving from injected NPs, the 
average TIV of untreated tumors was subtracted from the average TIV after probe 
injection; determined as the NP-derived TIV (Table 12). As the total fluorescence 
intensity of the injected probe (PI) is known for the 100, 25, and 15 nm PEGylated 
NPs, the NP-derived TIV, relative to the PI was calculated (NP-derived TIV/PI). Here, 
15 nm-PEG 10 kDa NPs show a more than 4-fold higher NP-derived TIV/PI ratio than 
the 100 nm-PEG 1.5 kDa NPs (0.18 to 0.04) and a 9-fold higher ratio than the 25 
nm-PEG 10 kDa NPs (0.18 to 0.02). This demonstrates that the 15 nm NPs show the 
highest fluorescence intensity in tumor tissue (normalized to the tumor volume) in 
relation to the intensity of the injected probe 
 
Table 12. NP-derived signals in MDA-MB-231 tumors ex vivo 
Total fluorescence intensities of NPs prior to injection in MDA-MB-231 tumor-bearing mice as well as of the 
excised tumors 24 h after injection were measured in the Optix MX2. The injected amounts of NPs were: 
400 µg of 100 nm-PEG 1.5 kDa NPs (100-PEG), 400 µg of 25 nm-PEG 10 kDa NPs (25-PEG), and 1 mg of 
15 nm-PEG 10 kDa NPs (15-PEG).   
probe 100-PEG 25-PEG 15-PEG 
NP-derived TIV  
[NC/cm 3] 
79,251 125,695 143,754 
PI [NC] 1,900,000 5,630,000 790,000 
NP-derived TIV/PI 
[1/cm3] 
0.04 0.02 0.18 
TIV = Total fluorescence intensity in the tumor normalized to the tumor volume                                            
PI = Total fluorescence intensity of the injected probe 
 
In summary, ex vivo analysis revealed that Herceptin-labeled and PEGylated NPs do 
not specifically bind to or accumulate in HER2-positive KPL-4 tumors. However, a 
passive accumulation of PEGylated NPs is seen in MDA-MB-231 breast tumors, 
especially for the smallest 15 nm-PEG 10 kDa NPs. 
 
The origin of fluorescence signals after treatment with 15 nm-PEG 10 kDa NPs was 
further assessed on the cellular level by NIR fluorescence microscopy. Therefore, 
tumor sections of KPL-4 and MDA-MB-231 tumors excised 24 h after injection of 15 
nm-PEG 10 kDa NPs were analyzed. KPL-4 tumors of untreated mice show a 
relatively high autofluorescence (Figure 42A; n = 2) whereas no fluorescece in KPL-4 
tumors of mice treated with NP can be observed (Figure 42B; n = 2). Compared to 
untreated KPL-4 tumors, MDA-MB-231 tumors of untreated mice show lower 
autofluorescence (Figure 42C; n = 2). After treatment of mice with 15 nm-PEG 10 
kDa NPs, MDA-MB-231 tumors (Figure 42D; n =2) show fluorescence deriving tumor 
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cells. The signal distribution within the tumor is not homogeneous with most parts 
showing comparably low fluorescence. In addition, more fluorescence was observed 




Figure 42. Detection of 15 nm NP-derived fluorescence in MDA-MB-231 tumor sections ex vivo 
Sections of KPL-4 and MDA-MB-231 tumors of mice 24 h after i.v. injection of 1 mg 15 nm-PEG 10 kDa 
NPs were examined under a fluorescence microscope with a x 40 objective. For each box, on the left upper 
side, counter stain of cell nuclei with DAPI and on the left lower side, probe-derived signals are illustrated. 
Merged images of the cell nuclei (blue) and the probe (red) are shown on the right. A. In untreated KPL-4 
tumors (n = 2) some autofluorescence can be detected. B. In KPL-4 tumors of mice treated with 15 nm-
PEG 10 kDa NPs fluorescence is not higher compared to untreated tumors in A. C. MDA-MB-231 tumors 
show almost no autofluorescence (n = 2). D. MDA-MB-231 tumors of mice treated with 15 nm-PEG 10 kDa 
NPs show fluorescence located around the tumor cells. The exposure time for detection of NPs was 800 
ms. Bars represent 50 µm. 
 
Best signal detection of Itrybe-loaded NPs was observed ex vivo for the PEGylated 15 
nm particles after injection in MDA-MB-231 tumor bearing mice. Here, illustration of 
tumor signals was also possible in vivo, as illustrated in Figure 43 (n = 2). As tumor-
derived fluorescence is relatively low after probe injection (compared to the prescan) 
this could only be achieved by scanning exclusively the tumor region. Thereby, the 
high probe-derived signals in the liver which were hampering the detection sensitivity 
of low fluorescent signals from the tumor are excluded (see Figure 36A for 
comparison). Although fluorescence in the tumor is relatively weak, the intensity in 
the tumor (black circle) is higher 1 h after injection of NPs and further increases up 







Figure 43. PEGylated 15 nm NPs can be detected in the tumor in vivo 
In vivo fluorescence intensity scan of a MDA-MB-231 breast tumor-bearing mouse before (prescan) and 1, 
4, and 24 h after i.v. injection of 1 mg 15 nm-PEG 10 kDa NPs (n = 2) performed in the Optix MX2. Only 
the tumor region (black circle) was scanned. After injection of NPs, fluorescence over the tumor increases 
over time. 
 
In summary, tumor-bearing mice treated with NPs of all sizes with PEG- and 
Herceptin surface-modifications showed no NP-derived fluorescence in the tumor in 
vivo in whole body scans. In contrary, a closer analysis of the tumor targeting ability 
of NPs ex vivo revealed low but clear accumulation of NPs in MDA-MB-231 breast 
tumors. Here, the 15 nm PEGylated NPs seem to be the most promising probes for 




4.1. Improvement of tumor detection via pH-sensitive 
NIRF probes 
The present work illustrates the potential of the pH-sensitive tumor-specific NIRF 
conjugate, pH-Her (Cyp-Her5E-Herceptin) to improve tumor-detection sensitivity in 
vivo in comparison to the always-on probe Alexa-Her (Alexa Fluor 647-Herceptin).  
4.1.1. Tumor imaging with target specific pH-activatable NIRF 
probes  
The use of pH-Her enabled non-invasive detection of tumors in vivo with a 2.5-fold 
increased sensitivity compared to the always-on probe Alexa-Her. The very high 
tumor contrast shown here by the use of pH-Her was achieved by a considerable 
increase in fluorescence intensity of pH-Her in the acidic environment of the tumor 
and after internalization in targeted tumor cells. At the same time pH-Her produced a 
low background fluorescence in the blood, where it faces an approximately neutral 
pH. The remaining autofluorescence was efficiently eliminated by subtraction of 
autofluorescence from prescans of mice. In contrast, the always-on fluorescence 
conjugate, Alexa-Her was fluorescent in the tumor as well as in the blood, as this 
probe did not respond to pH changes in the environment. Although Alexa-Her had a 
higher fluorescence intensity, this resulted in 2.5-fold lower CNRs in mice, compared 
to pH-Her, despite subtraction of autofluorescence, which was negligible compared to 
the high background fluorescence caused by Alexa-Her in the blood. The higher 
fluorescence intensity of Alexa-Her and Alexa-OH compared to pH-Her and pH-OH 
observed in this study in in vitro and in vivo measurements is due to the considerably 
higher quantum yield of Alexa Fluor 647 of 0.33 compared to CypHer5E which has a 
quantum yield of 0.27 at a pH of 5.3. 
Other groups, like Urano et al.38 and Ogawa and colleagues6, have also achieved high 
tumor-to-background ratios with a pH-sensitive Herceptin-conjugate utilizing PeT for 
photo quenching and a TAMRA-QSY7 fluorophore-quencher pair conjugated to 
Herceptin, respectively. However, as these probes both emit in the visible 
wavelength region, the limited tissue penetration restricted the generation of in vivo 
data and allowed only ex vivo measurements of the opened abdominal cavity which 
is of low importance for noninvasive tumor detection in living organisms. 
Furthermore, some studies, like those of Ogawa and colleagues lack information such 
as CNRs or tumor to background ratios of their activatable probes, thereby giving no 
quantitative data about the ability of their probes to improve tumor detection7. 
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The very low background fluorescence of pH-Her, which contributed to high tumor-
detection sensitivity was further attained by the lack of major signals in other organs 
in vivo and ex vivo. In contrast to that, it has been reported that some quenched 
fluorescence probes, like ICG coupled to Herceptin7 or Cy5.5-Herceptin conjugates8 
at high labeling densities, produce high liver signals resulting in decreased tumor 
contrast. Furthermore, since the applied fluorophore CypHer5E in pH-Her emits 
fluorescence in the near-infrared region, the probe is well suited for in vivo imaging 
in deeper mouse tissues as less autofluorescence is detected and tissue penetration 
is increased compared to fluorophores that emit in the visible wavelength region21.  
pH-Her was well detectable in the tumor as early as one hour after probe injection in 
KPL-4 tumor-bearing mice. This very early detection was probably mainly due to an 
increase in fluorescence of pH-Her in the acidic tumor interstitium, before receptor-
based internalization in the target tumor cells occurred. It is known that CypHer5E 
changes its absorption spectrum and thus its excitability with changes in pH due to 
protonation/deprotonation at the nitrogen atom39,43 and therefore is able to increase 
its fluorescence in the presence of protons already in the acidic tumor environment. 
Different to pH-Her, activatable fluorescence probes based on quenching mechanisms 
induced by homo- or hetero-FRET6,8, H-dimer formation5, or autoquenching7 are 
mainly dependent on lysosomal degradation which occurs after internalization in 
targeted cells. Here, processing by e.g. proteasomal cleavage leads to dequenching 
of the conjugates resulting in activation of fluorescence only within the cells.  
In the present study the majority of Herceptin-conjugates internalized after 8 h of 
incubation at 37 °C in HER2-positive cells in vitro, confirming previous studies which 
illustrate high internalization of fluorescent Herceptin-conjugates in target cells after 
a similar period rather than after a short time of one hour6,7. This indicates that the 
fluorescent Herceptin-conjugates activated by dequenching in the lysosomes, 
reported by others, need a longer time to be detected in vivo in the tumor, compared 
to the here used pH-Her. In the present work, the fluorescent signals in the tumor 
were well detectable as early as one hour after injection of pH-Her in mice and CNRs 
continuously increased in the first 24 h. In contrast to that, Ogawa and colleagues 
applied quenched fluorescence probes coupled to Herceptin for in vivo imaging of 
tumors, but did not show any fluorescence images of tumor-bearing mice, earlier 
than 24 h or 48 h after i.v. injection of the probes7,8, suggesting that tumor contrast 
at early times were low. 
The pH-sensitive probe used in the present study was earlier shown by others to be 
reversible activatable after protonation/deprotonation by changes in pH53. Although 
not investigated in this study, this reversible fluorescence activation might be 
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especially advantageous for imaging of the localization of probes in real-time as 
fluorescence disappears as soon as  pH-Her escapes the acidic environment of the 
tumor or of endolysosomal cell compartments, which might occur in case of cell 
damage or cell death. In contrast, activation of fluorescence-conjugates via 
dequenching by lysosomal processing is irreversible and thereby does not provide 
imaging of environmental changes in real time. 
Herceptin presents an excellent tumor targeting moiety for this study, as binding 
specificity and kinetics of Herceptin are well characterized5,38,111 The Herceptin-
conjugate, pH-Her selectively activates its fluorescence after internalization into 
HER2-positive KPL-4 cells after 8 h at 37 °C, but not when bound to the cell 
membrane at 4 °C, when cell physiology is slowed down and the pH is neutral. It has 
also been described by others that Herceptin-fluorophore-conjugates are internalized 
to a high extend after 8 h of incubation at 37 ° C but not at 4 °C5. The spectroscopic 
characterizations of the pH-Her probes, showing an increase in fluorescence only 
when the pH is decreased, are in accordance with the proposed pH-dependent 
increase in fluorescence of pH-Her after internalization in cells and points to the 
localization of these conjugates in acidic endolysosomal compartments. My means of 
lysosomal markers5,6,38, this was earlier confirmed by showing that Herceptin-
conjuated fluorescence dyes colocalize with lysosomal compartments, which are 
known to have an acidic pH of 5 to 638. 
pH-Her is especially advantageous for imaging purposes as a high DP ratio is not 
necessary for quenching of the probe. In contrast, activatable probes that utilize self-
quenching via conjugation of several fluorophores to one targeting ligand need, e.g. 
~7 to 20 dyes to be linked to one ligand8,112. The conjugation of many fluorophores 
to one ligand is challenging as, besides the higher costs for such an amount of 
hydrophilic dyes, some fluorophores, like ICG, form aggregates after conjugation to 
ligands113. The degree of aggregation is directly related to the amount of fluorophore 
loaded onto the protein113. In this study, a lower stability over time was observed for 
the pH-Her conjugates at high DP ratios of 5.0 and 6.4, compared to pH-Her at a low 
DP ratio of 1.6. The fact that pH-Her DP 5.0 and 6.4 showed very low tumor 
targeting capacity but high bladder signals early after application in tumor-bearing 
mice, pointed to a structural degradation of the antibody into non-functional smaller 
fragments (< 5.5 nm in HD) that are filtrated by the kidney rather than eliminated by 
the liver, representing the normal excretion route of IgGs75. The structural instability 
of these conjugates is likely caused by the high labeling density of Herceptin, which 
may lead to fragmentation of the IgG especially at the disulfide bridges (Jutta Pauli, 
personal communication). However, the amount of protein was also lower in the pH-
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Her DP 5.0 and 6.4 probes, compared to the pH-Her conjugate at a low DP ratio and 
the Alexa-Her conjugates. This suggests that a part of the pH-Her probes at high DP 
ratios had precipitated, probably due to enhanced agglomeration of these probes at a 
high labeling density (Jutta Pauli, personal communication). Most likely, both effects, 
structural degradation of Herceptin-conjugates into smaller non-functional fragments 
as well as partial precipitation of pH-Her with high DP ratios, occurred over time. The 
higher stability and the increased pH-sensitivity of pH-Her probes at a low DP ratio, 
observed in this work in spectroscopic measurements favor its use for in vivo tumor 
detection, when compared to pH-Her probes with high DP ratios. 
KPL-4 cells, applied in this study to generate orthotopic breast tumor xenografts in 
nude mice, showed high expression of HER2 and were efficiently targeted by 
Herceptin-conjugated fluorophores. This confirmed the suitability of KPL-4 cells as an 
optimal tumor model for the evaluation of Herceptin-conjugated fluorescence labels, 
as already reported in previous studies103.  
4.1.1. Suppression of background fluorescence in vivo 
In the present work, tumor detection sensitivity was improved via elimination of 
background fluorescence by subtraction of autofluorescence but not via LT-gated 
imaging. Background fluorescence was eliminated in this work, as it presents one of 
the greatest problems in fluorescence imaging of living mice, hampering the 
detection sensitivity of specific probes in vivo1,2,15,16.  
Subtraction of autofluorescence was especially advantageous in combination with the 
pH-sensitive probe, pH-Her. This probe exhibited a low fluorescence outside the 
tumor area. Thereby, and in contrast to Alexa-Her, pH-Her had only a minor 
contribution to the background fluorescence and after injection of pH-Her, the 
majority of background signals were caused by autofluorescence of the mice. This 
could be measured in prescans and efficiently eliminated by a software-based 
subtraction, thereby leading to a high detection sensitivity of the pH-Her-derived 
fluorescence in the tumor. This straightforward technique is possible with the 
majority of imaging devices, as most imaging softwares are capable to subtract a 
given value of fluorescence from the generated scans. In comparison, suppression of 
autofluorescence by LT imaging or spectral unmixing, performed by scanning the 
excitation and emission spectra of signals in objects, followed by their separation via 
their spectroscopic signatures21,22, both require a special hardware. However, only 
few commercially available imaging devices are equipped with photon-counting 
systems, needed for LT imaging or tunable excitation or emission filters, used for 
 99 
Discussion  
spectral unmixing. The software based subtraction of autofluorescence represents a 
simple and effective alternative. 
In the present study, subtraction of autofluorescence was performed by subtracting 
the average autofluorescence in the untreated tumor from whole scans of the same 
mice after probe injection. This technique may not precisely reflect the differences in 
autofluorescence in certain areas of the mice. As a second option, elimination of 
autofluorescence can be performed by subtraction of fluorescence images generated 
at two different excitation wavelengths, one at which mainly the autofluorescence is 
measured and another wavelength at which autofluorescence and probe signals can 
be measured114,115. However, subtraction of signals taken at different wavelengths, 
although they are not too far apart, is also inaccurate as the amount of 
autofluorescence varies at different wavelength (see section 1.1, Figure 1). 
For the probes applied in this study, pH-Her and Alexa-Her, LT-gated imaging, which 
offers the possibility to separate probe-derived fluorescence and autofluorescence2,15, 
did not improve tumor detection sensitivity in vivo. However, in other studies, LT 
imaging has been successfully applied as a tool to increase detection of specific 
signals in vivo2,15, for example, for illustration of tumors after injection of a small 
peptide-fluorophore conjugate2. Moreover, compared to fluorescence intensity 
imaging, LT measurements provide the advantage of being relatively independent on 
probe concentration, thereby increasing the sensitivity for the detection of weak 
signals108. Nevertheless, several factors are known to influence the LT of fluorescent 
probes which can lead to misinterpretation of specific signals. As also shown in this 
study for the free dyes, pH-OH and Alexa-OH, the LTs of fluorophores change after 
conjugation to Herceptin. It has also been shown that the LT of fluorescent probes 
can be influenced by factors, such as the presence of proteins and varying pH2,108,109. 
In this work, the pre-evaluation of probes under distinct conditions, such as varying 
pH, the presence of proteins, and after s.c. injection in vivo, was performed in order 
to predict a characteristic LT and thereby to identify the fluorescence probes when 
distributed in vivo after i.v. injection. However, for pH-Her in vivo, a higher LT of 
about 1.5 ns was measured at the tumor site compared to the predicted LT of 1.3 ns. 
Therefore, in pH-Her treated tumor-bearing mice, the majority of tumor signals was 
eliminated after gating of images to the predicted LT. These findings indicate, that 
some factors in the tumor environment influence the LT of pH-Her, which could not 
be assessed by the LT characterization in PBS and BSA, neither at different pH nor 
after s.c. injection in mice. Additional factors known to influence the LT are, amongst 
others, tissue depth, calcium concentration, and lipids16,108. Therefore, further studies 




LT of pH-Her in the tumor in vivo. As the increase in LT at the tumor site, in 
comparison to the predicted LT was not observed for Alexa-Her, it is likely that the 
sensitivity of the LT of pH-Her to the tumor environment is a characteristic of the 
dye, CypHer5E. This would provide an additional potential to use CypHer5E as a 
highly sensitive means of identifying tumors via LT-gated imaging, due to the 
characteristic change in LT of the probe at the tumor site. Fluorescence probes that 
utilize such a principle would be highly advantageous compared to probes, like Alexa-
Her which resulted in high background fluorescence when circulating in the blood of 
mice, thereby contributing to similar LTs in the background as well as at the tumor 
site. LT-gated imaging using Alexa-Her did not allow an efficient separation of 
background signals from tumor fluorescence and thereby did not lead to an increase 
in tumor detection sensitivity. Furthermore, the high background signals of the 
Alexa-Her conjugates are caused by the prolonged blood circulation time of IgGs34. In 
comparison, smaller molecules, such as peptides34 are cleared more rapidly from the 
blood and might be a better tumor-targeting moiety to be conjugated to always-on 
probes, such as Alexa Fluor. This may enable a better separation of probe-derived 
signals in the tumor from background signals, mainly caused by autofluorescence, 
according to their different LTs2 and thus improve tumor-detection sensitivity, 
compared to LT-gated imaging with IgG-conjugates. 
In future, the pH-sensitive NIRF probe, pH-Her may be applied for a fast and 




4.2. Evaluation of Itrybe-loaded PSNPs as in vivo NIRF 
imaging agents 
The broadband NIR fluorophore, Itrybe, enclosed in polystyrene nanoparticles 
(PSNPs) of different sizes (15, 25, and 100 nm) and surface modifications was 
evaluated, for the first time concerning its suitability for in vivo tumor imaging. The 
results presented here predict a great potential for the use of Itrybe-loaded NPs for 
application in highly sensitive in vivo NIRF imaging. Itrybe can be excited in the NIR 
region at two different wavelengths and is well detectable in mice down to amounts 
of 1.6 µg (for 15 nm NPs).  
4.2.1. Characterization of Itrybe-loaded NPs 
Enclosure of Itrybe in PSNPs with different surface modifications (NH2, PEG, or 
Herceptin) had no considerable influence on the shape of spectra of Itrybe, as shown 
by spectroscopic analyses. This ensured a good comparability of these probes when 
measurements were performed with the same excitation and emission settings. The 
enclosure of hydrophobic Itrybe fluorophores in PSNPs enabled its application in 
aqueous environments and therefore in vivo. In addition to the conservation of the 
spectral range of the dye after enclosure in NPs, a further advantage of this NP 
system is its protection of Itrybe against species in the environment that might 
impair its fluorescence properties55.  
In this study, with the exception of 15 nm NPs, none of the NH2-modifed particles 
showed major alteration in fluorescence with changes in pH or protein concentration. 
In the presence of BSA, 25 and 100 nm NPs showed a slight increase in fluorescence. 
The unexpected high increase in fluorescence observed for the smallest, 15 nm NPs 
in the presence of BSA is likely caused by interaction of proteins with fluorophores 
that are close to the surface of the small particles. As the ratio of particle surface to 
the volume increases with decreasing particle size (15 nm NPs have a surface area of 
0.38 m2/mg PS whereas 100 nm NPs only have a surface of 0.06 m2/mg PS), the 
fluorophores in the 15 nm NPs have the strongest contact to its surrounding. The 
here performed characterization of NPs by evaluation of factors known to influence 
fluorescence properties is an important investigation prior to preclinical studies, as 
NPs used for in vivo tumor imaging are exposed to the usually acidic pH in the tumor 
and to high amounts of protein in blood and tissue.  
The high amount of Itrybe molecules per NPs (which is 10 for 15 nm, 46 for 25 nm, 
and 3100 for 100 nm) contributes to the high brightness of NPs. Hydrophobic dyes, 
like Itrybe are especially suitable for dense loading into NPs of hydrophobic PS. In 
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contrast, loading with hydrophilic dyes is challenging, as the dyes commonly applied 
in fluorescence imaging, such as Cy- or Alexa dyes don’t incorporate efficiently in the 
hydrophobic PS matrix. Moreover, Itrybe is favorably incorporated in NPs in high 
amounts, because, in contrast to most other commonly used NIR fluorophores, a 
close proximity of Itrybe does not result in quenching of fluorescence (Thomas 
Behnke, personal communication).  
4.2.2. Detection sensitivity of Itrybe enclosed in NPs 
The broad absorption spectrum of Itrybe enabled excitation of dye-loaded NPs at 635 
and 670 nm, both resulting in a well measureable fluorescence above 700 nm. In 
vivo scanning revealed a stronger autofluorescence of mice at 635 nm compared to 
670 nm, which is in accordance with the fact that autofluorescence is reduced 
towards the infrared wavelength region1,21. On the contrary, fluorescence of the 
gastrointestinal (GI) tract of mice increased at the longer wavelength of 670 nm 
compared to the measurement at 635 nm. Therefore, one can take advantage of the 
fact that Itrybe can be excited at different wavelengths. The excitation wavelength of 
the dye can be selected according to the imaging purpose of the probe. In the case of 
detection of gastric cancer for instance, an excitation wavelength of 635 nm may be 
favorable, as at this wavelength background fluorescence from food in the GI tract is 
minimized, that may otherwise hamper the specific detection of probe derived 
signals.    
Itrybe-loaded 15 nm NPs were well detectable in vivo down to amounts of 1.6 µg 
when injected s.c. as well as intratumorally. For the latter, a slightly lower 
fluorescence intensity was measured in the tumor compared to s.c. application of the 
same amount of probe. This was presumably caused by absorption effects in the 
tumor tissue due to e.g. tumor blood vessels and the fact that the probe is 
distributed within the tumor in deeper layers of the mice9,116. As the 15 nm NPs were 
shown to have the lowest fluorescence intensity per mg PS, compared to the other 
probes, the 25 and 100 nm NPs would even show higher detection sensitivity in vivo. 
4.2.3. Surface functionalization of NPs 
The successful surface conjugation of ligands to Itrybe-loaded NPs is important to 
ensure specific binding of these probes to target structures, like tumor cells. Here, of 
all the probes, the 100 nm Herceptin-conjugated NPs showed the highest binding 
specificity to the HER2 antigen. 
By performing an immunoassay with HER2 antigen-coated plates, the reliable 
evaluation of the binding specificity of Herceptin-modified NPs was possible. 
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However, no absolute quantitative analysis of binding specificity of Herceptin-labeled 
NPs to HER2 (e.g. by determination of equilibrium constant or half maximal inhibitory 
concentration) was performed in this study. NPs are 3D structures allowing 3D 
surface conjugation of many Herceptin molecules per NP, whereas the immunoassay 
was performed on two-dimensional antigen-coated plates. Thus, due to sterical 
hindrances of the relatively large NPs bound to the antigen on the plate, the specific 
binding of Herceptin-coated NPs on the plate is presumably less effective than in 
vivo. In the animal, the 3D bioconjugation of NPs with many ligands may even result 
in a higher binding probability to target cells.    
For the 100 nm NPs the number of Herceptin molecules conjugated to the surface 
was ~70 to 100 molecules, depending on the Herceptin amount used for coupling 
procedure. For these probes in particular, functionalization with Herceptin was 
successful, with ratios between specific binding to the HER2 antigen and unspecific 
binding of 4.8, as measured in immunoassays. Binding specificity could not be 
enhanced by increasing the amount of Herceptin during the coupling procedure. Most 
likely, sterical hindrances did not allow further coupling of NPs with Herceptin 
molecules. The smaller, 25 and 15 nm sized probes showed low (ratio of 1.7) and no 
(ratio of 1.2) binding to the HER2 antigen, respectively. Since the amount of 
Herceptin molecules per NP was not determined for these probes (Thomas Behnke, 
personal communication), it is not clear whether antibody coupling to 25 and 15 nm 
NPs was successful but the antibody was non-functional after conjugation or whether 
Herceptin conjugation was not achieved.  
This study revealed that binding of NPs of all sizes to HER2 is more efficient when 
Herceptin is conjugated to the NP surface using 1.5 kDa- rather than 10 kDa PEG 
chains as linker. One possible explanation may be that sterical hindrance via the 
large 10 kDa PEG chains decreased binding efficiency of Herceptin to PEG. In 
addition, large PEG chains at a high density could form ravels with each other, 
further hampering the binding to Herceptin. On the other hand, conjugation of 1.5 
kDa PEG chains, especially to small, 15 nm NPs was challenging as particles tended 
to agglomerate after conjugation to 1.5 kDa PEG (Thomas Behnke, personal 
communication). Agglomeration might have been caused by the low electrokinetic 
potential (zeta potential) of the small particles, due to their low surface area, leading 
to lower repulsion of the particles among each other and thus to a higher 
agglomeration probability. 
Furthermore, a reduction of PEG amounts for coupling of 15 nm NPs to 1/10 (50 
nmol/mg PS) of the original amount did not improve Herceptin conjugation or binding 
specificity of particles to HER2. It may be possible that PEG was still in excess, 
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leading to a too high density of PEG chains on the particle surface and thus a 
decreased mobility of PEG chains62. This probably resulted in steric hindrances during 
antibody conjugation. In future, the procedure of bioconjugation should be further 
optimized for small NPs, e.g. by further reducing the amount of PEG for coupling 
procedures. 
4.2.4. Evaluation of PSNP toxicity 
To evaluate toxicity, the impact of Itrybe-containing PSNPs on cell viability was 
investigated. The toxicity of the free fluorophore was not assessed, since Itrybe 
fluorophores were sterically incorporated in the matrix of non-biodegradable PSNPs 
and no leakage of the dye from the 100 nm NPs was observed when incubated with a 
5 % BSA solution for 4 weeks (Thomas Behnke, personal communication). This 
implies that no release of free Itrybe fluorophores occurs in vivo, which could have 
potentially caused any unwanted effects. 100 nm PSNPs bearing NH2 surface groups 
and PSNPs with Herceptin molecules linked to the particle surface via 1.5 kDa PEG 
chains at concentrations up to 2 g/l showed no impact on cell viability of 3T3 mouse 
fibroblasts after 24 h of incubation. These findings are in accordance with various 
reports in the literature, describing NPs which consist of PS as generally non-toxic 
and a safe tool for in vivo applications77,79. However, particle size and surface charge 
have to be taken into account when analyzing toxicity117, as some studies report a 
higher toxicity for NH2-modified PSNPs than e.g. for carboxylated PS particles, 
indicating that surface coating plays a prominent role in cytotoxicity66,78. However, 
these findings could not be confirmed in the present work, as no impact of 100 nm-
NH2 PSNPs on cell viability was observed. An increase in cytotoxicity has also been 
reported with a decrease in particle size78,79, as well as with increasing incubation 
times and concentration66,79. These findings suggest that the reduction in cell viability 
may be caused by an overloading of cells with NPs leading to a disturbance of cellular 
functions rather than by toxicity of the NPs itself79.  
4.2.5. Binding-specificity of bioconjugated NPs in vitro 
Herceptin-modified 100 nm PSNPs specifically bound to HER2-positive, KPL-4 cells 
and -breast tumor tissue in vitro, whereas control probes, NH2-modified or PEGylated 
NPs unspecifically bound to KP-4 cells or tumors to a low degree. All probes showed 
low binding to HER2-negative, MDA-MB-231 cells and tumors as investigated by 
fluorescence microscopy. These findings are in accordance with immunoassay results, 
verifying specific binding of Herceptin-conjugated 100 nm NPs to HER2 expressed on 
tumor cells. Binding specificity of Herceptin-modified 100 nm and 25 nm NPs to the 
HER2 antigen was further proven in immunoassays by “blocking” of HER2 with 
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excess of unlabeled Herceptin, thereby prohibiting specific binding of Herceptin-
conjugated NPs.  
Moreover, unspecific uptake of PEGylated and Herceptin-modified NPs in KPL-4 and 
MDA-MB-231 tumor cells was observed, which increased over time. Unspecific uptake 
of NPs over time was also reported by Steinhauser et al. who applied NPs consisting 
of human serum albumin and conjugated to Herceptin. This group reported, that the 
unspecific uptake of PEGylated NPs increased after 3 h. After 5 h of incubation, no 
differences between Herceptin-modified and PEGylated NPs on HER2-positive breast 
cancer cells could be observed. Steinhauser et al. also reported unspecific uptake of 
both probes in HER2-negative cells107. These findings, together with the results 
reported here illustrate that unspecific uptake seems to be a common phenomenon 
for several NP formulations.  
In general, uptake of all particles by both cell types, KPL-4 and MDA-MB-231, 
increased over time and was reduced when cells were kept at 4 °C. However, NPs 
showed no differences in their cellular localization under incubation at 4 °C and at 37 
°C, which indicates no predominant binding or accumulation of NPs at the cell 
membrane or inside the tumor cells. The fluorescence microscope used for analysis of 
NP-derived signals on the cellular level revealed insufficient power of depth resolution 
to discriminate membrane-derived signals from fluorescence deriving from inside the 
cell.  
Enhanced fluorescence was observed on KPL-4 cells treated with 100 nm-Herceptin 
NPs at early time points of incubation. Since the internalization rate of Herceptin into 
HER2-overexpressing cells has been reported as low as 4 % per hour118, this could 
have predominantly been caused by antibody-receptor interaction, leading to an 
increase of NPs on the surface and enhanced unspecific uptake. Nevertheless, the 
exact way of uptake of target-specific NPs in cells is not entirely known, as reports 
about NP formulations of various sizes are contradictory and uptake is also known to 
be influenced by particle charge and material. Reports in the literature indicate that 
endocytosis of NPs from 43 nm to 150 nm is driven by clathrin-mediated pathways or 
calveolae-mediated endocytosis66,119,120 whereas 24 nm NPs consisting of PS have 
been reported to be internalized in a clathrin- and calveolae independent way120. 
Furthermore, 43 nm120 and 100 nm sized PSNPs were shown to colocalize with 
lysosomes after internalization66, whereas small, 24 nm PSNPs were shown to 
localize outside the lysosomes but near the perinuclear space120. This indicates a 
dependence of NP cell uptake mechanisms on their size. Interestingly, very small NPs 
(8 nm) composed of ironoxide and conjugated to PEG and Herceptin localize in 
lysosomes as well after internalization in HER2-positive tumor cells in vivo121.  
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As Itrybe-loaded NPs seem to be highly and rapidly internalized in cells, they may 
also present suitable tools for in vivo labeling of highly endocytotic cells, like 
macrophages and thereby may function as sensitive markers for imaging of 
inflammatory diseases. Furthermore, Itrybe-loaded NPs could be applied to monitor 
cell tracking in vivo. Stem cells for instance could be labeled ex vivo by endocytosis 
and then their migration followed in vivo by imaging. 
4.2.6. Tumor targeting capacity of NPs in vivo 
None of the NPs of different sizes, (100, 25, and 15 nm) or surface-modifications 
(PEG and Herceptin) were able to visualize KPL-4 or MDA-MB-231 tumors in whole 
body scans after i.v. injection in mice. However, imaging revealed that all NP probes 
accumulate rapidly and to a high extent in the liver. This indicates that these probes 
still need modification in order to increase their longevity in the blood and their 
accumulation in the targeted tumor in vivo. For efficient delivery to the tumor, NPs 
should present prolonged blood circulation times, reduced nonspecific uptake in 
normal tissue, as well as rapid accumulation in targeted tumor tissue122.  
NPs of all sizes bearing PEG surface-chains passively accumulated in MDA-MB-231 
tumors after injection in mice as shown by ex vivo imaging. The highest 
accumulation, relative to the injected amount of probe was found in tumors of mice 
that received 15 nm NPs. This is probably due to the size of these NPs, which are 
small enough to allow the most efficient extravasation from the vasculature into the 
tumor tissue74, mediated by the enhanced permeability and retention (EPR) effect. 
Reports in the literature describe 20 to 100 nm to be the optimal size for efficient 
extravasation and retention of NP from capillaries to the tumor interstitium65 as well 
as a cutoff size of >400 nm123. Tumor targeting with smaller NPs was also reported, 
e.g. for QDs of sizes of ~5 to 15 nm or PEGylated ironoxide NPs of ~8 nm72,74,121. 
Furthermore, PEGylated calcium phosphate NPs of 16 nm accumulated in the tumor 
of mice with a signal persisting up to 96 h after probe injection55. Nevertheless, in 
accordance with the result of the present work, nonspecific uptake in other organs, 
such as liver, kidney, and spleen was also reported55,72,74,121.  
Based on the ratio of tumor intensity, relative to the total intensity of the injected 
amount, the smallest, 15 nm NPs have the highest capacity for tumor targeting 
compared to both larger NPs. Calculations of the fluorescence intensity in the tumor 
relative to the injected amount of the respective probe revealed a ratio for the 15 nm 
NPs that was 4-fold higher than for the 100 nm particles (0.18 to 0.04) and 9-fold 
higher than for the 25 nm NPs (0.18 to 0.02). However, it should be taken into 
consideration that the number of NPs injected in vivo was different for each probe of 
different size. Thus, the injected probe of 15 nm NPs contained more particles than 
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the 25 and 100 nm NP probes (in this order), causing a higher number of NPs in the 
blood. Therefore, the higher fluorescence observed in the tumor after injection of the 
15 nm probe might have been influenced by the higher number of 15 nm NPs in the 
blood. However, this probe is nonetheless less fluorescent than the 25 and 100 nm 
NP probes (in this order). Therefore a direct comparison in absolute numbers of 
varying amounts of NPs with different sizes and fluorescence intensities is challenging 
and difficult. The ratio of tumor intensity, relative to the total intensity of the injected 
amount, was calculated to compare the tumor targeting capacity for different sizes of 
NPs. In addition, fluorescence reflectance imaging (FRI) of 3D structures, such as the 
tumor provides only semi-quantitative data, as fluorescence measurements are 
surface weighted9.  
Even when increasing the affinity of NPs to HER2-positive KPL-4 tumors via 
conjugation to the tumor-specific ligand Herceptin, no clear accumulation of NPs was 
detected in KPL-4 tumors in vivo as well as ex vivo after 24 h. Specific tumor 
targeting was also not achieved by others, who reported no clear differences between 
in vivo tumor-targeting capacities of target-specific NPs compared to non-targeted 
NPs, such as gadolinium124 or silica NPs125 coated with folic acid, or RGD labeled lipid 
NPs65. Specific targeting of tumors has mainly been achieved by use of QDs 
conjugated to tumor-specific antibodies72 or small ligands74. However, QDs, 
containing heavy metals, suffer from potentially toxic effects20,75, which limit their in 
vivo application. 
PEGylated NPs of all sizes accumulated in MDA-MB-231 tumors when injected in mice 
and revealed a higher fluorescence in comparison to the autofluorescence in tumors 
from untreated mice. This could be shown in ex vivo measurements, where 
fluorescence is not absorbed by the surrounding tissue of the mouse, leading to a 
higher sensitivity of signal detection of excised tumors. 
PSNPs used in this study are relatively inflexible spheres126, which may be one reason 
why they were limited in efficient extravasation from the blood and tumor 
penetration. In addition to the size of NPs and surface coatings, it is likely that the 
NP-shape and deformability is important for the probes to efficiently pass the 
endothelial barrier towards the tumor interstitium. Compared to the relatively rigid 
spheres used in this study, other groups showed that more flexible lipid NPs126 of 35 
nm used in vivo accumulate clearly in the tumor and resulted also in high NP-derived 
signals in the blood plasma65. Such liposomal NP-formulations of 100 nm are already 
used for efficient delivery of anthracyclines for cancer therapy in patients64. Other 
examples are relatively large but deformable glycol chitosan NPs of ~260 nm, which 
are well detectable in vivo for up to 7 days and reveal the highest signal in the tumor 
compared to other organs. These flexible NPs also showed longer circulation times 
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than the comparable unyielding PSNPs126 of similar size122. These observations 
indicate that the PSNP-sizes of up to 100 nm, applied in the present work have the 
potential for tumor targeting when modified to achieve sufficient bioavailability and 
that the relatively low flexibility of PSNPs might have considerable influence on the 
tumor penetration capacity of the NPs. However, another report shows that 
mesoporous silica NPs of 100 to 130 can accumulate in the tumor125. Interestingly, 
NPs formed of anorganic silica are expected to be relatively inflexible. However, 
these NPs showed stronger fluorescence in the tumor than in other organs up to 24 h 
after injection125. 
These findings underline the need for detailed and systematic investigations of the in 
vivo behavior of nanosized carriers to gain more knowledge about the influence of 
composition, size, surface charge, and deformability on biodistribution and tumor-
targeting abilities of NPs. Therefore, all NP systems should be optimized prior to 
routine application in preclinical studies.  
In this work, only the MDA-MB-231 tumor could be targeted by Itrybe-loaded NPs of 
all sizes. Histological examinations of both tumor types, MDA-MB-231 and KPL-4, 
revealed that vascularization was comparable, providing adequate conditions for NPs 
to reach both tumors through the blood system. However, in the present study, 
MDA-MB-231 tumors preferentially developed necrosis in the tumor center only, 
whereas KPL-4 tumors demonstrated necrotic areas in the tumor center as well as 
towards the tumor boarder. These findings confirmed previous observations for both 
tumor types of the frequent development of massive central necrosis101,127. One 
might speculate that since the effectiveness of penetration of the tumor by NPs is 
dependent on the tumor characteristics, the more frequent and expanded necrosis 
observed in KPL-4 tumors could probably hinder the efficient distribution of NPs in 
these tumors to a higher extend when compared to MDA-MB-231 tumors.  
These results further indicate that Itrybe-loaded PSNPs are in principle capable of 
reaching the tumor, but that tumor targeting with Itrybe-loaded PSNPs is not very 
effective, presumably due to 1.) fast elimination of NPs from the organism and 2.) 
relatively low flexibility of PSNPs probably impairing efficient tumor penetration. 
Consequently, NP formulations other than of PS should be used for incorporation of 
Itrybe fluorophores, e.g. built of more flexible glycol chitosan or lipids. These should 
be evaluated for their suitability to improve the longevity of Itrybe-loaded NPs in the 
blood and their accumulation in the targeted tumor in vivo.  
4.2.7. In vivo biodistribution of NPs 
Biodistribution studies of Herceptin-conjugated and PEGylated NPs in healthy mice 
revealed a rapid uptake of all probes in the liver which was accompanied by a fast 
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decrease in background fluorescence, defined as the amount of circulating probe in 
the blood. Knowledge about the bioavailability of Itrybe-loaded NPs, is of 
considerable importance for their use in tumor imaging as NPs have to be present in 
the bloodstream long enough to reach the targeted tumor tissue62. Uptake in non-
targeted tissue should be low or entirely prevented as it causes unspecific 
background signals, hampering the identification of target-specific signals, deriving 
from the tumor.  
A rapid uptake by the liver62,71 and short blood-circulation times71,128,129 have been 
observed in the literature for many NPs of various materials, including PSNPs67,130,131 
as well. The fast liver uptake of all NPs observed in this study can be explained, 
because the liver is part of the excretory system and its mononuclear phagocytic 
system (MPS) is the basic mechanism of excretion of NPs122. NPs can be bound by 
opsonins in the blood serum, most commonly by IgG and complement proteins. 
These opsonins are then recognized by macrophages, usually Kupffer cells or 
macrophages of the liver that clear the particles from the blood. The rapid 
elimination of Itrybe-loaded NPs from the blood was most likely caused by uptake in 
the MPS that can occur within minutes and presents a major drawback for the 
accumulation of NPs at the targeted site. As shown here and by others, this rapid 
elimination of NPs may result in short blood-circulation times, of a few minutes62.  
Biodistribution was analyzed, at early time points (6 min to 4 h) as uptake of probes 
occurred very rapidly after NP injection. PSNPs of all three sizes showed a rapid 
increase in liver signals, which remained high for 4 h when compared to the low 
background observed for all probes. Ex vivo analyses of excised organs confirmed the 
in vivo observations with highest signals found in the liver for all probes (average of 
~84 % of the total intensity measured in all tested organs).  
The elimination of NPs from the blood was assessed in dependence of their size, and 
surface modification. By comparing the distribution of NPs of different sizes, a slower 
uptake of NPs in the liver was found with an increase in size of NPs. The 100 nm NPs 
showed a peak intensity in the liver after ~1 h, whereas the 15 nm NPs peaked as 
early as ~6 min after probe injection in mice. This indicates that elimination of larger, 
100 nm Itrybe-loaded PSNPs from the blood by the liver is slower compared to 25 
and 15 nm NPs.  
Liver signals measured ex vivo 4.5 h after probe injection were slightly lower for the 
small 15 nm NPs (6 % and 2 % compared to the 25 and 100 nm NPs, respectively), 
presumably due to enhanced renal filtration of the smallest NPs by the kidney. This is 
demonstrated by a slightly increased signal in the kidney, of ~3 % after injection of 
15 nm NPs compared to larger NPs. These findings are in accordance with the 
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literature, showing a decrease in liver accumulation of smaller NPs71 especially at 
early time points after probe injection128 and also for PSNPs67. Furthermore, 
accumulation of small gandolinium oxide NPs of ~14 nm126 or of gold NPs of 20 nm71 
was reported to occur in the kidney rather than in liver. However, high liver 
accumulation was described for NP-formulations with a small diameter, such as QDs 
of ~5 to 15 nm72,74,116. Although the results presented here, showed lower uptake in 
the liver of 15 nm NPs, compared to 25 and 100 nm NPs as confirmed by ex vivo 
analyses, the background fluorescence in vivo was also considerable low over time. 
This indicates that the small size of NPs did not contribute to an increased blood 
circulation. Work by others indicates that smaller particles tend to have longer blood-
half-lives, presumably due to reduced plasma protein adsorption on their 
surface62,67,123.  
Furthermore, ex vivo analyses revealed low accumulation of NPs in the spleen and a 
slight tendency of decreased uptake with a decrease in NPs size, as shown by the 
average intensities in the spleen that were ~8 %, 6 %, and 5 % for the 100, 25, and 
15 nm NPs, respectively. Accumulation of NPs, including PSNPs130, in the spleen has 
been reported previously, and is likely mediated by macrophages as part of the MPS 
116, but has also been shown to be reduced with a decrease in size71. In addition to 
liver and spleen, uptake in the lung has been observed in this study, with an average 
intensity in the lung for NPs of all sizes of ~3 %. Lung accumulation was also 
described for other NPs128, including PSNPs130 and may be caused by endocytosis of 
particles by pulmonary endothelial cells.  
The results presented here reveal a change in the degree of liver uptake over time 
when NPs were PEGylated. For PEGylated 25 and 100 nm NPs, slightly higher liver 
signals were measured in vivo and ex vivo over time compared to the NH2 probes. 
Therefore, a decrease of sequestration of NPs in the liver by surface PEGylation, 
compared to NPs with NH2 surface groups could not be observed in the present 
study. These findings disaccord with the common believe that PEGylation leads to a 
decrease in liver signals due to avoidance of NP-elimination through the MPS, 
resulting in prolonged blood circulation and extravasation of NPs into permeable 
tissues, like the tumor62,123. PEG, belongs to a group of long hydrophilic, neutrally 
charged polymer chains shown to be very effective in creating a surface barrier 
between the NP and the opsonins by “blocking” electrostatic and hydrophobic 
interactions on the surface and thereby preventing elimination of NP from the blood 
stream62. It is known that, neutrally charged particles have a lower opsonization rate 
than charged NPs, bearing for instance, positively charged NH2 surface groups. 
Furthermore, hydrophilic NPs are reported to be less recognized by opsonins, 
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compared to hydrophobic ones, as blood serum proteins adsorb less on these 
surfaces. Apparently, as also shown in this work PEGylation does not definitively lead 
to a successful decrease in elimination of particles. This is in agreement with findings 
of Sun and colleagues who also observed no differences in biodistribution for PSNPs 
with sizes of 18 and 37 nm after PEGylation with 5 kDa PEG (except for a reduction 
in spleen uptake compared to non-PEGylated probes)67.  
In this work, no differences in biodistribution were observed for 25 nm NPs 
conjugated to 1.5 and 10 kDa PEG chains, both showing comparable high liver 
signals and low background signals over time in vivo. These results were confirmed 
by ex vivo analysis of organs, illustrating comparable high intensities (of 89 and 90 
% of the total intensity of all organs) for the 25 nm-PEG 1.5 kDa and -10 kDa 
probes, respectively. Therefore, conjugation of NPs with different lengths of PEG 
chains had no impact on elimination of NPs by the MPS. These findings are in 
contrast to some reports the literature, where PEG chains with a weight of at least 2 
kDa are required for MPS-avoidance, presumably due to a reduced flexibility of 
shorter PEG chains62,126.  
In addition to the length of the PEG chains, their surface density may also influence 
recognition of probes by the MPS. As reported by Owens et al., very low surface 
densities of PEG result in gaps on the surface of the particle, where opsonins may 
bind, thereby initiating NP-elimination. On the other hand, a too high density of PEG 
on the surface leads to restriction of motion of the PEG chains, thereby decreasing 
PEG mobility and thus steric hindrance properties for opsonins. In this regard, a 
moderate density of PEG would be optimal, with no gaps on the surface but providing 
sufficient mobility of PEG62. Therefore, in future the effect of reduced amounts of 
surface-PEG on a prolonged bioavailability of Itrybe-loaded NPs in the blood should 
be investigated. 
Independent on PEGylation of 15 and 25 nm NPs, the background fluorescence did 
not increase after probe injection. In contrast, application of the 100 nm-PEG 1.5 
kDa probe resulted in a slightly enhanced background fluorescence compared to the 
100 nm-NH2 NPs. However, this is in contrast to the finding that the PEGylated 100 
nm NPs also showed higher liver uptake over time compared to the NH2-modified 100 
nm NPs. Nevertheless, due to their enhanced fluorescence in the background, the 
PEGylated 100 nm NPs seem to have an increased blood circulation time, compared 
to all other NP probes. 
Characteristic for all probes investigated here was the peak in background 
fluorescence within the first few minutes after probe injection, showing that the 
circulating NPs in the blood are rapidly eliminated. This is in accordance with reports 
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of the literature for NPs built of PEGylated- (18 and 24 nm)67, serum albumin-coated- 
(50 nm)131, or carboxylated PS (100 nm)130, as well as of PEGylated gold (20 and 80 
nm)71, of silica of different shape (185 and 720 nm in length) 129, or of dextran-
coated salt-bridged polymer aggregates (100 and 500 nm)128. However, longer blood 
circulation times were observed for some probes, such as PEGylated gadolinium NPs 
of 85 nm, which in addition showed comparably low accumulation in liver, spleen, 
lungs and kidneys up to 8 h after injection124. Similar results were obtained by use of 
3 and 6 nm sized silica NPs up to 3 h after injection132. Furthermore, a long half-live 
of NPs in the blood was reported for lipid NPs of 35 nm with fluorescence clearly 
evident in the plasma after 24 h65. 
When compared to signals of single fluorophore-conjugates, like Alexa Fluor 647 
coupled to Herceptin (Alexa-Her DP ratio 1.3), the background signals in this study 
and thus blood circulation times were relatively low for all NPs probes after i.v. 
injection in mice. This underlines the suggestion that the excretion of NPs was 
relatively fast, thereby not providing sufficient time for the NPs to effectively reach 
the targeted tumor.  
Biodistribution analyses, performed systematically in this work, advanced the 
knowledge about the behavior and bioavailability of Itrybe-loaded PSNPs of different 
sizes and surface modifications. However, it should be mentioned, that fluorescence 
imaging performed in this study is not an absolutely quantitative method to assess 
biodistibution, mainly because different tissues (e.g. blood, plasma, and organs) 
absorb light in a different manner65. Of further importance for the future might be 
the direct analysis of fluorescence in the blood of mice at different time points after 
injection of diverse NPs, as this would provide a more precise calculation of probes 
present in the blood pool than measurement of background fluorescence.  
However, the biodistribution study explored the mechanisms for the inefficient 
tumor-targeting by Itrybe-loaded NPs and helped to conclude which improvements 
are needed for the future design of these probes to mediate tumor-detection in vivo. 
The overall goal is for NPs to be present in the bloodstream long enough to reach the 
targeted tumor tissue62. Therefore, the results obtained in this analyses, concerning 
the yet low bioavailability and tumor-targeting capacity of Itrybe-loaded PSNPs are 
helpful to further modify Itrybe loaded PSNP probes, in regards to surface density of 
PEG chains or the use of more flexible materials for their design. Systematically 
performed studies, addressing biodistribution and suitability of novel probes for 
efficient tumor targeting in vivo, including NP systems, are often missing in the 




Taken together, Itrybe-loaded NPs used in this study, demonstrate attractive probes 
in regard to their brightness and 3D appearance, allowing various surface 
modifications for in vivo imaging applications. However, the specificity and 
bioavailability of these probes has to be further improved to enable efficient tumor-
targeting in vivo. 
Summary and Conclusions 
5. SUMMARY AND CONCLUSIONS 
The work presented here illustrates a detailed and systematic in vitro and in vivo 
analysis of novel and innovative fluorescence probes, pH-sensitive conjugates and 
PSNPs loaded with the broadband fluorophore Itrybe, concerning their suitability for 
in vivo tumor imaging. Coupled to the tumor specific antibody Herceptin, the pH-
sensitive dyes and Itrybe-loaded NPs were evaluated in orthotopic mouse breast 
tumor models for tumor-specific targeting.  
This study illustrates, for the first time, the suitability of CypHer5E for its application 
in in vivo tumor imaging, with an enhanced sensitivity compared to commonly 
applied, commercially available always on fluorophores, such as AlexaFluor 647.  
The pH-sensitive Herceptin conjugate, pH-Her, only activated in the acidic pH of the 
tumor, significantly enhanced detection sensitivity of breast tumors in combination 
with subtraction of autofluorescence. Analysis of different methods for elimination of 
unwanted and perturbing autofluorescence or background fluorescence showed that 
especially subtraction of autofluorescence is a reliable method of image data analysis 
and, in combination with pH-Her, improves tumor detection sensitivity in vivo. In 
contrast, as shown for pH-Her and Alexa-Her, LT-gated imaging is more challenging, 
as it needs extensive pre-evaluation of LTs of applied probes under different 
conditions. Moreover, the results of LT-gated imaging have to be considered with 
caution as unknown influences, e.g. in the tumor environment may change the LT of 
some probes in vivo and therefore lead to misinterpretations of probe-derived 
signals. As a consequence, the unexpected changes in LT observed for pH-Her in 
tumor tissue require further investigations. Probes that display extensive drifts in LT 
upon distinct influences of a specific environment, such as a tumor, may have great 
potential for sensitive detection and monitoring of cancer in vivo when combined with 
LT-gated imaging. This would allow a simple separation of tumor-derived 
fluorescence from background signals caused by the fluorophore in the blood, 
according to different LTs of the probes in certain areas of the body. In future, the 
pH-sensitive fluorophore CypHer5E, in conjugation with other tumor-specific ligands, 
may be a promising tool for the sensitive detection of other malignancies as well as 
for monitoring of disease progression over time in vivo. The use of CypHer5E could 
also assist preclinical studies that evaluate novel anti-cancer therapies by detecting 
primary tumors as well as metastatic lesions.  
This work is the first report about the in vivo application of Itrybe-loaded NPs. The 
results obtained here underline the potential of this probe as a highly sensitive 
imaging tool in vivo. As large numbers of Itrybe fluorophores can be loaded in NPs, 
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very bright fluorescence probes were generated in comparison to single dye 
molecules. The broad spectra of Itrybe in NPs enable excitation at different 
wavelengths in the NIRF region and a sensitive detection of the fluorophore in vivo, 
thereby allowing, for example to selectively minimize unspecific signals in the GI 
tract. Enhanced detection sensitivity is especially important in in vivo fluorescence 
imaging, where autofluorescence or unspecific fluorescence from unbound probes or 
food decrease the detection sensitivity of probe-derived signals. Moreover, by 
analysis of binding specificity of Herceptin-conjugated NPs in vitro, the functionality 
of these probes was confirmed, excluding the lack of binding specificity as a factor 
that could limit or reduce tumor targeting of NPs in vivo. Although Itrybe-loaded 
PSNPs may present attractive tools for labeling of cells due to their high cellular 
uptake, their application for in vivo imaging of tumors has to be improved by 
increasing their bioavailability and tumor targeting capacity. In this regard, use of 
materials other than PS, for the generation of NPs, which exhibit e.g. more flexibility, 
could be advantageous. In addition, further investigations should be performed on 
the influences of a lower PEG surface density on biodistribution of NPs of different 
sizes. 
In this study, specific tumor targeting to KPL4 tumors, overexpressing HER2 was 
achieved by coupling the probes to the tumor specific antibody Herceptin. The 
application of antibody-single dye conjugates, such as pH-Her enabled specific 
targeting of tumor structures. This was possible due to a better bioavailability of 
these probes in vivo in comparison to Herceptin-conjugated or non-bioconjugated 
NPs. However, fluorophore-doped NPs also exhibit great potential for in vivo imaging 
and monitoring of tumors as they provide the possibility for various modifications 
depending on their application purpose.  By combining different labels in/on one NP, 
such carriers could be applied for simultaneous monitoring by different imaging 
methods, such as fluorescence imaging and MRI56,57. They can also be surface tagged 
with different markers to improve binding probability to the target structures in vivo. 
In addition, modifications of composition of NP-formulations can advance the 
biodegradability of NPs in vivo and by this means their use as drug carrier systems. 
In future, Itrybe-loaded NPs and CypHer5E may be used in combination with other 
disease-specific markers, such as antibodies or peptides for detection and evaluation 
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